

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68, C12P 19/34, C07K 13/00, C07H 21/04, A61K 38/00, 39/00, 39/395</b>		A1	(11) International Publication Number: <b>WO 97/38137</b> (43) International Publication Date: 16 October 1997 (16.10.97)
(21) International Application Number: <b>PCT/US97/06254</b> (22) International Filing Date: 4 April 1997 (04.04.97)  (30) Priority Data: 08/630,912 4 April 1996 (04.04.96) US 08/632,673 16 April 1996 (16.04.96) US 08/652,265 23 May 1996 (23.05.96) US		94402 (US). DRAYNA, Dennis, T. [US/US]; 536 Fordham Road, San Mateo, CA 94402 (US). FEDER, John, N. [US/US]; 1450 Chestnut Street, San Carlos, CA 94070 (US). GNRKE, Andreas [DE/US]; 1220 Highland Court, San Carlos, CA 94070 (US). RUDDY, David [US/US]; 885 Greenwich Street, San Francisco, CA 94133 (US). TSUCHIHASHI, Zenta [JP/US]; 9 Light Way, Menlo Park, CA 94025 (US). WOLFF, Roger, K. [US/US]; 916 Holly Road, Belmont, CA 94002 (US).	
(60) Parent Applications or Grants (63) Related by Continuation US 08/652,265 (CIP) Filed on 23 May 1996 (23.05.96) US 08/632,673 (CIP) Filed on 16 April 1996 (16.04.96) US 08/630,912 (CIP) Filed on 1 April 1996 (01.04.96)		(74) Agents: FITTS, Renee, A. et al.; Townsend and Townsend and Crew L.L.P., 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).	
(71) Applicant ( <i>for all designated States except US</i> ): MERCATOR GENETICS, INC. [US/US]; 4040 Campbell Avenue, Menlo Park, CA 94025 (US). (72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): THOMAS, Winston, J. [US/US]; 40 White Plains Court, San Mateo, CA		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
<p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
(54) Title: HEREDITARY HEMOCHROMATOSIS GENE			
(57) Abstract			
<p>The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also relates to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HEREDITARY HEMOCHROMATOSIS GENE

5

This application is a continuation-in-part of Serial No. 08/630,912, filed April 4, 1996, Serial No. 08/632,673, filed April 16, 1996 and Serial No. 08/652,265, filed May 23, 1996.

10

BACKGROUND OF THE INVENTION

Hereditary hemochromatosis (HH) is an inherited disorder of iron metabolism wherein the body accumulates excess iron. In symptomatic individuals, this excess iron leads to deleterious effects by being deposited in a variety of organs leading to their failure, and resulting in cirrhosis, diabetes, sterility, and other serious illnesses.

15 Neither the precise physiological mechanism of iron overaccumulation nor the gene which is defective in this disease has been described.

HH is typically inherited as a recessive trait; in the current state of knowledge, homozygotes carrying two defective copies of the gene are most frequently affected by the disease. In addition, heterozygotes for the HH gene are more susceptible 20 to sporadic porphyria cutanea tarda and potential other disorders (Roberts et al., *Lancet* 349:321-323 (1997). It is estimated that approximately 10-15% of individuals of Western European descent carry one copy of the HH gene mutation and that there are about one million homozygotes in the United States. HH, thus, represents one of the most common genetic disease mutations in individuals of Western European descent. Although 25 ultimately HH produces debilitating symptoms, the majority of homozygotes and heterozygotes have not been diagnosed.

The symptoms of HH are often similar to those of other conditions, and the severe effects of the disease often do not appear immediately. Accordingly, it would be desirable to provide a method to identify persons who may be destined to become 30 symptomatic in order to intervene in time to prevent excessive tissue damage associated with iron overload. One reason for the lack of early diagnosis is the inadequacy of

presently available diagnostic methods to ascertain which individuals are at risk, especially while such individuals are presymptomatic.

Although blood iron parameters can be used as a screening tool, a confirmed diagnosis often employs liver biopsy which is undesirably invasive, costly, and 5 carries a risk of mortality. Thus, there is a clear need for the development of an inexpensive and noninvasive diagnostic test for detection of homozygotes and heterozygotes in order to facilitate diagnosis in symptomatic individuals, provide presymptomatic detection to guide intervention in order to prevent organ damage, and for identification of heterozygote carriers.

10 The need for such diagnostics is documented, for example, in Barton, J.C. et al. Nature Medicine 2:394-395 (1996); Finch, C.A. West J Med 153:323-325 (1990); McCusick, V. Mendelian Inheritance in Man pp. 1882-1887, 11th ed., (Johns Hopkins University Press, Baltimore (1994)); Report of a Joint World Health Organization/Hemochromatosis Foundation/French Hemochromatosis Association Meeting

15 on the Prevention and Control of Hemochromatosis (1993); Edwards, C.Q. et al. New Engl J Med 328:1616-1620 (1993); Bacon, B.R. New Engl J Med 326:126-127 (1992); Balan, V. et al. Gastroenterology 107:453-459 (1994); Phatak, P.D. et al. Arch Int Med 154:769-776 (1994).

Although the gene carrying the mutation or mutations that cause HH has 20 previously been unknown, genetic linkage studies in HH families have shown that the gene that causes the disease in Caucasians appears to reside on chromosome 6 near the HLA region at 6p21.3 (Cartwright, Trans Assoc Am Phys 91:273-281 (1978); Lipinski, M. et al. Tissue Antigens 11:471-474 (1978)). It is believed that within this locus, a single mutation gave rise to the majority of disease-causing chromosomes present in the 25 population today. See Simon, M. et al. Gut 17:332-334 (1976); McCusick, V. *supra*. This is referred to herein as the "common" or "ancestral" or "common ancestral" mutation. These terms are used interchangeably. It appears that about 80% to 90% of all HH patients carry at least one copy of the common ancestral mutation which is closely linked to specific alleles of certain genetic markers close to this ancestral HH gene defect. 30 These markers are, as a first approximation, in the allelic form in which they were present at the time the ancestral HH mutation occurred. See, for example, Simon, M. et al. Am J Hum Genet 41:89-105 (1987); Jazwinska, E.C. et al. Am J Hum Genet

53:242-257 (1993); Jazwinska, E.C. et al. Am J Hum Genet 56:428-433 (1995);  
Worwood, M. et al. Brit J Hematol 86:863-866 (1994); Summers, K.M. et al. Am J  
Hum Genet 45:41-48 (1989).

Several polymorphic markers in the putative HH region have been  
5 described and shown to have alleles that are associated with HH disease. These markers  
include the published microsatellite markers D6S258, D6S306 (Gyapay, G. et al. Nature  
Genetics 7:246-339 (1994)), D6S265 (Worwood, M. et al. Brit J Hematol 86:833-846  
(1994)), D6S105 (Jazwinska, E.C. et al. Am J Hum Genet 53:242-257 (1993); Jazwinska,  
E.C. et al. Am J Hum Genet 56:428-433 (1995)), D6S1001 (Stone, C. et al. Hum Molec  
Genet 3:2043-2046 (1994)), D6S1260 (Raha-Chowdhury et al. Hum Molec Genet 4:1869-  
1874 (1995)) as well as additional microsatellite and single-nucleotide-polymorphism  
markers disclosed in co-pending PCT application WO 96/35802 published November 14,  
1996, the disclosure of which is hereby incorporated by reference in its entirety.

Although each of such markers may be of use in identifying individuals  
15 carrying the defective HH gene, crossing-over events have, over time, separated some of  
the ancestral alleles from the mutation that is responsible for HH, thereby limiting the  
utility of such surrogate markers. The limited diagnostic power of surrogate markers is  
obvious considering the fact that the frequency of the ancestral allele in the population is  
generally higher than the estimated frequency of the disease-causing mutation. The  
20 desirability of identifying the gene responsible for HH has long been recognized due to  
the health benefits that would be available via gene-based diagnostics, which has an  
intrinsically higher predictive power than surrogate markers and may eventually lead to  
the identification and diagnosis of disease-causing mutations other than the ancestral  
mutation. In addition, identification of the HH gene would further our understanding of  
25 the molecular mechanisms involved in HH disease thereby opening new approaches for  
therapy. This goal has motivated numerous, but previously unsuccessful attempts to  
identify the HH gene.

These attempts have been made by a variety of methods. For example,  
genes known to be involved in iron transport or metabolism have been examined as  
30 candidates. An example of one unsuccessful attempt is the assignment of the ferritin  
heavy chain gene to Chromosome 6p, and subsequent exclusion of this gene on the basis  
of its precise localization outside of the HH region, and failure to find mutations in HH

patients. See Dugast, I.J. et al. Genomics 6:204-211 (1990); Summers et al. Hum Genet 88:175-178 (1991).

Another strategy has been to employ the genomic DNA surrounding the postulated HH locus to select expressed genes from this region. These genes have been 5 evaluated in HH patients for mutations in an attempt to identify them as the causative gene. Examples of searches that have not resulted in the identification of the HH gene are illustrated in El Kahloun et al. Hum Molec Genet 2:55-60 (1992), Goei et al. Am J Hum Genet 54:244-251 (1994), and Beutler et al. Blood Cells, Molecules, and Diseases 21:206-216 (1995).

10 Finally, although the strategy of using positional information obtained from genetic studies has long been a widely used approach, estimates of the position of the HH gene remained imprecise. Examples of this uncertainty are demonstrated in Gruen et al. Genomics 14:232-240 (1992) and in Gasparini et al. Hematology 19:1050-1056 (1994). Indeed, a number of contradictory conclusions have been reported, some placing the HH 15 gene proximal of HLA-A (Edwards et al. Cytogenet Cell Genet 40:620 (1985); Gasparini, P. et al. Hum Molec Genet 2:571-576 (1993)) while others placed the gene distal of HLA-A (Calandro et al. Hum Genet 96:339-342 (1995)).

Until very recently, in spite of the linkage studies placing the HH disease gene in the HLA region of Chromosome 6, the biological relevance of alterations in HLA 20 Class I components has not been particularly well explored. Work by de Sousa et al. Immun Lett 39:105-111 (1994), and more recent work by Rothenberg, B.E. and Voland, J.R. Proc Natl Acad Sci USA 93:1529-1534 (1996) indicated that  $\beta$ -2-microglobulin knock-out mice develop symptoms of iron overload.  $\beta$ -2-microglobulin is presented on cell surfaces as a complex with HLA Class I MHC's. de Sousa et al. *supra.* (1994) and 25 Barton, J.C. and Bertoli, L.F. Nature Medicine 2:394-395 (1996) speculated that  $\beta$ -2-microglobulin associated proteins or a unique Class I gene could be involved in the control of intestinal iron absorption and possibly HH disease.

In spite of the extensive efforts in the art to find the gene responsible for HH, the gene has remained elusive. Nevertheless, as will be appreciated it would be 30 highly desirable to identify, isolate, clone, and sequence the gene responsible for HH and to have improved diagnostic methods for detection of affected individuals, whether homozygotes or heterozygotes.

SUMMARY OF THE INVENTION

One aspect of the invention is an isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of:

- nucleic acid sequences corresponding to the nucleic acid sequence of SEQ  
5 ID NO:1 (which corresponds to the genomic sequence of the HH gene including introns and exons as shown in Figure 3);
  - nucleic acid sequences corresponding to the nucleic acid sequences selected from the group consisting of SEQ ID NO:3 (which corresponds to the genomic sequence of the HH gene containing the 24d1 mutation as shown in Figure 3),
  - 10 SEQ ID NO:5 (which corresponds to the genomic sequence of the HH gene containing the 24d2 mutation as shown in Figure 3), SEQ ID NO: 7 (which corresponds to the genomic sequence of the HH gene containing the 24d1 and the 24d2 mutations as shown in Figure 3);
    - nucleic acid sequences corresponding to the nucleic acid sequence of SEQ  
15 ID NO:9 (which corresponds to the cDNA sequence including the coding sequence of the HH gene as shown in 4);
      - nucleic acid sequences corresponding to the nucleic acid sequences selected from the group consisting of SEQ ID NO:10 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d1  
20 mutation as shown in Figure 4), SEQ ID NO:11 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d2 mutation as shown in Figure 4), and SEQ ID NO:12 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d1 and the 24d2 mutations as shown in Figure 4);
        - 25 In one embodiment, the nucleic acid is DNA. In another embodiment, the DNA is cDNA. In another embodiment, the nucleic acid is RNA. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:1. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:9. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, and SEQ  
30 ID NO:7. In another embodiment, the nucleic acid is a nucleic acid sequence

corresponding to a nucleic acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

A further aspect of the invention is a cloning vector comprising a coding sequence of a nucleic acid as set forth above and a replicon operative in a host cell for the  
5 vector.

A further aspect of the invention is an expression vector comprising a coding sequence of a nucleic acid set forth above operably linked with a promoter sequence capable of directing expression of the coding sequence in host cells for the vector.

10 A further aspect of the invention is host cells transformed with a vector as set forth above.

A further aspect of the invention is a method of producing a mutant HH polypeptide comprising: transforming host cells with a vector capable of expressing a polypeptide from a nucleic acid sequence as set forth above; culturing the cells under  
15 conditions suitable for production of the polypeptide; and recovering the polypeptide.

A further aspect of the invention is a peptide product selected from the group consisting of: a polypeptide having the amino acid sequence corresponding to the sequence of SEQ ID NO:2; a polypeptide having the amino acid sequence corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8; a peptide  
20 comprising at least 6 amino acid residues corresponding to the sequence of SEQ ID NO:2; a peptide comprising at least 6 amino acid residues corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. In one embodiment, the peptide is labeled. In another embodiment, the peptide is a fusion protein.

A further aspect of the invention is a use of a peptide as set forth above as  
25 an immunogen for the production of antibodies. In one embodiment, there is provided an antibody produced in such application. In one embodiment, the antibody is labeled. In another embodiment, the antibody is bound to a solid support. In a further embodiment, the antibody is monoclonal.

A further aspect of the invention is a method to determine the presence or  
30 absence of the common hereditary hemochromatosis (HH) gene mutation in an individual, comprising: providing DNA or RNA from the individual; and assessing the DNA or RNA for the presence or absence of the HH-associated allele A of a base-pair mutation

24d1, wherein, as a result, the absence of the allele indicates the absence of the HH gene mutation in the genome of the individual and the presence of the allele the presence of the HH gene mutation in the genome of the individual. In a further embodiment, the method further comprises assessing the DNA or RNA for the presence of the base-pair mutation 5 designated 24d2.

In a further embodiment the assessment can be made in combination with one or more microsatellite repeats or other polymorphisms. Thus, in a further aspect of the invention, the assessing step further comprises assessing the DNA or RNA for the presence or absence of any one of the following HH-associated alleles of base pair 10 polymorphisms HHP-1, HHP-19, or HHP-29, wherein, as a result, the presence of the 24d1 and/or 24d2 allele in combination with the presence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of 24d1 and/or 24d2 allele in combination with the absence of at least one of the base pair polymorphisms HHP-1, 15 HHP-19, or HHP-29 indicates a likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step further comprises assessing the DNA or RNA for the presence of absence of any one of the following alleles defined by markers having microsatellite repeats: 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091- 20 1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241- 25 29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122, D6S105:124; D6S306:238; D6S464:206; and D6S1001:180, wherein, as a result, the presence of the 24d1A and/or 24d2 allele in combination with the presence of at least one microsatellite 30 repeat allele indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of the 24d1 and/or 24d2 allele in combination with the absence of any one or all of the microsatellite repeat alleles indicates the likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step is performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29. In another embodiment, the assessing

step is performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and oligonucleotide primers flanking at least one of the microsatellite repeat alleles. In another embodiment, the assessing step is performed by a process which

5 comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2, oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29, and oligonucleotide primers flanking at least one of the microsatellite repeat alleles.

A further aspect of the invention is a set of oligonucleotides for use in an  
10 oligonucleotide ligation assay determination of the presence or absence of an HH-associated allele of a base-pair polymorphism, wherein the base pair polymorphisms comprises 24d1 and the oligonucleotides comprise the sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

A further aspect of the invention is a kit for the detection of the presence  
15 or absence of an HH-associated allele of a base-pair polymorphism, the base-pair polymorphism comprising 24d1, as designated herein, the kit comprising the above oligonucleotide primer set. In another embodiment, the kit further comprises oligonucleotide primers for amplifying the DNA containing the base-pair polymorphism.

Another aspect of the invention is a kit for detection of a polymorphism in  
20 the HH gene in a patient, the sample kit comprising at least one oligonucleotide of at least 8 nucleotides in length selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, or 12, wherein the oligonucleotide is used to amplify a region of HH DNA or RNA in a patient sample. In another aspect of the invention the kit further comprises at least a second oligonucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, or 12, wherein the first and second oligonucleotides comprise a primer pair.

A further aspect of the invention is a method to evaluate potential  
responsiveness of an individual infected with hepatitis C to interferon treatment,  
comprising determining the presence or absence of the common hereditary  
30 hemochromatosis gene in the individual according to any of the above methods.

A further aspect of the invention is an oligonucleotide primer useful for  
amplification of DNA, the oligonucleotide primer designed on the basis of the DNA

sequence of any one of SEQ ID NO: 18, SEQ ID NO:19, SEQ ID NO:29, and SEQ ID NO:30.

A further aspect of the invention is a method for diagnosing whether a patient is afflicted with hereditary hemochromatosis (HH) disease, comprising: contacting 5 cells of the patient with antibodies directed against an epitope on an HH protein product corresponding substantially to SEQ ID NO:2; and observing whether the antibodies localize on the cells, wherein, in the observing step, if antibodies do not localize to the cell there is a probability that the patient is afflicted with HH. In one embodiment, the method is conducted *in vitro*. In another embodiment, the method is conducted *in vivo*.

10 A further aspect of the invention is a method for treating a patient diagnosed as having hereditary hemochromatosis (HH) disease, comprising delivering a polypeptide corresponding to the amino acid sequence of SEQ ID NO:2 to tissues of the patient. The patient can be homozygous or heterozygous for 24d1, and may be a compound 24d1/24d2 heterozygote. In an embodiment, the polypeptide is delivered 15 directly to the tissues. In another embodiment, the polypeptide is delivered intravenously. In another embodiment, the polypeptide is delivered to the tissues through gene therapy.

15 A further aspect of the invention is an animal model for hereditary hemochromatosis (HH) disease, comprising a mammal possessing a mutant or knocked-out HH gene.

20 A further aspect of the invention is metal chelation agents derived from nucleic acid sequences described above or from a peptide product as described above in a physiologically acceptable carrier. In one embodiment, the metal is selected from the group consisting of iron, mercury, cadmium, lead, and zinc.

25 A further aspect of the invention is a method to screen mammals for susceptibility to metal toxicities, comprising, screening such mammals for a mutation in the HH gene and wherein those mammals identified as having a mutation are more susceptible to metal toxicities than mammals not identified as having a mutation. In one embodiment, the metal is selected from the group consisting of iron, mercury, cadmium, lead, and zinc.

30 A further aspect of the invention is a method for selecting patients infected with hepatitis virus for  $\alpha$ -interferon treatment, comprising screening such patients for a mutation in the HH gene and wherein those patients not identified as having a mutation

are selected to proceed with  $\alpha$ -interferon treatment and those identified as having a mutation are selected to undergo phlebotomy prior to  $\alpha$ -interferon treatment.

A further aspect of the invention is a T-cell differentiation factor comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described above.

A further aspect of the invention is a method for screening potential therapeutic agents for activity in connection with HH disease, comprising: providing a screening tool selected from the group consisting of a cell line, a cell free, and a mammal containing or expressing a defective HH gene or gene product; contacting the screening tool with the potential therapeutic agent; and assaying the screening tool for an activity selected from the group consisting of HH protein folding, iron uptake, iron transport, iron metabolism, receptor-like activities, upstream processes, downstream processes, gene transcription, and signaling events.

A further aspect of the invention is a therapeutic agent for the mitigation of injury due to oxidative processes *in vivo*, comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described above.

A further aspect of the invention is a method for diagnosing a patient as having an increased risk of developing HH disease, comprising: providing DNA or RNA from the individual; and assessing the DNA or RNA for the presence or absence of the HH-associated allele A of a base mutation designated herein 24d1 in combination with assessing the DNA or RNA for the HH-associated allele G of a base mutation designated herein 24d2, wherein, as a result, the absence of the alleles indicates the absence of the HH gene mutation in the genome of the individual and the presence of the alleles indicates the presence of the HH gene mutation in the genome of the individual and an increased risk of developing HH disease. In an embodiment, this assessment is done in combination with one or more microsatellite repeats or other polymorphisms. Thus, in a further aspect of the invention, the assessing step further comprises assessing the DNA or RNA for the presence or absence of any one of the following HH-associated alleles of base pair polymorphisms HHP-1, HHP-19, or HHP-29, wherein, as a result, the presence of the 24d1 and/or 24d2 allele in combination with the presence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates the likely presence of the HH

gene mutation in the genome of the individual and the absence of 24d1 and/or 24d2 allele in combination with the absence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates a likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step further comprises assessing the

5 DNA or RNA for the presence of absence of any one of the following alleles defined by markers having microsatellite repeats: 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241-10 29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122, D6S105:124; D6S306:238; D6S464:206; and D6S1001:180, wherein, as a result, the presence of the 24d1A and/or 24d2 allele in combination with the presence of at least one microsatellite repeat allele indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of the 24d1 and/or 24d2 allele in combination with the absence

15 of any one or all of the microsatellite repeat alleles indicates the likely absence of the HH gene mutation in the genome of the individual.

A further aspect of the invention is a therapeutic agent for the mitigation of iron overload, comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described

20 above.

A further aspect of the invention is a method for treating hereditary hemochromatosis (HH) disease, comprising: providing an antibody directed against an HH protein sequence or peptide product; and delivering the antibody to affected tissues or cells in a patient having HH.

25 A further aspect of the invention is an antisense oligonucleotide directed against a transcriptional product of a nucleic acid sequence selected from the group consisting of therapeutic agent for the mitigation of iron overload, comprising a moiety selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

30 A further aspect of the invention is an oligonucleotide of at least 8 nucleotides in length selected from nucleotides 1-46, 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080; 1083-1109; 1106-1304; 1301-1366; 1363-1386; 1389-

1514; 1516-1778; 1773-1917; 1921-2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422;  
2420-2464; 2465-2491; 2488-2568; 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-  
3042; 3420-3435; 3451-3708; 3703-3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978;  
3974-3992; 3990-4157; 4153-4251; 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-  
5 4400; 4398-4436; 4444-4547; 4572-4714; 4709-4777; 5165-5397; 5394-6582; 5578-5696;  
5691-5709; 5708-5773; 5773-5816; 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-  
6133; 6150-6296; 6292-6354; 6356-6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917;  
6913-7027; 7023-7061; 7056-7124; 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-  
9037; 9486-9502; 9743-9811; 9808-9831; 9829-9866; 9862-9986; 9983-10075; 10072-  
10 10091; 10091-10195; 10247-10263; 10262-10300; 10299-10448; 10448-10539; 10547-  
10564; 10580-10612; 10608-10708; 10703-10721; 10716-10750; 10749-10774; 10774-  
10800; and 10796-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 9  
nucleotides in length selected from nucleotides 1-47; 47-124; 119-370; 364-395; 389-541;  
15 537-647; 642-1005; 1000-1081; 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-  
1515; 1515-1918; 1920-2011; 2050-2147; 2153-2210; 2233-2369; 2366-2423; 2419-2465;  
2464-2492; 2487-2569; 2871-2935; 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-  
3771; 3773-3841; 3839-3963; 3963-3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283;  
4283-4334; 4336-4401; 4397-4437; 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-  
20 5710; 5707-5774; 5772-5817; 5817-5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134;  
6149-6355; 6355-6556; 6554-6576; 6574-6793; 6787-7125; 7318-7508; 7881-8001; 7997-  
8073; 8072-8099; 8999-9038; 9485-9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987;  
9982-10076; 10071-10092; 10090-10196; 10246-10264; 10261-10301; 10298-10449;  
10447-10540; 10546-10565; 10579-10751; 10748-10775; 10773-10801; and 10795-10825  
25 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 10  
nucleotides in length selected from nucleotides 1-48; 46-125; 118-1006; 999-1082; 1081-  
1111; 1104-1306; 1299-1368; 1361-1388; 1387-1516; 1514-1919; 1919-2012; 2049-2148;  
2152-2211; 2232-2370 2365-2424; 2418-2466; 2463-2493; 2486-2570; 2870-2936; 2934-  
3003; 2998-3044; 3418-3437; 3449-3772; 3772-3842; 3838-3964; 3962-3994; 3988-4284;  
4282-4335; 4335-4402; 4396-4438; 4442-4549; 4570-4779; 5163-5711; 5706-5775; 5771-  
5818; 5816-5851; 5867-6047; 6040-6077; 6071-6110; 6111-6135; 6148-6356; 6354-6577;

6573-7126; 7317-7509; 7880-8074; 8071-8100; 8998-9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093; 10089-10197; 10245-10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566; 10578-10752; 10747-10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

5 A further aspect of the invention is an oligonucleotide of at least 11 nucleotides in length selected from nucleotides 1-49; 45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212; 2231-2371; 2364-2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-3438; 3448-3773; 3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403; 4395-4439; 4441-4550; 4569-4780; 5162-5712; 5705-10 5776; 5770-5819; 5815-5852; 5886-6111; 6100-6136; 6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101; 8997-9040; 9483-9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-10542; 10544-10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 12 nucleotides in length selected from nucleotides 1-50, 44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213; 2230-2372; 2363-2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-3774; 3770-3844; 3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781; 5161-5713; 5704-5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-6579; 6571-7128; 7315-7511; 7878-8076; 8069-8102; 20 8996-9041; 9482-9506; 9739-10199; 10243-10267; 10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-10754; 10745-10778; and 10770-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 13 nucleotides in length selected from nucleotides 1-51; 43-1391; 1384-1519; 1511-1922; 25 1916-2015; 2046-2151; 2149-2214; 2229-2469; 2460-2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-3967; 3959-4287; 4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821; 5813-5854; 5884-6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544; 10542-10567; 10575-10779; and 10769-10825 of 30 SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 14 nucleotides in length selected from nucleotides 1-52; 42-1392; 1383-1520; 1510-1923;

1915-2016; 2045-2152; 2148-2215; 2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-  
3776; 3768-3968; 3959-4288; 4278-4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822;  
5812-5855; 5883-6114; 6107-6139; 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-  
8078; 8067-8104; 8994-9043; 9480-9508; 9737-10201; 10241-10454; 10442-10545;  
5 10541-10568; and 10574-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 15  
nucleotides in length selected from nucleotides 1-53; 41-1393; 1382-1521; 1509-1924;  
1914-2017; 2044-2153; 2147-2216; 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-  
3777; 3767-3969; 3958-4289; 4277-4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823;  
10 5811-5856; 5882-6115; 6106-6140; 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-  
9044; 9479-9509; 9736-10202; 10240-10546; 10540-10569; and 10573-10825 of SEQ ID  
NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 16  
nucleotides in length selected from nucleotides 1-1394; 1381-1925; 1913-2018; 2043-  
15 2154; 2146-2217; 2226-2576; 2864-3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444;  
4436-4555; 4564-4785; 5157-5857; 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-  
8106; 8992-9045; 9478-9510; 9735-10203; 10239-10547; 10539-10570; and 10572-10825  
of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 17  
20 nucleotides in length selected from nucleotides 1-1926; 1912-2019; 2042-2155; 2145-  
2218; 2225-2577; 2863-3051; 3411-3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786;  
5156-5858; 5880-6117; 6104-6142; 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-  
9511; 9734-10204; 10238-10548; 10538-10571; and 10571-10825 of SEQ ID NO:1, 3, 5,  
or 7.

25 A further aspect of the invention is an oligonucleotide of at least 18  
nucleotides in length selected from nucleotides 1-2020; 2041-2156; 2144-2219; 2224-  
2578; 2862-3052; 3410-3780; 3764-4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118;  
6103-6143; 6140-7134; 7309-7517; 7872-8108; 8990-9047; 9476-9512; 9733-10205;  
10237-10549; 10537-10572; and 10570-10825 of SEQ ID NO:1, 3, 5, or 7.

30 A further aspect of the invention is an oligonucleotide of at least 8  
nucleotides in length selected from nucleotides 1-55; 55-251; 250-306; 310-376; 380-498;  
500-528; 516-543; 541-578; 573-592; 590-609; 611-648; 642-660; 664-717; 712-727;

725-763; 772-828; 813-874; 872-928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 9  
5 nucleotides in length selected from nucleotides 1-56; 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9, 10, 11 or 12.

10 A further aspect of the invention is an oligonucleotide of at least 10  
nucleotides in length selected from nucleotides 1-57; 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109; 2114-2202; and 2451-2471 of SEQ ID NO:9,  
15 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 11  
nucleotides in length selected from nucleotides 1-58; 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185; 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-  
20 2110; 2113-2203; and 2450-2472 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 12  
nucleotides in length selected from nucleotides 1-255; 246-310; 306-380; 376-502; 496-  
596; 586-613; 607-664; 660-767; 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-  
1211; 1436-1487; 1478-1632; 1999-2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ  
25 ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 13  
nucleotides in length selected from nucleotides 1-311; 305-381; 375-503; 495-614; 606-  
665; 659-768; 767-1051; 1049-1076; 1071-1121; 1110-1187; 1181-1212; 1435-1633;  
1998-2060; 2052-2205 and 2448-2474 of SEQ ID NO:9, 10, 11 or 12.

30 A further aspect of the invention is an oligonucleotide of at least 14  
nucleotides in length selected from nucleotides 1-312; 304-382; 374-504; 494-615; 605-

666; 658-769; 766-1052; 1048-1077; 1070-1188; 1180-1213; 1434-1634; 1997-2061;  
2051-2206; and 2447-2475 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 15  
nucleotides in length selected from nucleotides 1-313; 303-383; 373-505; 493-616; 604-  
5 667; 657-770; 765-1053; 1047-1078; 1069-1189; 1179-1214; 1433-1635; 1996-2062;  
2050-2207; and 2446-2476 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 16  
nucleotides in length selected from nucleotides 1-314; 302-384; 372-668; 656-771; 764-  
1054; 1046-1079; 1068-1190; 1178-1215; 1432-1636; 1995-2208; and 2445-2477 of SEQ  
10 ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 17  
nucleotides in length selected from nucleotides 1-315; 301-385; 371-669; 655-772; 763-  
1055; 1045-1080; 1067-1191; 1177-1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ  
ID NO:9, 10, 11 or 12.

15 A further aspect of the invention is an oligonucleotide of at least 18  
nucleotides in length selected from nucleotides 1-773; 762-1056; 1044-1081; 1066-1192;  
1176-1217; 1430-1638; 1993-2210; and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

#### BRIEF DESCRIPTION OF THE DRAWING FIGURES

20 Figure 1 is a physical map showing the positions of markers on  
Chromosome 6 telomeric of the HLA region and the set of genomic clones used in our  
gene discovery efforts. In the Figure, "y" designates a YAC (yeast artificial  
chromosome) clone, "p" designates a p1 clone, "b" designates a BAC (bacterial artificial  
chromosome) clone, and "pc" designates a PAC (p1 artificial chromosome).

25 Figure 2 is a subset of chromosomes showing the overlap of ancestral DNA  
between HH affected chromosomes from patients at markers in a narrow region of  
Chromosome 6, approximately 4.8 Mbp telomeric of the HLA region. These overlapping  
regions were used to define the minimal HH region. Shaded regions are "ancestral  
regions" maintained "identical by descent." The region that is ancestral and in common  
30 between all of these chromosomes is between markers 241-29 and 63-3. This is where  
the HH gene should reside.

Figure 3 is a nucleotide sequence of the genomic DNA containing the HH gene (SEQ ID NO:1). The sequence comprises approximately 11,000 nucleotides. The sequence corresponding to the HH gene coding regions have been capitalized and underlined. The positions of the 24d1 and the 24d2 mutations and the 24d7 sequence variants are shown where base 5474 corresponds to the position of the 24d1 mutation, base 3512 corresponds to the position of the 24d2 mutation, and base 3518 corresponds to the position of the 24d7 sequence variation. Sequences corresponding to the genomic DNA including the 24d1 mutation are referred to herein as SEQ ID NO:3, sequences corresponding to the genomic DNA including the 24d2 mutation are referred to herein as SEQ ID NO:5, and sequences corresponding to the genomic DNA including the 24d1 and the 24d2 mutations are referred to herein as SEQ ID NO:7.

Figure 4 is the nucleotide sequence of the translated portion of the cDNA (SEQ ID NO:9) corresponding to coding regions in the HH gene. The nucleotide sequence of the cDNA is arbitrarily numbered beginning at 1 with the A in the start codon (ATG). The predicted amino acid sequence of the protein product is provided (SEQ ID NO:2); and sequence variants in the gene, as well as the associated changes in the amino acid sequence caused by such variants are indicated on the Figure at base 187 (residue 63), base 193 (residue 65), and base 845 (residue 282). Sequences corresponding to cDNA including the 24d1 mutation are referred to herein as SEQ ID NO:10, sequences corresponding to the cDNA including the 24d2 mutation are referred to herein as SEQ ID NO:11, and sequences corresponding to the cDNA including the 24d1 and the 24d2 mutations are referred to herein as SEQ ID NO:12. Sequences of the predicted protein product including the amino acid change caused by the 24d1 mutation is referred to herein as SEQ ID NO:4, sequences of the predicted protein product including the amino acid change caused by the 24d2 mutation is referred to herein as SEQ ID NO:6, and sequences of the predicted HH protein product including the amino acid change caused by the 24d1 and 24d2 mutations is referred to herein as SEQ ID NO:8.

Figure 5 shows the oligonucleotide sequences used for amplification (SEQ ID NOS:13 and 14) and OLA determination (SEQ ID NOS: 15, 16 AND 17) of the 24d1 gene mutation of the present invention.

Figure 6 shows a 517 base sequence representing the genomic DNA surrounding the 24d1 gene mutation of the present invention. Figure 6a shows the

position of 24d1 in the normal G allele and the portions of the sequence used for the design of the primers illustrated in Figure 5 (SEQ ID NO:20), and Figure 6b shows the position of 24d1 in the mutated A allele and the portions of the sequence used for the design of the primers illustrated in Figure 5 (SEQ ID NO:21).

5                  Figure 7 shows the sequence alignment between the predicted amino acid sequence of the HH gene protein product (SEQ ID NO:2) in comparison to RLA (rabbit leukocyte antigen) (SEQ ID NO:22) and an MHC Class I protein (SEQ ID NO:23). The dots above certain amino acids correspond to conservative amino acid residue differences, i.e., glycine for alanine, valine for isoleucine for leucine, aspartic acid for glutamic acid, 10 asparagine for glutamine, serine for threonine, lysine for arginine, and phenylalanine for tyrosine, or the reverse.

Figure 8 is a schematic diagram showing the association between an HLA molecule and  $\beta$ -2-microglobulin highlighting the homologous positions of the three base-pair changes that have been found in the predicted HH gene protein product.

15                  Figure 9 shows the oligonucleotide sequences used for amplification (SEQ ID NOS:24 and 25) and OLA determination (SEQ ID NO:26, 27 and 28) of the 24d1 gene mutation of the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

20    I.     Definitions

As used herein, the term "random chromosomes" refers to chromosomes from randomly chosen individuals who are not known to be affected with HH. Similarly, the term "unaffected individuals" refers to individuals who are not known to be affected with HH. The term "affected chromosomes" as used herein refers to chromosomes from 25 individuals who have been diagnosed as having HH as determined by hepatic iron index and liver biopsy. Similarly, the term "affected individuals" refers to individuals who have been diagnosed as having HH.

As used herein, "marker" refers to a DNA sequence polymorphism flanked by unique regions. These regions flanking the "marker" can be utilized for the design 30 and construction of oligonucleotides for amplifying the relevant DNA portions and detecting the polymorphisms therein.

The term "HH disease" refers to hereditary hemochromatosis disease. The criteria utilized herein to assess whether a patient is affected with the HH disease (i.e., whether the patient is an "affected individual" having "affected chromosomes") has been established by the diagnostic criteria set out in Crawford et al. Am J Hum Genet 57:362-367 (1995) where at least two of the following four criteria were met: (i) liver biopsy showing HIC greater than 4660 micrograms/gram of liver, (ii) HII greater than or equal to 2.0, (iii) Perl stain of 3 or greater, or (iv) greater than 4 grams of iron removed by phlebotomy (greater than 16 therapeutic phlebotomies).

"HH gene" as used herein refers to a gene whose mutated forms are associated with HH disease. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein nucleotide substitutions in the gene sequence do not affect the function of the gene product. Generally, the HH gene is found on Chromosome 6 and includes the DNA sequences shown in Figures 3 and 4 and all functional equivalents. The term "HH gene" includes not only coding sequences but also regulatory regions such as promoter, enhancer, and terminator regions. The term further includes all introns and other DNA sequences spliced from the final HH gene RNA transcript. Further, the term includes the coding sequences as well as the non-functional sequences found in non-human species. All DNA sequences provided herein are understood to include complementary strands unless otherwise noted. It is understood that an oligonucleotide may be selected from either strand of the HH genomic or cDNA sequences. Furthermore, RNA equivalents can be prepared by substituting uracil for thymine, and are included in the scope of this definition, along with RNA copies of the DNA sequences of the invention isolated from cells. The oligonucleotide of the invention can be modified by the addition of peptides, labels, and other chemical moieties and are understood to be included in the scope of this definition.

The terms "HH protein" and "HH gene product" refer to MHC Class I-like molecules encoded by the HH gene. The term includes protein as isolated from human and animal sources, produced by enzymatic or chemical means, or through recombinant expression in an organism. The term further includes "normal" and "wild-type" forms of the protein and mutant forms of the protein that are responsible or involved in HH disease. Encompassed within this definition are forms of the protein including polymorphic forms of the protein in which the amino acid changes do not affect the

essential functioning of the protein in its role as either "normal" or "wild-type" or mutant forms of the protein.

"Ancestral DNA" as used herein refers to DNA that is inherited in unchanged form through multiple generations. Such DNA is sometimes referred to herein 5 as DNA that is "identical by descent."

The term "ancestral mutation" as used herein refers to the disease causing mutation inherited through multiple generations.

## II. Introduction to HH Gene Discovery

10 Through the analysis of affected chromosomes as compared to random chromosomes, in accordance with the present invention, we have identified, isolated, and sequenced the cDNA corresponding to the normal and mutant HH gene (Feder, J.N. et al., Nature Genetics 13:399-408(1996). In addition, we have sequenced the cDNA corresponding to the gene's mRNA and have predicted the gene's protein product.

15 The HH disease gene is a novel gene on Chromosome 6 having significant sequence homology with HLA Class I genes. Interestingly, however, the gene is located at significant distance telomeric (approximately 4 Mbp) from the HLA Class I gene cluster on Chromosome 6. A single mutation in the gene appears responsible for the majority of HH disease. The mutation comprises a single nucleotide substitution of  
20 Guanine (G) to Adenine (A), where Guanine (G) is present in the unaffected DNA sequence and Adenine (A) is present in the affected DNA sequence. This mutation, referred to herein as 24d1, is illustrated in two partial sequences from the genomic DNA of the HH gene below and represented by SEQ ID NO:29 (unaffected) and SEQ ID NO:30 (affected):

25 24d1 Unaffected Sequence:

5'-GGAAGAGCAGAGATACGT**G**CCAGGTGGAGCACCCAGG-3' (SEQ ID NO:29)

24d1 Affected Sequence:

5'-GGAAGAGCAGAGATACGT**A**CCAGGTGGAGCACCCAGG-3' (SEQ ID NO:30)

The G to A mutation at 24d1 is present in approximately 86% of all  
30 affected chromosomes and in only 4% of unaffected chromosomes, exemplifying its enrichment in the affected chromosomes.

As will be discussed in greater detail below, several factors provide a compelling conclusion that the above-mentioned gene of the present invention is in fact the HH gene, and that the 24d1 mutation is responsible for the majority of cases of HH disease. First, the location of the gene on Chromosome 6, in relative proximity to the HLA region, is the predicted location based on linkage disequilibrium mapping studies and haplotype analysis. Second, recent evidence demonstrated that  $\beta$ -2-microglobulin knock-out mice developed symptoms of iron overload disease. The predicted amino acid sequence of the gene product of the present invention possesses significant homology to HLA Class I molecules which are known to interact with  $\beta$ -2-microglobulin. Third, the principal mutation (24d1) causes a marked amino acid change (cys -- > tyr) at a critical disulfide bridge held in common with HLA Class I proteins that is important to the secondary structure of such protein products. Changes affecting the disulfide bridge in HLA Class I molecules have been shown to prevent or minimize presentation of the protein on cell surfaces. Further, such amino acid changes would appear to substantially modify the manner in which the protein could associate or interact with  $\beta$ -2-microglobulin. Fourth, the 24d1 mutation is present in over 87% of HH patients while only present in 4% of random individuals, consistent with estimates of the frequency of the ancestral HH mutation in patients and the carrier frequency in random individuals.

20           A.     Discovery of the HH Gene

1.     Strategy

In order to identify the HH gene, we set out to determine allelic association patterns between known markers and the HH locus in the HLA region of Chromosome 6. Based upon this data, we generated physical clone coverage extending from D6S265, 25 which is a marker that is centromeric of HLA-A, in a telomeric direction through D6S276, a marker at which the allelic association was no longer observed.

2.     Allelic Association

As mentioned above, it is believed that there was a common ancestor who 30 possessed a distinct DNA sequence within whose genome the common or ancestral HH mutation occurred. It appears that approximately 87% of the patients today are descendants of this disease founding individual and thus share the common mutation. As

will be appreciated, through the generations, chromosomes undergo genetic recombination during meiosis. Both genetic linkage mapping and disequilibrium mapping take advantage of this natural process to narrow and define the location of the disease causing gene. The smaller the distance between a disease locus and a genetic marker, the less likely that a 5 recombination event will occur between them. Thus, as genetic markers are tested in a population of HH patients the markers closest to the disease locus will tend more often to have the allele that was present on the ancestral chromosome, while others, farther away, will tend to have different alleles brought in by genetic recombination. Our strategy for identifying the HH gene, and the mutation(s) responsible for the HH disease, exploited 10 this phenomenon by first reconstructing the haplotype of the founding or ancestral chromosome spanning an 8Mb region. Secondly, we determined the minimal HH region that is "identical by descent" or shared in the chromosomes in our sample of HH patients.

The approach is shown in Figure 2 where areas of ancestral sequence that is "identical by descent" are indicated in shade and areas of non-identity are unmarked.

15 Particular markers are shown at the top of the Figure.

Towards the goal of identifying the HH gene, we undertook this type of strategy. Owing to the published allelic association of the HH gene with the HLA region, we directed our initial efforts to this region of Chromosome 6. Existing genetic markers were tested for association with the HH gene. Because of the founder or ancestral effect, 20 described above, we expected that markers closer to the HH gene would display a greater degree of allelic association. Based upon this initial data we designed a strategy to develop markers over a 8Mb region extending telomeric from HLA-A.

The markers were generally developed by cloning random pieces of genomic DNA, known to represent this region of the chromosome as described in the 25 next section and as shown in Figure 1. The clones containing CA repeat elements were identified by hybridization and their sequences determined. The sequence information was used to design primers within the unique DNA flanking the CA repeat, for use in PCR. If the CA repeat proved to be polymorphic in a random sample of chromosomes, then the markers were assayed in HH patients. In this effort 46 CA microsatellite markers 30 covering approximately 8Mb, were identified and scored in our patients. We detected the pattern of overlapping ancestral DNA present on patient chromosomes as depicted in Figure 2. As will be appreciated, the minimal area of DNA that is "identical by descent"

on all the ancestral HH chromosomes is between, but not including, markers 241-29 and 63-3, surrounding marker 241-5. This is the region within which the HH gene must lie and where we conducted our search for the gene as described below.

5        **3. Physical Mapping**

Primary clone coverage of the genomic region telomeric of the MHC locus on Chromosome 6p was obtained by assembling an overlapping set of YAC clones that span the region between D6S265 and D6S276. Initial YAC contigs were seeded by screening the CEPH MegaYAC library for the sequence tag sites (STSs) D6S258,  
10 D6S306, D6S105, D6S464 and D6S276. Additional YACs containing these STSs were identified in the CEPH and the MIT/Whitehead databases. The three initial YAC contigs were expanded and eventually merged into a single contig by bidirectional walking using STSs developed from the ends of YAC inserts. An STS-content map comprising 64 STSs and 44 YACs across the HH region was constructed. In order to determine precise  
15 physical distances, a set of 14 YACs were selected for RARE-cleavage mapping (Gnirke et al. *Genomics* 24:199-210 (1994)) and the construction of the distance-calibrated YAC-contig and STS content maps which are shown in Figure 1.

Bacterial clones were identified by PCR-based and hybridization-based screening of comprehensive human cosmid, p1, BAC, and PAC libraries. Figure 1 also  
20 shows the bacterial clone contig across approximately 1 Mbp of genomic DNA that includes the region represented by YAC 241. The STS-content map indicating the STS and clone order is depicted in Figure 1. YACs, BACs, PACs and P1 clones are denoted by the suffices y, b, pc and p, respectively.

In Figure 1, the markers are characterized as follows: D6S248 (Orphanos,  
25 V. et al. *Hum Mol Genet* 2:2196 (1993)); D6S258, D6S265, D6S276, D6S306, D6S464 (Gyapay, G. et al. *Nature Genetics* 7:246-339 (1994)); 258-2, G4, HHp61, HHp89, HLA-A, H241-4, H241-6, H4073-3, RFP (Unpublished STS's to genomic DNA developed by the Assignee of the present application.); D6S1281, P6116 (Murray, J.C. et al. *Science* 265:2049-2054 (1994)); HLA-F (Fullan, A. and Thomas, W. *Hum Molec Genet.* 3:2266 (1994)); MOG (Roth, M-P. et al. *Genomics* 28:241-250 (1995)); 1A2, 1E.4, 2B8, 18B4, 19D9, 24E.2, 63-1, 63-3, 3321-1, 4073-1, HB63-2, HB65-1, HB65-2, HB68-1, HB373-8, H241-5, H241-29, H731-1, H950-1, H950-2, H950-3, H950-4, H950-

6, H950-8, H3216-1, H4072-2, H4440-1, H4440-2, H5091-1 (CA repeats described in co-pending U.S. Patent Application Serial No.08/599,252, filed February 9, 1996, which is a continuation-in-part of U.S. Patent Application Serial No. 08/559,302, filed November 15, 1995, which is a continuation-in-part of U.S. Patent Application Serial No. 5 08/436,074, filed May 8, 1995, the disclosures of which are hereby incorporated by reference in their entirety.); D6S1001 (Stone, C. et al. Hum Molec Genet 3:2043-2046 (1994)); D6S105 (Weber, J.L. et al. Nucl. Acids Res. 19:968 (1991)).

The markers indicated at the top of Figure 2 are those that are labeled with asterisks in Figure 1. Other than marker 24d1, all of the markers indicated (i.e., 241-4, 10 96-1, 65-2, 65-1, 241-6, 241-29, 241-5, 63-3, 63-1, 63-2, 373-8, and 373-29) are CA repeat markers. The numbers indicated in the chart with respect to the CA repeat markers refers to the size of the allele upon PCR amplification and sizing of the resulting product on acrylamide gels. The 24d1 marker, as discussed above, is a single base-pair mutation as represented by the G to A base substitution that is present in affected 15 chromosomes as illustrated in SEQ ID NO:29 and SEQ ID NO:30. The results of genotyping for each of the two chromosomes from the patients are indicated. DNA that is identical by descent is indicated by shading.

As will be appreciated, eight patient haplotypes displayed evidence of recombination events delineating the minimal HH region. The tract of DNA that is 20 "identical by descent" on all of the ancestral HH chromosomes is between, but not including, markers 241-29 and 63-3. Genomic sequencing has determined this region to be approximately 250 Kb in size. This region includes markers 241-5 and 24d1. For definition of telomeric and centromeric boundaries, *see* Figure 2, Patient HC75 and Patients HC2, HC22, HC50, HC87, HC91, HC125, and HC143.

25

#### 4. Identification of cDNA 24

Based upon allelic association data, we delineated a region encompassed by YAC 241 as the region most likely to contain the HH gene. As one of our approaches to identify genes within the HH region, direct selection experiments were performed on 30 YAC 241. Morgan, J.G. et al. Nucl Acids Res 20:5173-5179 (1992).

Briefly, YAC DNA was isolated by pulse-field gel electrophoresis, digested with Mbo I and linkers ligated to the resulting fragments. The DNA was then amplified

by PCR using primers containing biotin on their 5' end. Similarly, cDNA was prepared from poly A+ RNA from fetal brain, small intestine and liver, digested with Mbo I, linkers ligated and amplified by PCR. The cDNA was 'blocked' with DNA clones representing human ribosomal RNA, histone genes as well as with repetitive DNA (Cot-1, 5 Gibco).

Two rounds of solution hybridization were carried out to the prescribed value of Cot 100. The DNA fragments were cloned into pSP72 and sequenced. Four hundred and sixty-five clones were sequenced and arranged into 162 overlapping contigs, referred to herein as DS clones.

10 Representative DS clone sequences from each contig were searched against the public databases (NCBI) and interesting homologies were noted. One in particular, known as DS34 showed convincing homology to MHC Class I protein encoding genes. Small STSs were designed from each of the 162 contigs and the contigs were mapped in relation to the existing STS content map of the region.

15 Clones that mapped to the delineated minimal HH region of YAC 241 were given priority for further analysis. In conjunction with its homology to MHC Class I genes, DS34 mapped within our minimal region, and thus was considered a candidate for the HH gene. The STSs were subsequently used to determine which cDNA library was appropriate for obtaining full length cDNA clones.

20 Three directionally cloned plasmid-based cDNA libraries were employed (Gibco); brain, liver and testis. It was discovered that DS34 was present in all three libraries. Subsequently, DS34 was random primer labeled and used to screen colony lifts of cDNA libraries using standard procedures. Three clones were obtained from the testis library. The largest of these, 2.7 Kb, was designated cDNA24 and was sequenced 25 completely on both strands.

##### 5. Mutation Analysis of cDNA24

The candidate gene encompassed in cDNA24 was analyzed to detect mutations in the HH affected chromosomes as compared to unaffected chromosomes.

30 In connection with this work, patient DNA and RNA was obtained as follows. Lymphoblastoid cell lines from random and HH affected individuals were established by transformation of peripheral blood mononuclear cells with Epstein-Barr

Virus. Chromosomal DNA was purified from these cells by standard methods (Maniatis et al. Molecular Cloning - A Laboratory Manual (2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989))). PolyA+ RNA was purified using Fast Track (Invitrogen).

Mutation analysis was accomplished as follows. Initial searching for the

5 HH mutation in cDNA24 was accomplished through RT-PCR (reverse transcription-polymerase chain reaction, Dracopoli, N. et al. eds. Current Protocols in Human Genetics (J. Wiley & Sons, New York (1994)) method. First, from the genotype analysis, homozygous HH patients with the ancestral haplotype were identified (see previous sections). First strand cDNAs were synthesized through use of Superscript

10 reverse transcriptase (Life Technologies) using polyA+ RNA from transformed lymphoblastoid cell lines from two homozygous ancestral patients (HC9 and HC14) and those from two unaffected individuals (NY8 and CEPH 11840) as templates.

From these first strand cDNAs, coding regions corresponding to the cDNA24 sequence were amplified into three overlapping PCR products (designated herein 15 as A, B, and C) to facilitate efficient amplification and sequencing. A nested set of primers were used to increase specificity in generating the three products. The primers utilized are shown in Table 1:

TABLE 1

20	PCR Product	Name	Primer Set for 1st Nested PCR	Name	Primer Set for 2nd Nested PCR
"A"	P17	5'-CAA AAG AAG CGG AGA TTT AAC G-3'	P19	5'-AGA TTT AAC GGG GAC GTG C-3'	
	P18	5'-AGA GGT CAC ATG ATG TGT CAC C-3'	P20	5'-AGG AGG CAC TTG TTG GTC C-3'	
"B"	P5	5'-CTG AAA GGG TGG GAT CAC AT-3'	P7	5'-AAA ATC ACA ACC ACA GCA AAG-3'	
	P6	5'-CAA GGA GTT CGT CAG GCA AT-3'	P8	5'-TTC CCA CAG TGA GTC TGC AG-3'	
"C"	P9	5'-CAA TGG GGA TGG GAC CTA C-3'	P11	5'-ATA TAC GTG CCA GGT GGA GC-3'	
	P10	5'-CCT CTT CAC AAC CCC TTT CA-3'	P12	5'-CAT AGC TGT GCA ACT CAC ATC A-3'	

30 P17 (SEQ ID NO:31); P19 (SEQ ID NO:32); P18 (SEQ ID NO:33); P20 (SEQ ID NO:34); P5 (SEQ ID NO:18); P7 (SEQ ID NO:35); P6 (SEQ ID NO:19); P8 (SEQ ID NO:36); P9 (SEQ ID NO:37); P11 (SEQ ID NO:38); P10 (SEQ ID NO:39); and P12 (SEQ ID NO:40).

Amplified DNA products (PCR-products) were purified using gelase (Epicentre), and DNA sequences of these PCR-fragments were determined by the dideoxy 35 chain termination method using fluorescently labeled dideoxy nucleotides on an ABI 377 DNA sequencer.

Comparison of DNA sequences derived from these PCR-fragments identified a single nucleotide change in the cDNA24 coding region as represented by SEQ ID NO:29 and SEQ ID NO:30 at nucleotide 845. (Note, the first nucleotide of the open reading frame was counted as nucleotide 1. *See Figure 4*). The nucleotide at this 5 position in two unaffected individuals was a G, while two HH affected individuals had an A at this position.

This mutation was designated as 24d1. The allele containing a G at this position was named as 24d1(G) and the allele containing an A in this position was named 24d1(A). The mutation causes an amino acid change from a cysteine (Cys282) to a 10 tyrosine. This cysteine residue is conserved in all the known Class I MHC molecules and contributes a sulfur to the formation of a disulfide bridge that is present in the immunoglobulin constant region like domain (Ig domain, Gussow et al. Immunogenetics 25:313-322 (1987); Bjorkman and Parham Ann Rev Biochem 59:253 (1990)). In the case of Class I MHC molecules, it has been shown that a similar change in the reciprocal 15 cysteine involved in the disulfide bridge abolishes the function of the protein by causing a defect in cell surface expression (Miyazaki et al. Proc. Natl. Acad. Sci. U.S.A. 83:757-761 (1986)). Thus, due to the high degree of conservation seen in the structure, it is likely that the 24d1 mutation would interfere with the function of cDNA 24 protein products.

20 The genomic sequence surrounding the 24d1 mutation is provided in SEQ ID NO:29 (unaffected 24d1(G) allele) and SEQ ID NO:30 (affected 24d1(A) allele).

The frequency of the mutant 24d1(A) allele and the normal 24d1(G) allele was determined in random chromosomes and affected chromosomes through use of an oligonucleotide ligation assay (OLA assay). *See Nickerson et al. Proc. Natl. Acad. Sci. 25 U.S.A.* 87:8923-8927 (1990). Chromosomal DNA from these individuals was prepared from either a lymphoblastoid cell line or peripheral blood cells. First, DNA corresponding to exon 4 was amplified by PCR using primers designed against intron DNA sequences flanking exon 4. *See Figure 6* which provides the precise location of the sequences used for primer design. The presence of the 24d1(A) allele or the 24d1(G) 30 allele was determined by OLA using the oligonucleotides outlined in Figure 5. Figure 5 shows the sequences of preferred primers used for amplification and analysis of the above base mutation. The amplification primers for 24d1 are labeled 24d1.P1 (SEQ ID NO:13)

and 24d1.P2 (SEQ ID NO:14). The oligonucleotides used in the sequence determination by OLA for 24d1 are designated 24d1.A (SEQ ID NO:15), 24d1.B (SEQ ID NO:16), and 24d1.X (SEQ ID NO:17). As indicated in the sequences shown, "bio" indicates biotin coupling, "p" indicates 5'-phosphate, and "dig" indicates coupled digoxigenin.

5 The result from this OLA assay with 164 HH affected individuals and 134 unaffected random individuals is shown in Table 2.

**TABLE 2**

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=328)	Random Chromosomes (N=268)
10	24d1 "A"	86%
	24d1 "G"	14%

The 24d1(A) mutation occurs in 86% of the chromosomes from HH affected individuals (affected chromosomes) as compared to 4% in the chromosomes from 15 random individuals (random chromosomes). This approximates the estimated frequency of the ancestral HH mutation in the general population. Among these 164 affected individuals, 137 were homozygous for the 24d1(A) allele and 9 were heterozygous for the 24d1(A) and the 24d1(G) alleles, while the remaining 18 were homozygous for the 24d1(G) allele. The distribution of homozygotes and heterozygotes for the 24d1 alleles 20 significantly deviates from that expected by Hardy-Weinberg equilibrium, suggesting the possibility of either mutant alleles that complement one another or genetic heterogeneity. Regardless of this fact, 24d1 homozygosity provides identification of 84% of HH patients in our sample.

In addition to the 24d1 mutation, other sequence variants were also detected 25 within certain subpopulations of patients. In this regard, sequence analysis of the cDNA24 gene was extended to the remaining individuals who are either 24d1(G) homozygotes or 24d1(A)/24d1(G) heterozygotes. Eighteen 24d1(G) homozygous HH patient and nine 24d1 heterozygotes patients were analyzed. All the exons that contain the cDNA24 open reading frame were amplified from these individuals through the use of 30 PCR primers directed against introns and exons. DNA sequences of these PCR products

were determined by dideoxy chain termination methods. This analysis identified two additional sequence variants (24d2 and 24d7) in the coding region of cDNA24.

The first additional variant, 24d2, occurs at nucleotide 187. (Note, the first nucleotide of the open reading frame was counted as nucleotide 1. *See Figure 4*).

5 The two alleles of this variant are 24d2(C) (C at this position) and 24d2(G) (G at this position). CDNA24 as well as NY8 and CEPH 11840 were homozygous for the 24d2(C) allele, while DNAs from some patients (HC74, HC82 and others) were 24d2(C)/24d2(G) heterozygous. The 24d2(C) allele encodes a histidine (His63) while 24d2(G) encodes an aspartic acid, thus creating an amino acid change in the presumed peptide binding domain

10 of the protein product. As with 24d1, changes to certain amino acids in the peptide binding domains of MHC Class I proteins can also disrupt intracellular transport and assembly (Salter, *Immunogenetics* 39:266-271 (1994)).

The genomic sequence surrounding the variant for 24d2(C) and 24d2(G) is provided below:

15 **24d2(C):**

AGCTGTTCGTGTCTATGAT**C**ATGAGAGTCGCCGTGGA      (SEQ ID NO:41)

**24d2(G):**

AGCTGTTCGTGTCTATGAT**G**ATGAGAGTCGCCGTGGA      (SEQ ID NO:42)

The frequency of the 24d2 mutant allele versus the normal allele was

20 determined through OLA as described above. The results from the OLA assays are shown in Table 3.

**TABLE 3**

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=328)	Random Chromosomes (N=158)
25	24d2 "C"	95%
	24d2 "G"	5%
		82%
		18%

As shown in Table 3, the 24d2(G) allele occurs in 5% of the chromosomes from HH affected individuals (affected chromosomes) and in 18% of the chromosomes

30 from random individuals (random chromosomes). The frequency of the 24d2(G) allele in

the patients was lower than that of random chromosomes because this allele was associated with some of the nonancestral chromosomes and the majority of the HH patient chromosomes were ancestral. The remainder of the chromosomes had the 24d2(C) allele. When one looks at the distribution of the 24d2(G) allele containing chromosomes within

5 the patient population, one notices an enrichment of the 24d2(G) allele in 24d1 heterozygotes. Eighty-nine percent or 8 out of 9 heterozygotes for 24d1 have the 24d2(G) allele as compared to the expected 18%. Thus, the 24d2(G) allele is enriched in 24d1 heterozygous patients indicating that the 24d2 mutation has a role in HH disease.

A third nucleotide change was identified at nucleotide 193 in one patient  
10 (HC43) and was named 24d7. (Note, the first nucleotide of the open reading frame was  
counted as nucleotide 1. *See Figure 4*). All other patients analyzed, as well as random  
controls, including NY8 and CEPH 11840 had an allele 24d7(A) (A at this position),  
while HC43 was a 24d7(A)/24d7(T) heterozygote. The 24d7(A) allele encodes a serine  
15 (Ser65) while the 24d7(T) allele changes this to a cysteine codon, also within the  
presumed peptide binding domain of the cDNA 24 protein product.

The genomic sequence surrounding the polymorphism for 24d7(A) and 24d7(T) is provided below:

**24d7(A):**

TGTTCTATGATCATGAGAGTCGCCGTGTGGAG (SEQ ID NO:43)

20 24d7(T):

TGTTCTATGATCATGAG TGTGCCGTGGAG (SEQ ID NO:44)

The frequency of the 24d7 mutant allele versus normal allele was determined through OLA as described above. The results from the OLA assays are shown in Table 4.

25

TABLE 4

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=266)	Random Chromosomes (N=156)
24d7 "A"	99.6%	97%
24d7 "T"	0.4%	3%

In Table 4, The 24d7(T) allele was observed in only one chromosome present in the patient sample (HC43) (0.4%) and present in four chromosomes from the unaffected individuals (3%). The presence of the 24d7(T) allele shows no increase in risk 5 of acquiring HH and thus may only be a polymorphic variant within the population.

**B. Characterization of the HH Gene**

**1. Sequence**

The complete sequence of cDNA24 (of which the coding region is shown 10 in Figure 4) was used to search public databases (NCBI) for homology to known gene sequences using the BlastX search algorithm. Substantial homology to MHC Class I molecules from a variety of species was obtained.

Next, the sequence was analyzed for the existence of open-reading frames (ORF's). The largest ORF, as shown in Figure 4, encodes a polypeptide of 348 amino 15 acids with a predicted molecular mass of approximately 38 KD. As will be appreciated, the molecular weight/mass can vary due to possible substitutions or deletions of certain amino acid residues. In addition, the molecular weight/mass of the polypeptide can vary due to the addition of carbohydrate moieties and in connection with certain phosphorylation events and other post-translational modifications. The remainder of the 20 cDNA, 1.4 Kb appears to be non-coding; one poly A addition site (AATAAA) is present 20 bp upstream of the poly A tail (not shown in Figure 4).

A search of translated public database (NCBI) using a six way translation of cDNA24 showed significant homology between cDNA 24 and previously cloned MHC proteins. The search revealed 39% identity and 58% similarity of the amino acid 25 residues. Besides MHC Class I proteins, the HH gene product shows similarity to other proteins known to contain motifs related to the immunoglobulin constant region, such as  $\beta$ -2-microglobulin and zinc- $\alpha$ -2-glycoprotein. See Bjorkman, P. and Parham, P. Ann Rev Biochem 59:253 (1990). A multiple sequence alignment was carried out between several MHC Class I proteins (Fig. 7). The results indicate that the homology between cDNA 24 30 and MHC extends throughout the cDNA 24 protein, including the peptide-binding region, immunoglobulin-like region, transmembrane region and cytoplasmic region. Of particular

interest is the conservation of the position of several cysteine residues which function in protein folding via disulfide bonds.

cDNA 24 tissue expression was determined by probing polyA + RNA Northern blots (Clontech). One major transcript of approximately 4.4 Kb was observed 5 in all of the 16 tissues tested including small intestine and liver.

The genomic region corresponding to cDNA 24 was cloned and sequenced. CDNA 24 is comprised of apparently seven exons, covering approximately 11 Kb of sequence. The putative seventh exon is completely non-coding and contains one poly (A)+ addition signal. In the region of the predicted start site of transcription, there are 10 no consensus CAAT or TATA boxes, nor are there any start like  $\beta$ GAP-like sequences recently suggested by Rothenberg and Voland, *supra* (1996). One CpG island was found to overlap the first exon and extend into the first intron. Within this island are the consensus cis-acting binding sites for the transcription factors Sp1 (2 sites) and AP1 (1 site) (McVector software, Oxford Molecular). The lack of any recognizable TATA boxes 15 and the presence of Sp1 and AP2 binding sites is consistent with the low level of transcription associated with the gene.

## 2. Structure/Function of the HH Gene Product

The predicted translation product of cDNA 24, herein referred to as the 20 HH gene and HH gene product or HH protein, was aligned to other MHC proteins for which there was a high degree of homology at the amino acid level (Figure 7). MHC Class I proteins are comprised of several distinct domains: peptide binding domains ( $\alpha$ 1 and  $\alpha$ 2), immunoglobulin like domain ( $\alpha$ 3), a transmembrane region, and a small cytoplasmic portion. The HH gene product shows homology throughout all four of these 25 domains. Further confirmation of the structural relationship between the HH gene product and MHC Class I molecules was obtained through analysis of the primary sequence using McVector software (Oxford Molecular).

The HH gene product is similar to MHC Class 1 molecules when comparing hydrophilicity, surface probability, and secondary structure. A conserved 30 structural feature of Class 1 molecules is the presence of several intradomain disulfide bonds between positions Cys-101 and Cys-164 in the  $\alpha$ 2 helix and between Cys-203 and Cys-259 in the  $\alpha$ 3 helix. This domain structure is conserved between all Class 1

molecules. The disulfide bond in the  $\alpha 3$  helix forms the interface through which the molecule interacts with the  $\beta$ -2-microglobulin protein, a protein which associates with MHC Class 1 molecules in the endoplasmic reticulum and functions as a molecular chaperone.

5       The HH protein possesses all four cysteine residues in conserved positions common to MHC Class I molecules. This data indicates a structural relationship with MHC Class I Molecules and a potential interaction with  $\beta$ -2-microglobulin (or a related protein) as well.

10      It has been demonstrated that when the cysteine at position 203 is mutated, thus disrupting the disulfide bridge that is formed between Cys-203 and Cys-259, intracellular transport of the mutated protein is blocked. See Miyazaki et al. *supra* (1986). As will be appreciated, the mutation (24d1) of the present invention corresponds to the reciprocal cysteine (Cys-259; Cys-282 in the HH protein) in the disulfide bridge that was demonstrated by Miyazaki et al. to abolish intracellular transport. Thus, it is 15 predicted that the 24d1 mutation ablates expression of the HH protein on cell surfaces.

16      Sequence studies of MHC Class I molecules have shown that these molecules are among the most polymorphic proteins known to date. The majority of this variation is located in the  $\alpha 1$  and  $\alpha 2$  domains of the molecule. In contrast, the HH gene product displays little polymorphism in this region. In this respect, the HH protein is 20 more similar to the non-classical MHC class of proteins which show little or no allelic variation. The functions of the non-classical MHC Class I proteins, such as HLA-E, F, and G proteins, are unknown, although HLA-G may play a role in maternal/fetal immune interactions. Campbell, R.D. and Trousdale, J. *Immunology Today* 14:349 (1993).

17      Therefore, the HH protein appears to differ from MHC Class I molecules 25 in one important respect. Although it has maintained all of the structural hallmarks of MHC Class I molecules, it does not appear to be polymorphic and has presumably evolved a different function. This function appears to be participation in the control of body iron levels, for example, through the direct binding of free iron, binding of other iron-bound proteins, or signaling involved in regulation of iron levels. Iron-bound 30 proteins or other proteins involved in signaling could associate with the HH protein in a manner similar to  $\beta$ -2-microglobulin or could be bound in the peptide-binding region of the protein.

In addition, the protein could exert its effects by indirectly regulating iron adsorption through intercellular signaling, i.e., T-cell activation and subsequent specific cell proliferation via cytokine release. Alternatively, the expression of the HH protein could be regulated by iron or cytokines. As such, its interaction with other signaling molecules or receptors, such as Tfr, would be modulated. Directly related to our discovery of the gene responsible for HH is the data of de Sousa et al. (Immun Lett 39:105-111 (1994)). Analysis of previously constructed,  $\beta$ -2-microglobulin knockout mice indicated that mice homozygous for the defect progressively accumulated iron in a manner indistinguishable from human hemochromatosis. These mice also mimic an additional phenotype observed in HH patients, an abnormally low number of CD8+ T cells. Therefore,  $\beta$ -2-microglobulin knock-out mice possess two characteristics of human HH, iron loading of the internal organs and a defective T cell repertoire. Clearly, human  $\beta$ -2-microglobulin which maps to Chromosome 15 is not responsible for HH. However,  $\beta$ -2-microglobulin knock-out mice could phenocopy HH by preventing the associated murine HH homolog of cDNA 24 from assuming its functional structure and presentation on the surface of cells.

An important link between the HH protein and iron metabolism has been demonstrated. One of the major mechanisms by which cells and tissues uptake iron is via receptor-mediated endocytosis of iron-loaded transferrin. Transferrin itself binds to cell surface receptors (transferrin receptors, Tfr) which are responsible for iron uptake. Transferrin receptors are regulated by a variety of physiologic stimuli including cytokines and iron. It has now been demonstrated that the HH protein interacts directly with the Tfr in the plasma membrane. Labeling of cell-surface proteins by biotinylation followed by immunoprecipitation with HH protein specific antibodies demonstrates that Tfr physically interacts with the HH protein. Co-immunoprecipitation experiments by first immunoprecipitating with HH protein antibodies followed by Western blotting with Tfr antibodies corroborates these results. In contrast, the HH protein containing the 24d1 mutation fails to interact with the Tfr. The normal HH protein/Tfr interaction could regulate the activity of the Tfr to transport iron-bound transferrin either by change in receptor affinity, receptor number (including expression), or by a change in the rate of receptor internalization and recycling. The HH protein containing the 24d1 mutation

would then lead to unregulated iron metabolism and HH disease by failing to interact with the Tfr and modulating its activity.

Thus, the HH gene encodes a protein with striking similarity to MHC Class I proteins. The gene product has maintained a structural feature essential for proper and functional recognition of a chaperone protein ( $\beta$ -2-microglobulin) whose disruption in mice causes a phenocopy of HH disease. The HH protein interacts with  $\beta$ 2-microglobulin and the Tfr and is expressed on the cell-surface. When mutated as in 24d1, the interactions with  $\beta$ 2-microglobulin and Tfr are lost and the protein no longer is located on the cell-surface.

10

### 3. Protein Purification

The HH protein can be purified by one of several methods which have been selected based upon the molecular properties revealed by its sequence and its homology to MHC Class I molecules. Since the molecule possesses properties of an integral membrane protein, i.e. contains a transmembrane domain, the protein must first be isolated from the membrane fraction of cells using detergent solubilization. A variety of detergents useful for this purpose are well known in the art.

Once solubilized, the HH protein can be further purified by conventional affinity chromatography techniques. The conventional approaches of ion exchange, hydrophobic interaction, and/or organomercurial chromatographies can be utilized. These methodologies take advantage of natural features of the primary structure, such as: charged amino acid residues, hydrophobic transmembrane domains, and sulphydryl-containing cysteine residues, respectively. In the affinity chromatography approach use is made of immunoaffinity ligands or of the proposed interaction of the HH protein with  $\beta$ -2-microglobulin, calnexin or similar molecules. In the former, the affinity matrix consists of antibodies (polyclonal or monoclonal) specific to the HH protein coupled to an inert matrix. The production of antibodies specific to the HH protein are described in Section (III)(A)(3), entitled "Antibodies". In the latter method, various ligands which are proposed to specifically interact with the HH protein based on its homology with MHC Class I molecules could be immobilized on an inert matrix. For example,  $\beta$ -2-microglobulin,  $\beta$ -2-microglobulin-like molecules, or other specific proteins such as calnexin or calnexin-like molecules, and the like, or portions and/or fragments

thereof, can be utilized. General methods for preparation and use of affinity matrices are well known in the art.

Criteria for the determination of the purity of the HH protein include those standard to the field of protein chemistry. These include N-terminal amino acid 5 determination, one and two-dimensional polyacrylamide gel electrophoresis, and silver staining. The purified protein is useful for use in studies related to the determination of secondary and tertiary structure, as aid in drug design, and for *in vitro* study of the biological function of the molecule.

10 III. Applications

A. HH Screening

With knowledge of the primary mutation of the HH gene as disclosed herein, screening for presymptomatic homozygotes, including prenatal diagnosis, and screening for heterozygotes can be readily carried out.

15

1. General

There are at least four levels at which the diagnostic information from the HH gene can be used. The first is to assist in the medical diagnosis of a symptomatic patient. In this application, a patient with a high index of suspicion for being affected 20 with HH could be tested with the gene-based diagnostic. A positive result would show that the individual was homozygous for the common HH mutation. This would provide a rapid and non-invasive confirmation that the individual corresponded to the fraction of the population homozygous for this mutation. Such a result would help rule out other causes of iron overload in that individual. In the case of a heterozygote or compound 25 heterozygote for 24d1 and 24d2, this individual may also be affected with HH.

The second level of application would be in first degree relatives of newly diagnosed probands. Currently recommended medical practice is to screen all such first degree relatives, as they are at a higher risk for disease and, if identified, could benefit from therapeutic intervention.

30 The third level of screening would be in individuals afflicted with diseases that are known to be sequelae of HH disease. Such diseases include cirrhosis of the liver, diabetes, arthritis, reproductive dysfunction, and heart disease. It has been estimated, for

example, that as many as 1% of individuals with diabetes may be so afflicted because of HH disease. In addition, other conditions such as sporadic porphyria cutanea tarda can be screened for using an HH gene mutation diagnosis. When secondary to HH disease, some of the pathology of these diseases can be reversed upon phlebotomy therapy.

5 Furthermore, it has been disclosed that the potential for hemochromatosis interferes with the effectiveness of interferon treatment of hepatitis C (Bacon, B. Abstracts of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism 15-16 1995)). Therefore, it will be beneficial to perform screening with gene-based diagnostics in these disease populations.

10 The fourth level of screening is to screen the general population for homozygotes and, potentially, heterozygotes. Several cost-benefit analyses have suggested that there is value in such screenings for the identification of presymptomatic individuals. Once identified, such individuals could be targeted for preventative phlebotomy or treatment with the therapeutic compositions of the invention.

15

**2. Nucleic Acid Based Screening**

Individuals carrying mutations in the HH gene may be detected at either the DNA, the RNA, or the protein level using a variety of techniques that are well known in the art. The genomic DNA used for the diagnosis may be obtained from body cells, such 20 as those present in peripheral blood, urine, saliva, bucca, surgical specimen, and autopsy specimens. The DNA may be used directly or may be amplified enzymatically *in vitro* through use of PCR (Saiki et al. Science 239:487-491 (1988)) or other *in vitro* amplification methods such as the ligase chain reaction (LCR) (Wu and Wallace Genomics 4:560-569 (1989)), strand displacement amplification (SDA) (Walker et al. 25 Proc. Natl. Acad. Sci. U.S.A. 89:392-396 (1992)), self-sustained sequence replication (3SR) (Fahy et al. PCR Methods Appl. 1:25-33 (1992)), prior to mutation analysis. The methodology for preparing nucleic acids in a form that is suitable for mutation detection is well known in the art.

The detection of mutations in specific DNA sequences, such as the HH 30 gene, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy Lancet ii:910-912 (1978)), hybridization with

allele-specific oligonucleotide probes (Wallace et al. Nucl Acids Res 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al. Proc. Natl. Acad. Sci. U.S.A. 86:6230-6234 (1989)) or oligonucleotide arrays (Maskos and Southern Nucl Acids Res 21:2269-2270 (1993)), allele-specific PCR (Newton et al. Nucl Acids Res 17:2503-2516 (1989)), mismatch-repair detection (MRD) (Faham and Cox Genome Res 5:474-482 (1995)), binding of MutS protein (Wagner et al. Nucl Acids Res 23:3944-3948 (1995)), denaturing-gradient gel electrophoresis (DGGE) (Fisher and Lerman et al. Proc. Natl. Acad. Sci. U.S.A. 80:1579-1583 (1983)), single-strand-conformation-polymorphism detection (Orita et al. Genomics 5:874-879 (1983)), RNAase cleavage at mismatched base-pairs (Myers et al. Science 230:1242 (1985)), chemical (Cotton et al. Proc. Natl. Acad. Sci. U.S.A. 85:4397-4401 (1988)) or enzymatic (Youil et al. Proc. Natl. Acad. Sci. U.S.A. 92:87-91 (1995)) cleavage of heteroduplex DNA, methods based on allele specific primer extension (Syvänen et al. Genomics 8:684-692 (1990)), genetic bit analysis (GBA) (Nikiforov et al. Nucl Acids Res 22:4167-4175 (1994)), the oligonucleotide-ligation assay (OLA) (Landegren et al. Science 241:1077 (1988)), the allele-specific ligation chain reaction (LCR) (Barrany Proc. Natl. Acad. Sci. U.S.A. 88:189-193 (1991)), gap-LCR (Abravaya et al. Nucl Acids Res 23:675-682 (1995)), and radioactive and/or fluorescent DNA sequencing using standard procedures well known in the art.

In addition to the genotype described above, as described in co-pending PCT application WO 96/35802 published November 14, 1996, genotypes characterized by the presence of the alleles 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98 (denoted 3321-1:197 therein); 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091-1:148; 3216-1:221; 4072-2:170 (denoted 4072-2:148 therein); 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, alleles D6S258:199, D6S265:122, D6S105:124, D6S306:238, D6S464:206; and D6S1001:180, and/or alleles associates with the HHP-1, the HHP-19 or HHP-29 single base-pair polymorphisms can also be used to assist in the identification of an individual whose genome contains the common HH mutation. For example, the assessing step can be performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and

oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29, oligonucleotide primers flanking at least one of the microsatellite repeat alleles, or oligonucleotide primers for any combination of polymorphisms or microsatellite repeat alleles thereof.

5           Oligonucleotides useful in diagnostic assays are typically at least 8 consecutive nucleotides in length, and may range upwards of 18 nucleotides in length. Such oligonucleotides can be derived from either the HH genomic or cDNA sequences. Preferred oligonucleotides of at least 8 nucleotides in length include 1-46, 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080; 1083-1109; 1106-1304; 1301-10 1366; 1363-1386; 1389-1514; 1516-1778; 1773-1917; 1921-2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422; 2420-2464; 2465-2491; 2488-2568; 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-3042; 3420-3435; 3451-3708; 3703-3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978; 3974-3992; 3990-4157; 4153-4251; 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-4400; 4398-4436; 4444-4547; 4572-4714; 4709-4777; 5165-5397; 15 5394-6582; 5578-5696; 5691-5709; 5708-5773; 5773-5816; 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-6133; 6150-6296; 6292-6354; 6356-6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917; 6913-7027; 7023-7061; 7056-7124; 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-9037; 9486-9502; 9743-9811; 9808-9831; 9829-9866; 9862-9986; 9983-10075; 10072-10091; 10091-10195; 10247-10263; 10262-10300; 10299-10448; 20 10448-10539; 10547-10564; 10580-10612; 10608-10708; 10703-10721; 10716-10750; 10749-10774; 10774-10800; and 10796-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 9 nucleotides in length include 1-47; 47-124; 119-370; 364-395; 389-541; 537-647; 642-1005; 1000-1081; 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-1515; 1515-1918; 1920-2011; 2050-2147; 2153-2210; 25 2233-2369; 2366-2423; 2419-2465; 2464-2492; 2487-2569; 2871-2935; 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-3771; 3773-3841; 3839-3963; 3963-3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283; 4283-4334; 4336-4401; 4397-4437; 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-5710; 5707-5774; 5772-5817; 5817-5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134; 6149-6355; 6355-6556; 6554-6576; 6574-6793; 6787-30 7125; 7318-7508; 7881-8001; 7997-8073; 8072-8099; 8999-9038; 9485-9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987; 9982-10076; 10071-10092; 10090-10196; 10246-

10264; 10261-10301; 10298-10449; 10447-10540; 10546-10565; 10579-10751; 10748-10775; 10773-10801; and 10795-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 10 nucleotides in length include 1-48; 46-125; 118-1006; 999-1082; 1081-1111; 1104-1306; 1299-1368; 1361-1388; 1387-1516; 5 1514-1919; 1919-2012; 2049-2148; 2152-2211; 2232-2370 2365-2424; 2418-2466; 2463-2493; 2486-2570; 2870-2936; 2934-3003; 2998-3044; 3418-3437; 3449-3772; 3772-3842; 3838-3964; 3962-3994; 3988-4284; 4282-4335; 4335-4402; 4396-4438; 4442-4549; 4570-4779; 5163-5711; 5706-5775; 5771-5818; 5816-5851; 5867-6047; 6040-6077; 6071-6110; 6111-6135; 6148-6356; 6354-6577; 6573-7126; 7317-7509; 7880-8074; 8071-8100; 8998-10 9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093; 10089-10197; 10245-10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566; 10578-10752; 10747-10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 11 nucleotides in length include 1-49; 45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212; 2231-2371; 2364-15 2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-3438; 3448-3773; 3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403; 4395-4439; 4441-4550; 4569-4780; 5162-5712; 5705-5776; 5770-5819; 5815-5852; 5886-6111; 6100-6136; 6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101; 8997-9040; 9483-19 9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-10542; 10544-10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 12 nucleotides in length include 1-50, 44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213; 2230-2372; 2363-2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-3774; 3770-3844; 3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781; 5161-5713; 5704-25 5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-6579; 6571-7128; 7315-7511; 7878-8076; 8069-8102; 8996-9041; 9482-9506; 9739-10199; 10243-10267; 10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-10754; 10745-10778; and 10770-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 13 nucleotides in length include 1-51; 30 43-1391; 1384-1519; 1511-1922; 1916-2015; 2046-2151; 2149-2214; 2229-2469; 2460-2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-3967; 3959-4287; 4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821; 5813-5854; 5884-

6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544; 10542-10567; 10575-10779; and 10769-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 14 nucleotides in length include 1-52;

5 42-1392; 1383-1520; 1510-1923; 1915-2016; 2045-2152; 2148-2215; 2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-3776; 3768-3968; 3959-4288; 4278-4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822; 5812-5855; 5883-6114; 6107-6139; 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-8078; 8067-8104; 8994-9043; 9480-9508; 9737-10201; 10241-10454; 10442-10545; 10541-10568; and 10574-10825 of SEQ ID NO:1, 3, 10 5, or 7. Preferred oligonucleotides of at least 15 nucleotides in length include 1-53; 41-1393; 1382-1521; 1509-1924; 1914-2017; 2044-2153; 2147-2216; 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-3777; 3767-3969; 3958-4289; 4277-4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823; 5811-5856; 5882-6115; 6106-6140; 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-9044; 9479-9509; 9736-10202; 10240-10546; 10540-10569; 15 and 10573-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 16 nucleotides in length include 1-1394; 1381-1925; 1913-2018; 2043-2154; 2146-2217; 2226-2576; 2864-3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444; 4436-4555; 4564-4785; 5157-5857; 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-8106; 8992-9045; 9478-9510; 9735-10203; 10239-

20 10547; 10539-10570; and 10572-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 17 nucleotides in length include 1-1926; 1912-2019; 2042-2155; 2145-2218; 2225-2577; 2863-3051; 3411-3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786; 5156-5858; 5880-6117; 6104-6142; 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-9511; 9734-10204; 10238-10548; 10538-10571; and 25 10571-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 18 nucleotides in length include 1-2020; 2041-2156; 2144-2219; 2224-2578; 2862-3052; 3410-3780; 3764-4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118; 6103-6143; 6140-7134; 7309-7517; 7872-8108; 8990-9047; 9476-9512; 9733-10205; 10237-10549; 10537-10572; and 10570-10825 of SEQ ID 30 NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 8 nucleotides in length include 1-55; 55-251; 250-306; 310-376; 380-498; 500-528; 516-543; 541-578; 573-592; 590-609; 611-

648; 642-660; 664-717; 712-727; 725-763; 772-828; 813-874; 872-928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 9 nucleotides in length include 1-56;  
5 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 10 nucleotides in length include 1-57;  
10 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109; 2114-2202; and 2451-2471 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 11 nucleotides in length include 1-58;  
15 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185; 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-2110; 2113-2203; and 2450-2472 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 12 nucleotides in length include 1-  
20 255; 246-310; 306-380; 376-502; 496-596; 586-613; 607-664; 660-767; 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-1211; 1436-1487; 1478-1632; 1999-2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 13 nucleotides in length include 1-  
311; 305-381; 375-503; 495-614; 606-665; 659-768; 767-1051; 1049-1076; 1071-1121;  
25 1110-1187; 1181-1212; 1435-1633; 1998-2060; 2052-2205 and 2448-2474 of SEQ ID  
NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 14 nucleotides in length include 1-  
312; 304-382; 374-504; 494-615; 605-666; 658-769; 766-1052; 1048-1077; 1070-1188;  
1180-1213; 1434-1634; 1997-2061; 2051-2206; and 2447-2475 of SEQ ID NO:9, 10, 11  
30 or 12.

Preferred oligonucleotides of at least 15 nucleotides in length include 1-  
313; 303-383; 373-505; 493-616; 604-667; 657-770; 765-1053; 1047-1078; 1069-1189;

1179-1214; 1433-1635; 1996-2062; 2050-2207; and 2446-2476 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 16 nucleotides in length include 1-314; 302-384; 372-668; 656-771; 764-1054; 1046-1079; 1068-1190; 1178-1215; 1432-5 1636; 1995-2208; and 2445-2477 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 17 nucleotides in length include 1-315; 301-385; 371-669; 655-772; 763-1055; 1045-1080; 1067-1191; 1177-1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 18 nucleotides in length include 1-10 773; 762-1056; 1044-1081; 1066-1192; 1176-1217; 1430-1638; 1993-2210; and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

Such preferred oligonucleotides can also be used as part of an oligonucleotide pair, wherein the second member of the pair is any oligonucleotide of at least 8 consecutive nucleotides selected from SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, or 12.

15 It will be appreciated that such preferred oligonucleotides can be a part of a kit for detecting polymorphisms in the HH gene, especially for the detection of polymorphisms in HH DNA or RNA in a patient sample.

As will be appreciated, the mutation analysis may also be performed on samples of RNA by reverse transcription into cDNA therefrom. Furthermore, mutations 20 may also be detected at the protein level using antibodies specific for the mutant and normal HH protein, respectively. It may also be possible to base an HH mutation assay on altered cellular or subcellular localization of the mutant form of the HH protein.

### 3. Antibodies

25 As mentioned above, antibodies can also be used for the screening of the presence of the HH gene, the mutant HH gene, and the protein products therefrom. In addition, antibodies are useful in a variety of other contexts in accordance with the present invention. As will be appreciated, antibodies can be raised against various epitopes of the HH protein. Such antibodies can be utilized for the diagnosis of HH and, 30 in certain applications, targeting of affected tissues.

Thus, in accordance with another aspect of the present invention a kit is provided that is suitable for use in screening and assaying for the presence of the HH

gene by an immunoassay through use of an antibody which specifically binds to a gene product of the HH gene in combination with a reagent for detecting the binding of the antibody to the gene product.

Antibodies raised in accordance with the invention can also be utilized to  
5 provide extensive information on the characteristics of the protein and of the disease process and other valuable information which includes but is not limited to:

1. Antibodies can be used for the immunostaining of cells and tissues to determine the precise localization of the protein. Immunofluorescence and immuno-electron microscopy techniques which are well known in the art can be  
10 used for this purpose. Defects in the HH gene or in other genes which cause an altered localization of the HH protein are expected to be localizable by this method.
2. Antibodies to distinct isoforms of the HH protein (i.e., wild-type or mutant-specific antibodies) can be raised and used to detect the presence or  
15 absence of the wild-type or mutant gene products by immunoblotting (Western blotting) or other immunostaining methods. Such antibodies can also be utilized for therapeutic applications where, for example, binding to a mutant form of the HH protein reduces the consequences of the mutation.
3. Antibodies can also be used as tools for affinity purification of HH protein. Methods such as immunoprecipitation or column chromatography using immobilized antibodies are well known in the art and are further described in  
20 Section (II)(B)(3), entitled "Protein Purification" herein.
4. Immunoprecipitation with specific antibodies is useful in characterizing the biochemical properties of the HH protein. Modifications of the  
25 HH protein (i.e., phosphorylation, glycosylation, ubiquitization, and the like) can be detected through use of this method. Immunoprecipitation and Western blotting are also useful for the identification of associating molecules that are involved in signal transduction processes which regulate iron transport or other metabolic functions important in the HH disease process.
5. Antibodies can also be utilized in connection with the isolation and characterization of tissues and cells which express HH protein. For example, HH protein expressing cells can be isolated from peripheral blood, bone marrow, liver,  
30

and other tissues, or from cultured cells by fluorescence activated cell sorting (FACS) ("Antibodies" Cold Spring Harbor Press). Cells can be mixed with antibodies (primary antibodies) with or without conjugated dyes. If non-conjugated antibodies are used, a second dye-conjugated antibody (secondary antibody) which binds to the primary antibody can be added. This process allows 5 the specific staining of cells or tissues which express the HH protein.

Antibodies against the HH protein are prepared by several methods which include, but are not limited to:

1. The potentially immunogenic domains of the protein are predicted 10 from hydropathy and surface probability profiles. Then oligopeptides which span the predicted immunogenic sites are chemically synthesized. These oligopeptides can also be designed to contain the specific mutant amino acids to allow the detection of and discrimination between the mutant versus wild-type gene products. Rabbits or other animals are immunized with the synthesized 15 oligopeptides coupled to a carrier such as KLH to produce anti-HH protein polyclonal antibodies. Alternatively, monoclonal antibodies can be produced against the synthesized oligopeptides using conventional techniques that are well known in the art ("Antibodies" Cold Spring Harbor Press). Both *in vivo* and *in vitro* immunization techniques can be used. For therapeutic applications, 20 "humanized" monoclonal antibodies having human constant and variable regions are often preferred so as to minimize the immune response of a patient against the antibody. Such antibodies can be generated by immunizing transgenic animals which contain human immunoglobulin genes. See Jakobovits et al. Ann NY Acad Sci 764:525-535 (1995).
2. Antibodies can also be raised against expressed HH protein products 25 from cells. Such expression products can include the full length expression product or parts or fragments thereof. Expression can be accomplished using conventional expression systems, such as bacterial, baculovirus, yeast, mammalian, and other overexpression systems using conventional recombinant DNA techniques. The proteins can be expressed as fusion proteins with a histidine 30 tag, glutathione-S-transferase, or other moieties, or as nonfused proteins. Expressed proteins can be purified using conventional protein purification methods

or affinity purification methods that are well known in the art. Purified proteins are used as immunogens to generate polyclonal or monoclonal antibodies using methods similar to those described above for the generation of antipeptide antibodies.

5 In each of the techniques described above, once hybridoma cell lines are prepared, monoclonal antibodies can be made through conventional techniques of priming mice with pristane and interperitoneally injecting such mice with the hybrid cells to enable harvesting of the monoclonal antibodies from ascites fluid.

In connection with synthetic and semi-synthetic antibodies, such terms are  
10 intended to cover antibody fragments, isotype switched antibodies, humanized antibodies (mouse-human, human-mouse, and the like), hybrids, antibodies having plural specificities, fully synthetic antibody-like molecules, and the like.

B. Molecular Biology

15 1. Expression Systems

"Expression systems" refer to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. In order to effect transformation, the expression system may be included on a vector; however, the relevant  
20 DNA may then also be integrated into the host chromosome.

As used herein "cell", "cell line", and "cell culture" are used interchangeably and all such designations include progeny. Thus, "transformants" or "transformed cells" includes the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not  
25 be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny which have the same functionality as screened for in the originally transformed cell, are included. Where distinct designations are intended, it will be clear from the context.

In general terms, the production of a recombinant form of HH gene  
30 product typically involves the following:

First a DNA encoding the mature (used here to include all normal and mutant forms of the proteins) protein, the preprotein, or a fusion of the HH protein to an

additional sequence cleavable under controlled conditions such as treatment with peptidase to give an active protein, is obtained. If the sequence is uninterrupted by introns it is suitable for expression in any host. If there are introns, expression is obtainable in mammalian or other eukaryotic systems capable of processing them. This sequence 5 should be in excisable and recoverable form. The excised or recovered coding sequence is then placed in operable linkage with suitable control sequences in an expression vector. The construct is used to transform a suitable host, and the transformed host is cultured under selective conditions to effect the production of the recombinant HH protein. Optionally the HH protein is isolated from the medium or from the cells and purified as 10 described in Section (II)(B)(3), entitled "Protein Purification".

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences can be obtained by preparing suitable cDNA from cellular mRNA and manipulating the cDNA to obtain the complete sequence.

Alternatively, genomic fragments may be obtained and used directly in appropriate hosts. 15 The construction of expression vectors operable in a variety of hosts are made using appropriate replicons and control sequences, as set forth below. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors.

The control sequences, expression vectors, and transformation methods are 20 dependent on the type of host cell used to express the gene. Generally, prokaryotic, yeast, insect, or mammalian cells are presently useful as hosts. Prokaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins. However, eukaryotic cells, and, in particular, mammalian cells, are often preferable because of their processing capacity and post-translational processing of human proteins.

25 Prokaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, such as *Bacillus subtilis* and various species of *Pseudomonas* or other bacterial strains. In such prokaryotic systems, plasmid or bacteriophage vectors which contain origins of replication and control sequences compatible with the host are used. A wide variety of vectors for many prokaryotes are 30 known (Maniatis et al. Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982)); Sambrook et al. Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989));

Meth. Enzymology 68 (Academic Press, Orlando, Fla. (1979, 1983, 1987)); Pouwells et al. Cloning Vectors: A Laboratory Manual (Elsevier, Amsterdam (1987))). Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems, the tryptophan (trp) promoter system and the lambda derived PL promoter and N-gene ribosome binding, site, which has become useful as a portable control cassette (U.S. Patent No. 4,711,845). However, any available promoter system compatible with prokaryotes can be used (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)).

In addition to bacteria, eukaryotic microbes, such as yeast, may also be used as hosts. Laboratory strain *Saccharomyces cerevisiae* or Baker's yeast, is most often used although other strains are commonly available.

Vectors employing the 2 micron origin of replication and other plasmid vectors suitable for yeast expression are known (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. Additional promoters known in the art include the promoters for 3-phosphoglycerate kinase, and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. See Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987). It is also believed that terminator sequences at the 3' end of the coding sequences are desirable. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Many of the useful vectors contain control sequences derived from the enolase gene containing plasmid peno46 or the

LEU2 gene obtained from Yepl3, however, any vector containing a yeast compatible promoter, origin of replication, and other control sequences is suitable (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); *Meth. Enzymology supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)).

5           It is also, of course, possible to express genes encoding polypeptides in eukaryotic host cell cultures derived from multicellular organisms (Cruz and Patterson *Tissue Culture* (Academic Press, Orlando (1973)); *Meth. Enzymology supra.* (1979); Freshney *Culture of Animal Cells: A Manual of Basic Techniques* (2d ed., Alan R. Liss, NY (1987))). Useful host cell lines include murine myelomas N51, VERO and HeT

10          cells, SF9 or other insect cell lines, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and later promoters from Simian Virus 40 (SV 40), or other viral promoters such as those from polyoma, adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, herpes virus family (such

15          as cytomegalovirus, herpes simplex virus, or Epstein-Barr virus), or immunoglobulin promoters and heat shock promoters (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); *Meth. Enzymology supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)). In addition, regulated promoters, such as metallothioneine (i.e., MT-1 and MT-2), glucocorticoid, or antibiotic gene "switches" can be used.

20          General aspects of mammalian cell host system transformations have been described by Axel (U.S. Patent No. 4,399,216). It now appears also that "enhancer" regions are important in optimizing transformation. Generally, "enhancer" regions are sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a

25          common mechanism for DNA replication in eukaryotes. Plant cells are also now available as hosts, and control sequences compatible with plant cells such as the nopaline synthase promoter and polyadenylation signal sequences are available (Pouwells et al. *supra.* (1987); *Meth Enzymology 118* (Academic Press, Orlando (1987)); Gelvin et al. *Plant Molecular Biology Manual* (Kluwer Academic Publishers, Dordrecht (1990))).

30          Depending on the host cell used, transformation is done using standard techniques appropriate to such cells (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); *Meth. Enzymology supra.* (1979, 1983, 1987); U.S. Patent No. 4,399,216; *Meth*

Enzymology *supra* (1986); Gelvin et al. *supra*. (1990)). Such techniques include, without limitation, calcium treatment employing calcium chloride for prokaryotes or other cells which contain substantial cell wall barriers; infection with *Agrobacterium tumefaciens* for certain plant cells; calcium phosphate precipitation, DEAE, lipid transfection systems 5 (such as Lipofectin™ and Lipofectamine™), and electroporation methods for mammalian cells without cell walls, and, microprojectile bombardment for many cells including, plant cells. In addition, DNA may be delivered by viral delivery systems such as retroviruses or the herpes family, adenoviruses, baculoviruses, or semliki forest virus, as appropriate for the species of cell line chosen.

10

### C. Function Experiments

Expression systems for the HH gene product, for example as described in the previous Section, allow for the study of the function of the HH gene product, in either normal or wild-type form and/or mutated form. Such analyses are useful in providing 15 insight into the disease causing process that is derived from mutations in the gene.

Judging from the sequence similarity of the HH gene to MHC Class I molecules, the HH gene product is expected to be expressed on cell surfaces. As discussed earlier, the HH protein is known to be expressed on the surfaces of cells of tissues from normal individuals and on cells transfected with the non-mutated gene.

20

#### 1. Analysis of Iron Metabolism

The HH gene (mutated, normal, or wild-type) can be utilized in an assay of iron metabolism. The gene is expressed, with or without any accompanying molecules, in cells lines or primary cells derived from HH patients, healthy individuals, or cells from 25 other organisms (such as rodents, insects, bacteria, amphibians, etc.). Uptake of iron by these cells is measured, for example through the use of radioactive isotopes.

Methodology for assessing affinity, binding , and transport of I<sup>125</sup>-transferrin binding to the Tfr have been described in detail (Mulford and Lodish, *J. Biol. Chem.* 263(11):5455-5461 (1988)). It can be predicted that the unmutated HH protein would modulate the 30 activity of the Tfr whereas, the HH protein containing the 24d1 mutation would be unable to modulate the Tfr by virtue of its failure to interact with and modulate other molecules important to iron metabolism such as iron transport "channels". In such cases the 24d1

mutation could be expected to result in unregulated iron transport. Further, binding of iron to the HH gene product can also be measured. Such experiments assist in assessing the role of the HH gene and HH gene product in iron uptake, binding, and transport by and in cells.

5

## 2. Analysis of Lead and other Metal Metabolism

Increased accumulation of lead and certain other metals has been reported in HH homozygotes. See Barton et al. *J Lab Clin Med* 124:193-198 (1994). As discussed above in connection with iron, the metabolism of lead and other metals can be  
10 assessed.

## 3. Analysis of MHC Function

As discussed above, the HH gene products share significant structural similarity with Class I MHC molecules. Class I MHC molecules have several well  
15 known and measurable activities. Expression of the HH gene products through the use of appropriate expression systems allows for the analysis of whether the HH gene products possess similar activities.

### a. Peptide Presentation Assay

20 Peptide presentation can be measured through use of a number of well known techniques. One method is to express the HH gene product on the surface of mammalian cells. Thereafter, the HH gene product can be purified from the cell surface analyzed for peptide binding, through, for example, high performance liquid chromatography (HPLC) after elution. Amino acid sequences of any bound peptides can  
25 be determined through conventional sequencing techniques (i.e., Edman degradation).

Another technique to analyze peptide presentation is to express the HH gene product on a cell that does not conventionally possess peptide presentation activity (i.e., *Drosophila melanogaster* derived Schneider cells. See Rammensee et al. *Ann Rev Immunol* 11:213-244 (1993). In such a system, MHC Class I molecules are expressed on  
30 the cell surface "empty" (i.e., without any bound peptide). Thereafter, through the addition of a particular peptide to the system, the binding of the particular peptide to the

empty Class I molecule can be measured. See Rammensee et al. *supra*. (1993). A similar assay can be utilized in connection with the HH gene products.

b. T-cell Activation and Activation of Other Cells

5 It has been observed that, in at least some HH patients, there is a decrease in the numbers of CD8+ T-cells. (Reimao et al. *C.R. Acad Sci Paris* 313:481 (1991)). This is a striking phenotype as a similar phenotype is associated with the  $\beta$ -2-microglobulin knock-out mice (Koller et al. *Science* 248:1127 (1990); Zijlstra et al. *Nature* 344:742 (1990)). The role of MHC Class I proteins in the development of the T-cell repertoire is well documented. See Doherty *Adv Immun* 27:51 (1979). Animals lacking CD8+ T-cells would be expected to be more susceptible to a variety of infections and cancers. The  $\beta$ -2-microglobulin knock-out mice have been kept under pathogen-free conditions so that the long-term consequences of lacking CD8+ T-cells has not been ascertained. Humans, however, when deficient in CD8+ T-cells, have shown several 10 conditions that are consistent with a compromised immune system, most notably a 200 fold increase in the incidence of hepatocellular carcinomas. See Niederau et al. *N Engl J Med* 313:1256 (1985).

Further, it is known that Class I MHC molecules are involved in the activation and differentiation of T-cells through the interaction between MHC molecules 20 and  $\alpha/\beta$  or  $\gamma/\delta$  T-cell receptors. Methods to measure T-cell activation are well known in the art. See Schild et al. *Cell* 76:29-37 (1994) and others). Signaling events in other cell types can also be measured. See Leibson *Immunity* 3:5-8 (1995). Thus, expression of the HH gene product on cells that are co-cultured with various T-cells can be used as an assay to measure T-cell differentiation and activation induced by the HH gene product. 25 In particular, as mentioned above, differentiation and activation of CD8+ T-cells can be determined and measured and the role of the normal and mutant HH gene and gene products therein assessed.

c. Identification of Downstream Cells

30 The assays described above can be utilized to monitor and determine other cellular interactions between "downstream cells" and the HH gene protein product. Cells

that interact with the HH gene protein product can be analyzed for uptake of iron and iron binding as described above.

d. Determination of Cellular Markers

5 As discussed above, the HH protein is expressed on the surface of cells. As such, the HH gene product can be utilized as a cell-surface marker and detected through the use of FACS or other means utilizing antibodies to the HH protein. The failure of the HH protein with the 24d1 mutation to be presented on cell surfaces provides the opportunity for use as a non-DNA based diagnostic for HH disease.

10

D. Therapeutics

Identification of the HH gene and its gene product also has therapeutic implications. Indeed, one of the major aims of the present invention is the development of therapies to circumvent or overcome the defect leading to HH disease. Envisioned are 15 pharmacological, protein replacement, antibody therapy, and gene therapy approaches. In addition, the development of animal models useful for developing therapies and for understanding the molecular mechanisms of HH disease are envisioned.

Peptide binding domains of MHC molecules have ligands, or are known to bind ligands, and we expect that the HH protein may directly bind iron or other metals or 20 bind to a ligand (such as a peptide) that binds iron or other metals. Therefore, we expect that the HH protein represents a new approach to iron and other metal chelation, which may be useful, in addition to its role in iron overload in HH disease, in a variety of other diseases and conditions that are secondary to other disease interventions, including, without limitation, transfusions, thalassaemias, and hemolytic anemias. Delivery of the 25 HH protein or parts thereof, or its ligand by either gene therapy or through protein replacement represents a new approach to metal chelation or iron modulatory agents.

Further, because molecules that bind to iron or other metals, we envision that the approach can be utilized for chelation or sequestration of metals, such as copper, lead, zinc, cadmium, or other toxic moieties. Further, since iron is a catalyst for 30 oxidative processes that are known to be deleterious in multiple biological systems, including, without limitation, vascular disease, inflammation, atherosclerosis, lung injury,

ischemia, and the like, we envision that the HH protein and/or fragments thereof, including ligands and fragments thereof, can be utilized in anti-oxidative therapies.

An additional aspect of HH disease and iron overload disease is that hepatic iron concentration has been shown to correlate with non-response to  $\alpha$ -interferon treatment for chronic hepatitis. See Van Tiel et al. *J Hepatology* 20:410-415 (1994) and Olynyk et al. *Gastroenterology* 108:1104-1109 (1995). Thus, the HH protein and/or fragments or ligands thereto can be utilized in the lowering of hepatic iron levels so as to facilitate increased response to  $\alpha$ -interferon in the treatment of these diseases.

10

### 1. Pharmacological

In the pharmacological approach, drugs which circumvent or overcome the defective HH gene function are sought. In this approach modulation of HH gene function can be accomplished by agents or drugs which are designed to interact with different aspects of the HH protein structure or function or which mimic the HH protein interaction with other molecules such as the Tfr. For example, a drug, antibody or other modulating protein (i.e.  $\beta$ -2-microglobulin or calnexin or similarly acting molecules or parts thereof) could be designed to bind to the HH protein and correct a defective structure.

Alternatively, a drug might bind to a specific functional residue(s) thereby, increasing or decreasing the affinity for ligand, substrate or cofactor such as Tfr. The assay for such a compound would be to promote or inhibit an interaction between the HH protein and the Tfr or similar molecule or could be a measure of Tfr turnover or endocytosis.

Efficacy of a drug or agent can be identified in a screening program in which modulation is monitored in *in vitro* cell systems. Indeed, the present invention provides for host cell systems which express various mutant HH proteins (especially the 24d1 and 24d2 mutations noted in this application) and are suited for use as primary screening systems. Candidate drugs can be evaluated by incubation with these cells and measuring cellular functions dependent on the HH gene or by measuring proper HH protein folding or processing. Such assays might also entail measuring receptor-like activity, iron transport and metabolism, gene transcription or other upstream or downstream biological function as dictated by studies of HH gene function.

Alternatively, cell-free systems can also be utilized. Purified HH protein can be reconstituted into artificial membranes or vesicles and drugs screened in a cell-free system. Such systems are often more convenient and are inherently more amenable to high throughput types of screening and automation.

5 A variety of drugs and other therapeutic agents have been proposed as useful in the treatment of HH disease and other iron or other metal overload type diseases. *See, for example,* Great Britain Patent Application No. 2,293,269 A, assigned to Merck Sharp & Dohme Ltd., World Patent Application No. WO 95/16663, assigned to Ciba Geigy AG, German Patent Application No. 4,327,226 A1, assigned to Hoechst AG,

10 10 World Patent Application No. WO 94/21243, assigned to the University of Nebraska, Canadian Patent Application No. 2,115,224 A, assigned to Bayer Corp., Miles Inc., and others, Canadian Patent Application No. 2,115,222 A, assigned to Bayer Corp., Miles Inc., and others, U.S. Patent No. 5,385,918 and Canadian Patent Application No.

15 15 2,115,221 A, assigned to Bayer Corp., Miles Inc., and others, World Patent Application No. WO 94/11367, assigned to Ciba Geigy AG and the University of Florida, World Patent Application No. WO 94/01463, assigned to the University of British Columbia, U.S. Patent No. 5,256,676, assigned to British Technology Group Ltd., U.S. Patent No. 5,420,008, assigned to Oriental Yeast Co. Ltd., World Patent Application No. WO 94/04186, U.S. Patent No. 5,075,469, assigned to Yissum Research and Development

20 20 Co., European Patent Application No. 346,281, assigned to Ciba Geigy AG, European Patent Application No. 315,434, assigned to Yissum Research and Development Co., U.S. Patent Nos. 5,424,057, 5,328,992, and 5,185,368, assigned to Ciba Geigy AG, U.S. Patent Nos. 5,104,865, 4,912,118, 4,863,913, and 4,666,927, assigned to National Research and Development Corp., DD Patent Application No. 208,609, assigned to Akad

25 25 Wissenschaft, and U.S. Patent No. 4,434,156, assigned to the Salk Institute for Biological Studies. The invention is useful for the screening of such proposed drugs or other therapeutic agents for specific activity in HH disease models, assays, and design of molecules based thereon.

30 30 *In vivo* testing of HH disease-modifying compounds is also required as a confirmation of activity observed in the *in vitro* assays. Animal models of HH disease are envisioned and discussed in the section entitled "Animal Models", below, in the present application.

Drugs can be designed to modulate HH gene and HH protein activity from knowledge of the structure and function correlations of HH protein and from knowledge of the specific defect in various HH mutant proteins. For this, rational drug design by use of X-ray crystallography, computer-aided molecular modeling (CAMM), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can further focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with and modify the HH protein activity. Such structures may be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al., *Genetically Engineered Human Therapeutic Drugs*,  
5 Stockton Press, New York (1988). Further, combinatorial libraries can be designed,  
10 synthesized and used in screening programs.

The present invention application also envisions that the treatment of HH disease can take the form of modulation of another protein or step in the pathway in which the HH gene or its protein product participates in order to correct the physiological  
15 abnormality. Without being limited to any one theory, Tfr may be the appropriate target for therapeutic treatments for HH. Furthermore, as an MHC-like molecule one could envision that the HH protein acts as a receptor or modulator for iron-binding or iron-regulating molecules. As such intracellular signalling or transport functions could be affected by alterations in HH protein function. Such functions and their effector  
20 molecules would also be targets for HH disease-modifying therapies.

In order to administer therapeutic agents based on, or derived from, the present invention, it will be appreciated that suitable carriers, excipients, and other agents may be incorporated into the formulations to provide improved transfer, delivery, tolerance, and the like.

25 A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, (15th Edition, Mack Publishing Company, Easton, Pennsylvania (1975)), particularly Chapter 87, by Blaug, Seymour, therein. These formulations include for example, powders, pastes, ointments, jelly, waxes, oils, lipids, anhydrous absorption bases, oil-in-water or  
30 water-in-oil emulsions, emulsions carbowax (polyethylene glycols of a variety of molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.

Any of the foregoing formulations may be appropriate in treatments and therapies in accordance with the present invention, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible.

5

## 2. Protein Replacement Therapy

The present invention also relates to the use of polypeptide or protein replacement therapy for those individuals determined to have a defective HH gene.

Treatment of HH disease could be performed by replacing the defective HH protein with  
10 normal protein or its functional equivalent in therapeutic amounts.

HH polypeptide can be prepared for therapy by any of several conventional procedures. First, HH protein can be produced by cloning the HH cDNA into an appropriate expression vector, expressing the HH gene product from this vector in an *in vitro* expression system (cell-free or cell-based) and isolating the HH protein from the  
15 medium or cells of the expression system. General expression vectors and systems are well known in the art. In addition, the invention envisions the potential need to express a stable form of the HH protein in order to obtain high yields and obtain a form readily amenable to intravenous administration. Stable high yield expression of proteins have been achieved through systems utilizing lipid-linked forms of proteins as described in  
20 Wettstein et al. J Exp Med 174:219-228 (1991) and Lin et al. Science 249:677-679 (1990).

HH protein or portions thereof can be prepared synthetically.

Alternatively, the HH protein can be prepared from total protein samples by affinity chromatography. Sources would include tissues expressing normal HH protein, *in vitro*  
25 systems (outlined above), or synthetic materials. The affinity matrix would consist of antibodies (polyclonal or monoclonal) coupled to an inert matrix. In addition, various ligands which specifically interact with the HH protein could be immobilized on an inert matrix. For example,  $\beta$ -2-microglobulin or portions thereof,  $\beta$ -2-microglobulin-like molecules, or other specific proteins such as calnexin and calnexin-like molecules or  
30 portions thereof. General methods for preparation and use of affinity matrices are well known in the art.

Protein replacement therapy requires that HH protein be administered in an appropriate formulation. The HH protein can be formulated in conventional ways standard to the art for the administration of protein substances. Delivery may require packaging in lipid-containing vesicles (such as Lipofectin™ or other cationic or anionic lipid or certain surfactant proteins) that facilitate incorporation into the cell membrane. The HH protein formulations can be delivered to affected tissues by different methods depending on the affected tissue. For example, iron absorption is initiated in the GI tract. Therefore, delivery by catheter or other means to bypass the stomach would be desirable. In other tissues, IV delivery will be the most direct approach.

10

### 3. Gene Therapy

Gene therapy utilizing recombinant DNA technology to deliver the normal form of the HH gene into patient cells or vectors which will supply the patient with gene product *in vivo* is also contemplated within the scope of the present invention. In gene therapy of HH disease, a normal version of the HH gene is delivered to affected tissue(s) in a form and amount such that the correct gene is expressed and will prepare sufficient quantities of HH protein to reverse the effects of the mutated HH gene. Current approaches to gene therapy include viral vectors, cell-based delivery systems and delivery agents. Further, *ex vivo* gene therapy could also be useful. In *ex vivo* gene therapy, cells (either autologous or otherwise) are transfected with the normal HH gene or a portion thereof and implanted or otherwise delivered into the patient. Such cells thereafter express the normal HH gene product *in vivo* and would be expected to assist a patient with HH disease in avoiding iron overload normally associated with HH disease. *Ex vivo* gene therapy is described in U.S. Patent No. 5,399,346 to Anderson et al., the disclosure of which is hereby incorporated by reference in its entirety. Approaches to gene therapy are discussed below:

#### a. Viral Vectors

Retroviruses are often considered the preferred vector for somatic gene therapy. They provide high efficiency infection, stable integration and stable expression (Friedman, T. Progress Toward Human Gene Therapy. Science 244:1275 (1989)). The full length HH gene cDNA or portions thereof can be cloned into a retroviral vector

driven by its endogenous promoter or from the retroviral LTR. Delivery of the virus could be accomplished by direct implantation of virus directly into the affected tissue.

Other delivery systems which can be utilized include adenovirus, adeno-associated virus (AAV), vaccinia virus, bovine papilloma virus or members of the 5 herpes virus group such as Epstein-Barr virus. Viruses with tropism to the gut and viruses engineered with tissue specific promoters are also envisioned. Viruses can be, and preferably are, replication deficient.

b. Cell-based Delivery

10 Much work has been performed in recent years regarding producing transgenic cells possessing therapeutic genes. Such cells could be directly implanted or implanted within a membrane-based matrix. For these purposes, many cell types would suffice but cells particularly derived from the target organs such as gut or liver are particularly useful. Examples include fetal liver or fetal gut epithelial cells.

15

c. Non-viral gene transfer

Other methods of inserting the HH gene into the appropriate tissues may also be productive. Many of these agents, however, are of lower efficiency than viral vectors and would potentially require infection *in vitro*, selection of transfectants, and 20 reimplantation. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. A particularly attractive idea is the use of liposomes (i.e., LIPOFECTIN™), which might be possible to carry out *in vivo*. Synthetic cationic lipids and DNA conjugates also appear to show some promise and may increase the efficiency and ease of carrying out this approach.

25

4. Animal Models

The generation of a mouse or other animal model of HH disease is important for both an understanding the biology of the disease but also for testing of potential therapies. Currently only a single animal model of HH disease exists. As was 30 demonstrated by de Sousa et al. (Immunol. Letts 39:105-111 (1994)) and Rothenberg and Voland (Proc. Natl. Acad. Sci. U.S.A. 93:1529-1534 (1996)) it is possible to develop a model of HH disease by interfering with the normal expression of  $\beta$ 2-microglobulin.  $\beta$ 2-

microglobulin is necessary for the proper folding and surface presentation of MHC class I molecules. Mice with a disrupted  $\beta$ 2-microglobulin gene were created that do not express  $\beta$ 2-microglobulin protein on the surface of most cells. Mice with this mutation possess almost no CD8+ cytotoxic T lymphocytes and develop progressive hepatic iron overload 5 similar to HH disease. This model is somewhat limited in its representation of HH disease in humans as  $\beta$ 2-microglobulin serves as a chaperone-like molecule for most, if not all, MHC I molecules thereby, affecting more biological systems than just those anticipated to be affected by disruption of the HH gene.

This invention envisions the creation of a more specific animal model of 10 HH disease by inactivation of the homologous HH gene in a number of species including mice, rats, pigs, and primates. These models will be novel in that targeting the homologous HH gene alone will more specifically represent the diseases as described in humans.

Techniques for specifically inactivating genes by homologous recombination 15 in embryonic stem cells (ES cells) have been described (Capecci Science 244:1288 (1989)). More specifically, as isogenic SvJ-129 mouse genomic BAC library can be screened with a human HH gene cDNA probe. The resultant clones are then sequenced to ensure sequence identity to the house HH gene homologue cDNA. A targeting vector is then constructed from the mouse genomic DNA consisting of two approximately 3 Kb 20 mouse HH gene genomic fragments as 5' and 3' arms. These arms would be chosen to flank a region critical to the function of the HH gene product, such as exon 4 (the immunoglobulin-like region which contains the proposed critical  $\beta$ 2-microglobulin interactive domain and essential disulfide linkage). However, other regions such as the initiation codon in exon 1 or membrane-proximal regions could also be targeted. In place 25 of the exon 4 region would be placed a neomycin resistance gene under the control of the phosphoglycerate kinase (pgk 1) promoter. The 5' arm of the vector is flanked externally by the pgk 1-herpes thymidine kinase gene for negative selection.

The targeting vector is then transfected into R1 ES cells and the transfectants subjected to positive and negative selection (G418 and ganciclovir, 30 respectively). PCR is then used to screen surviving colonies for the desired homologous recombinations. These are confirmed by Southern blot analysis.

Subsequently, several mutant clones are picked and injected into C57BL/6 blastocysts to produce high-percentage chimeric animals. These are then mated to C57BL/6 females. Heterozygous offspring are then mated to produce homozygous mutants. These offspring can then be tested for the HH gene mutation by Southern blot analysis. In addition, these animals are tested by RT-PCR to assess whether the targeted homologous recombination results in ablation of HH gene mRNA. These results can be confirmed by Northern blot analysis and RNase protection assays.

Once established, the HH gene -/- mice can be studied for development of HH-like disease and also be utilized to examine which tissues and cell types are involved in the disease process. These animals can also be used to introduce the mutant or normal human HH gene or for introduction of the homologous gene to that species and containing the 24d1 or other HH disease-causing mutations. Methods for these transgenic procedures are well known to those versed in the art and have been described by Murphy and Carter, *Transgenesis Techniques*, Humana Press, 1993. Alternatively, homologous recombination procedures similar to those described above can be utilized to introduce the 24d1 or 24d2 mutations directly into the endogenous mouse gene.

##### 5. Down Regulation of the HH Gene or HH Gene Product

In certain therapeutic applications, it is desirable to down regulate the expression and/or function of the HH gene, the mutant HH gene, the HH protein, or the mutant HH protein. For example, down regulation of the normal HH gene or the normal HH protein is desirable in situations where iron is underaccumulated in the body, for example in certain anemias (i.e., thalassaemias, hemolytic anemias, transfusions). On the other hand, down regulation of the mutant HH gene or the HH protein is desirable in situations where iron is overaccumulated in the body.

As discussed above in the Section entitled "Antibodies," antibodies specific to the normal or the mutant HH protein can be prepared. Such antibodies can be used therapeutically in HH disease. For example, to block the action of the mutant or normal HH gene if the function associated with the mutant protein is an upregulation of the normal HH protein function and leads to an overaccumulation of iron in the body, as mentioned above. Similarly, antibodies can be used therapeutically to block action of an HH protein that is causing an underaccumulation of iron in the body.

In a similar manner, the HH gene, either in normal or in a mutant form, can be downregulated through the use of antisense oligonucleotides directed against the gene or its transcripts. A similar strategy can be utilized as discussed above in connection with antibodies. For a particularly valuable review of the design

5 considerations and use of antisense oligonucleotides, see Uhlmann et al. Chemical Reviews 90:543-584 (1990) the disclosure of which is hereby incorporated by reference. The antisense oligonucleotides of the present invention may be synthesized by any of the known chemical oligonucleotide synthesis methods. Such methods are generally described, for example, in Winnacker From Genes to Clones: Introduction to Gene

10 Technology, VCH Verlagsgesellschaft mhH (H. Ibelgaufs trans. 1987). Antisense oligonucleotides are most advantageously prepared by utilizing any of the commercially available, automated nucleic acid synthesizers. One such device, the Applied Biosystems 380B DNA Synthesizer, utilizes  $\beta$ -cyanoethyl phosphoramidite chemistry.

Since the complete nucleotide synthesis of DNA complementary to the HH gene and the mutant HH genes' mRNA transcript is known, antisense oligonucleotides hybridizable with any portion of such transcripts may be prepared by oligonucleotide synthesis methods known to those skilled in the art. While any length oligonucleotide may be utilized in the practice of the invention, sequences shorter than 12 bases may be less specific in hybridizing to the target mRNA, may be more easily destroyed by

15 enzymatic digestion, and may be destabilized by enzymatic digestion. Hence, oligonucleotides having 12 or more nucleotides are preferred. Long sequences, particularly sequences longer than about 40 nucleotides, may be somewhat less effective in inhibiting translation because of decreased uptake by the target cell. Thus, oligomers of 12-40 nucleotides are preferred, more preferably 15-30 nucleotides, most preferably

20 18-26 nucleotides. Sequences of 18-24 nucleotides are most particularly preferred.

25

#### ILLUSTRATIVE EXAMPLES

The following examples are provided to illustrate certain aspects of the present invention and not intended as limiting the subject matter thereof:

**Example 1 HH Diagnostic: OLA Assay**

As discussed above, the oligonucleotide ligation assay (OLA) (Nickerson, D.A. et al. *Proc Natl Acad Sci USA* 87:8923-8927 (1990)) is highly effective for detecting single nucleotide changes in DNA and RNA, such as the 24d1, 24d2, and 24d7 mutations or sequence variations. Thus, in accordance with the present invention, there is provided an assay kit to detect mutations in the HH gene through use of an OLA assay.

In the OLA assay, a sample of DNA or cDNA reverse transcribed from RNA is amplified, generally through use of polymerase chain reaction (PCR) amplification, followed by ligation with upstream and downstream oligonucleotides specific to either side of the mutation sought to be assayed. Either the upstream or the downstream oligonucleotide includes a base complementary to the mutated or normal allele and the upstream or downstream oligonucleotide is labeled to enable detection of hybridization to the variant base.

Oligonucleotides complementary to the upstream or downstream sequence of the DNA or RNA in the sample, plus the mutated or normal allele, are ordinarily utilized in parallel so that detection of heterozygosity and homozygosity is possible.

Generally, the kit includes reaction chambers in which to conduct amplification of DNA or reverse transcribed RNA from patient samples, ligation reactions, and detection of ligation products. One exemplary reaction chamber that can be utilized to conduct such steps is a microtiter plate. The kit can be provided with or without reagents and oligonucleotides for use in the assay. In general, however, in a preferred embodiment, the kit is provided with oligonucleotides for amplifying at least a portion of a patient's DNA or RNA across the mutation that is to be detected. As will be appreciated, oligonucleotide primers can be designed to virtually any portion of the DNA or transcription products flanking the nucleotide sought to be assayed, up to and including, and in some cases even exceeding 500 bases away from the mutation to be assayed. Further, ligation oligonucleotides can be designed in a variety of lengths.

Samples (either DNA or reverse transcribed RNA) are placed into the reaction vessel(s) with appropriate primers, nucleotides, buffers, and salts and subjected to PCR amplification. The PCR products are then assayed for single base mutations using OLA.

Suitable genomic DNA-containing samples from patients can be readily obtained and the DNA extracted therefrom using conventional techniques. For example, DNA can be isolated and prepared in accordance with the method described in Dracopoli, N. et al. eds. Current Protocols in Human Genetics (J. Wiley & Sons, New York 5 (1994)), the disclosure of which is hereby incorporated by reference in its entirety. Most typically, a blood sample, a buccal swab, a hair follicle preparation, or a nasal aspirate is used as a source of cells to provide the DNA.

Alternatively, RNA from an individual (i.e., freshly transcribed or messenger RNA) can be easily utilized in accordance with the present invention for the 10 detection of the selected base mutation. Total RNA from an individual can be isolated according to the procedure outlined in Sambrook, J. et al. Molecular Cloning - A Laboratory Manual (2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989)) the disclosure of which is hereby incorporated by reference.

When using either DNA or RNA samples for the detection of base 15 mutations in an OLA assay, the patient DNA or reverse transcribed RNA is first amplified, followed by assaying for ligation. In a preferred embodiment, the amplification primers for detecting the 24d1 mutation in DNA are shown in Figure 5 and labeled 24d1.P1 (SEQ ID NO:13) and 24d1.P2 (SEQ ID NO:14), designed as shown in Figure 6. Also on Figure 5, the oligonucleotides used in the sequence determination by 20 OLA for 24d1 are designated 24d1.A (SEQ ID NO:15), 24d1.B (SEQ ID NO:16), and 24d1.X (SEQ ID NO:17). As indicated in the sequences shown, "bio" indicates biotin coupling, "p" indicates 5'-phosphate, and "dig" indicates coupled digoxigenin. It will be appreciated that the binding of biotin and digoxigenin can be reversed. In other words, digoxigenin can be bound to the 5' end of oligonucleotides 24d1.A and 24d1.B and biotin 25 can be bound to the 3' end of the 24d1.X oligonucleotide.

The use of RNA, as opposed to DNA, follows essentially an identical approach: the RNA is isolated and after reverse transcription the characteristic base mutation can be detected as described above. In order to perform PCR amplification of the RNA prior to OLA assay, the following oligonucleotide primers are preferably 30 utilized:

**Forward Primer**

24d1.P3      CTG AAA GGG TGG GAT CAC AT      (SEQ ID NO:18)

**Reverse Primer**

24d1.P4      CAA GGA GTT CGT CAG GCA AT      (SEQ ID NO:19)

5                In amplification, a solution containing the DNA sample (obtained either directly or through reverse transcription of RNA) is mixed with an aliquot of each of dATP, dCTP, dGTP and dTTP (i.e., Pharmacia LKB Biotechnology, NJ), an aliquot of each of the DNA specific PCR primers, an aliquot of *Taq* polymerase (i.e., Promega, WI), and an aliquot of PCR buffer, including MgCl<sub>2</sub> (i.e., Promega) to a final volume.

10               Followed by pre-denaturation (i.e., at 95°C for 7 minutes), PCR is carried out in a DNA thermal cycler (i.e., Perkin-Elmer Cetus, CT) with repetitive cycles of annealing, extension, and denaturation. As will be appreciated, such steps can be modified to optimize the PCR amplification for any particular reaction, however, exemplary conditions utilized include denaturation at 95°C for 1 minute, annealing at 55°C for 1

15               minute, and extension at 72°C for 4 minutes, respectively, for 30 cycles. Further details of the PCR technique can be found in Erlich, "PCR Technology," Stockton Press (1989) and U.S. Patent No. 4,683,202, the disclosure of which is incorporated herein by reference.

Following PCR amplification, the PCR products are subjected to a ligation assay. Generally, ligation of the oligonucleotides requires a 5'-phosphate and a 3'-OH held in proximity by annealing to a complementary DNA strand (i.e., the PCR product), ligation buffer, and DNA ligase. A phosphodiester bond is formed through the reaction. If, however, there is a sequence dissimilarity at the point of ligation, ligation will not be accomplished and no phosphodiester bond will be formed.

25               In a preferred assay, two ligation oligonucleotides are utilized (i.e., such as the ligation oligonucleotides mentioned above for the detection of the 24d1 mutation (SEQ ID NO:15 and SEQ ID NO:17 for detection of the G allele or SEQ ID NO:16 and SEQ ID NO:17 for detection of the A allele)). The PCR products and the ligation oligonucleotides are suspended in ligation buffer, including NAD, with a DNA ligase, preferably amp-ligase (Epicentre) which is a thermal ligase. Ten cycles of ligation are performed at 94°C for 20 seconds and 58°C for 2 minutes in a thermal cycler. The reaction is stopped with EDTA and the product is transferred to streptavidin-coated plates

and incubated for 45 minutes. Thereafter the wells are alkaline washed to denature the oligonucleotides from the initial PCR products and then washed with TRIS buffer to remove any unbound materials (i.e., all products other than the biotinylated products which bind to the streptavidin on the plates).

5           Detection is accomplished, preferably, through use of an anti-digoxigenin antibody conjugated with alkaline phosphatase (Boehringer-Mannheim) which is added and incubated at 37°C for 30 minutes. The plates are washed with TRIS buffer to remove any unbound antibody. An ELISA detection kit (Life Technologies) is utilized where NADPH is used as a substrate where the alkaline phosphatase conjugated to the antibody 10 cleaves NADPH to NADH. The NADH produced by this reaction is used as a cofactor for diaphorase to turn INF-violet to Formazan which generates a red color. Presence of the red color provides a positive signal that ligation occurred and lack of the red color indicates that ligation did not occur, which indicates the presence or absence of the specific base being assayed.

15          As will be appreciated, the OLA assay allows the differentiation between individuals who are homozygous versus heterozygous for particular mutations (such as the 24d1 mutation, for which the ligation oligonucleotides mentioned above are designed, or the 24d2 mutation). This feature allows one to rapidly and easily determine whether an individual is at a significant risk of developing HH. Oligonucleotides useful for 20 amplifying and detecting the 24d2 mutant and normal alleles are provided in Figure 9.

In the OLA assay, when carried out in microtiter plates, for example, one well is used for the determination of the presence of the normal allele (i.e., the 24d1:G allele) and a second well is used for the determination of the presence of the mutated allele (i.e., the 24d1:A allele). Thus, the results for an individual who is heterozygous 25 for the 24d1 mutation will show a signal in each of the A and G wells and an individual who is homozygous for the 24d1:A allele will show a signal in only the A well. Those individuals who are homozygous for the A allele at 24d1 are, as discussed above, homozygous for the common ancestral HH-mutation and are at a significant risk of developing HH disease.

30          In particular, therefore, a kit for detecting the 24d1 mutation by OLA assay is provided. In the kit, amplification primers for DNA or RNA (or generally primers for amplifying a sequence of genomic DNA, reverse transcription products, complementary

products) including the 24d1 mutated and normal alleles are provided. Ligation assay oligonucleotides are also preferably provided. The kit further includes separate reaction wells and reagents for detecting the presence of homozygosity or heterozygosity for the 24d1 mutation.

5 Within the same kit, or in separate kits, oligonucleotides for amplification and detection of other differences (such as the 24d2 mutation and/or the 24d7 sequence variant) can also be provided. If in the same kit as that used for detection of the 24d1 mutation, separate wells and reagents are provided, and homozygosity and heterozygosity can similarly be determined.

10 Because of the enrichment of the 24d2 mutation in individuals who are heterozygous for the 24d1 mutation, kits are specifically envisioned in accordance with the invention which screen for the presence of the 24d2 mutation when 24d1 heterozygosity is detected.

15 **Example 2 HH Diagnostic: Other Nucleotide Based Assays**

As will be appreciated, a variety of other nucleotide based detection techniques are available for the detection of mutations in samples of RNA or DNA from patients. *See, for example, Section (III)(A)(2), above, entitled "Nucleic Acid Based Screening."* Any one or any combination of such techniques can be used in accordance 20 with the invention for the design of a diagnostic device and method for the screening of samples of DNA or RNA for HH gene mutations in accordance with the invention, such as the mutations and sequence variants identified herein (24d1, 24d2, and 24d7). Further, other techniques, currently available, or developed in the future, which allow for the specific detection of mutations and sequence variants in the HH gene are contemplated in 25 accordance with the invention.

Through use of any such techniques, it will be appreciated that devices and methods can be readily developed by those of ordinary skill in the art to rapidly and accurately screen for mutations and sequence variants in the HH gene in accordance with the invention.

30 Thus, in accordance with the invention, there is provided a nucleic acid based test for HH gene mutations and sequence variants which comprises providing a sample of a patient's DNA or RNA and assessing the DNA or RNA for the presence of

one or more HH gene mutations or sequence variants. Samples of patient DNA or RNA (or genomic, transcribed, reverse transcribed, and/or complementary sequences to the HH gene) can be readily obtained as described in Example 1. Through the identification and characterization of the HH gene as taught and disclosed in the present invention, one of ordinary skill in the art can readily identify the genomic, transcribed, reverse transcribed, and/or complementary sequences to the HH gene sequence in a sample and readily detect differences therein. Such differences in accordance with the present invention can be the 24d1, 24d2, and/or 24d7 mutations or sequence variations identified and characterized in accordance herewith. Alternatively, other differences might similarly be detectable.

10 Kits for conducting and/or substantially automating the process of identification and detection of selected changes, as well as reagents utilized in connection therewith, are therefore envisioned in accordance with the invention of the present invention.

15 **Example 3 HH Diagnostic: Antibody Based Assay**

As discussed in Section (III)(A)(3), herein, entitled "Antibodies," antibodies specific to both the normal/wild-type or mutated gene products of the HH gene can be readily prepared. Thus, in accordance with the invention a kit for the detection of an HH gene product, and particularly, the mutated HH gene product is provided for use 20 in a diagnostic test for the presence of HH disease.

Antibody based tests are well known in the art. In general, a sample of tissue, cells, or bodily fluid is obtained, or provided, from a patient. If the sample contains cells or tissues, typically the sample is disrupted to free the HH gene product. Alternatively, if surface expression exists, whole cells can be utilized. Thereafter, the 25 sample is contacted with an antibody specific to the selected HH gene product and binding of the antibody, if any, is detected. Typically, the antibody is bound to, either directly, or through another moiety (i.e., biotin), a label to facilitate detection of hybridization. Such label can be radioactive, fluorescent, a dye, a stain, or the like.

Thus, antibodies for diagnostic applications, and diagnostic kits including 30 antibodies (and/or other reagents utilized in connection therewith) are provided in accordance with the invention.

**Example 4    HH Therapy: In Vivo Gene Therapy**

The discovery of the HH gene in accordance with the invention also provides a therapeutic for HH disease in the form of gene therapy. In the present example, gene therapy is accomplished *in vivo*. In *in vivo* gene therapy, a patient is 5 treated with a gene product in a form that is designed to cause the patient to express the gene.

The coding region of the HH gene, or parts or portions thereof, can be incorporated into a suitable vector for use in the treatment of HH disease. Indeed, the coding region of the HH gene is of a manageable size for incorporation in a viral vector, 10 such as a retroviral or adenoviral vectors. Generally, the vector will be construct to include suitable promoters, enhancers, and the like. Additional information related to the design of HH gene construct for use in gene therapy is provided in Section (III)(B)(1), entitled "Expression Systems."

Viral vector systems have been indicated as highly efficient in transferring 15 genes to mammals containing deficient genes. See, for example, Crystal Am. J. Med. 92(6A):44S-52S (1992); Lemarchand et al. Proc. Nat'l Acad. Sci. USA 89(14):6482-6486 (1992) the disclosures of which are hereby incorporated by reference.

The viral vector can also be conveniently administered to a patient. For example, administration may be accomplished through, for example, liquid lavage, direct 20 injection, or through *ex vivo* treatment of cells, followed by reinfusion of such cells into the patient. Particularly preferred tissues for delivery of vectors including the HH gene are the liver and the gut. It will be appreciated that liquid lavage or direct injection can be utilized for delivery of the vector to the gut, while direct injection will presumably be necessary for delivery to the liver.

25

**Example 5    HH Therapy: Protein Replacement Therapy**

As discussed above, also provided in accordance with the invention is a therapy for HH disease involving replacement of the HH protein product. Where a patient is diagnosed as having HH disease and is not producing, or is underproducing, the 30 normal HH gene product, such patient can be treated by replacing the normal HH gene product to assist the patient's body in combating HH disease.

The HH gene product can be produced through the methods discussed above in connection with the Section entitled "Protein Purification" above.

Delivery of the HH gene product can be accomplished as discussed in connection with Section entitled "Therapeutics" above.

5

**Example 6 HH Therapy: Drug Design and Screening**

As discussed above in connection with the Section entitled "Pharmacological," the HH gene and parts and portions thereof can be utilized for drug screening. Cell-based and cell-free assays are envisioned in accordance with the 10 invention. As discussed above, a variety of drugs and other therapeutics have been proposed to have activity in HH disease. Compounds such as those described can be assayed in cellular systems containing the HH gene or the mutations therein. Cellular functions such as HH protein folding, iron uptake, transport, metabolism, receptor-like activities, other upstream or downstream processes, such as gene transcription and other 15 signaling events, and the like can be assayed. Each of these functions can be analyzed using conventional techniques that are well known in the art.

It is expected that through use of such assays, compounds can be rapidly screened for potential activity in HH disease and compounds showing high activity can be used for the construction of combinatorial libraries. Candidates from the combinatorial 20 libraries can be re-assayed and those with better activity than the parent compound can be analyzed for clinical development.

**Example 7 HH Study: Animal Models of HH Disease**

As discussed above, through knowledge of the gene-associated mutations 25 responsible for HH disease, it is now possible to prepare transgenic animals as models of the HH disease. Such animals are useful in both understanding the mechanisms of HH disease as well as use in drug discovery efforts. The animals can be used in combination with cell-based or cell-free assays for drug screening programs.

In preparation of transgenic animals in accordance with the invention, 30 genes within embryonic stem cells (ES cells) can be inactivated by homologous recombination. *See* Capecci *supra*. (1989). Specifically, an isogenic mouse genomic library (i.e., an Sv-129 library) can be screened with a human HH gene cDNA probe.

The resultant clones from the library are then sequenced to ensure sequence identity to the mouse HH gene homologous cDNA. A targeting vector is then constructed from the mouse genomic DNA consisting of two approximately 3 Kb genomic fragments from the mouse HH gene as 5' and 3' homologous arms. These arms would be chosen to flank a 5 region critical to the function of the HH gene product, such as exon 4 (the immunoglobulin-like region which contains the proposed critical  $\beta$ -2-microglobulin interactive domain and essential disulfide linkage). However, other regions could also be targeted.

In place of exon 4, negative and positive selectable markers can be placed, 10 for example, to abolish the activity of the HH gene. As a positive selectable marker a neo gene under control of phosphoglycerate kinase (pgk-1) promoter may be used and as a negative selectable marker the 5' arm of the vector can be flanked by a pgk-1 promoted herpes simplex thymidine kinase (HSV-TK) gene can be used.

The vector is then transfected into R1 ES cells and the transfectants are 15 subjected to positive and negative selection (i.e., G418 and gancyclovir, respectively, where neo and HSV-TK are used). PCR is then used to screen for surviving colonies for the desired homologous recombination events. These are confirmed by Southern blot analysis.

Subsequently, several mutant clones are picked and injected into C57BL/6 20 blastocytes to produce high-percentage chimeric animals. The animals are then mated to C57BL/6 females. Heterozygous offspring can then be tested for the HH gene mutation by Southern blot analysis. In addition, these animals are tested by RT-PCR to assess whether the targeted homologous recombination results in the ablation of the HH gene mRNA. These results are confirmed by Northern blot analysis and RNase protection 25 assays.

Once established, the HH gene -/- mice can be studied for the development 30 of HH-like disease and can also be utilized to examine which cells and tissue-types are involved in the HH disease process. The animals can also be used to introduce the mutant or normal HH gene or for the introduction of the homologous gene to that species (i.e., mouse) and containing the 24d1, 24d2, or other disease causing mutations. Methods for the above-described transgenic procedures are well known to those versed in the art and are described in detail by Murphy and Carter *supra* (1993).

The techniques described above can also be used to introduce the 24d1 or 24d2 mutations, or other homologous mutations in the animal, into the homologous animal gene. As will be appreciated, similar techniques to those described above, can be utilized for the creation of many transgenic animal lines, i.e., pig, sheep, goat, ape, orangutan, primate, or the like, and mice are only demonstrative.

**Example 8    HH Diagnostic: Allele-specific oligonucleotide-hybridization assay**

As discussed above, an allele-specific oligonucleotide-hybridization assay (Wallace et al., *Nucleic Acids Res.* 6:3543-3556 (1978)) can be used to discriminate 10 between normal and mutated alleles of the hemochromatosis gene.

A sample of DNA or cDNA reverse transcribed from RNA is subjected to PCR so as to amplify the DNA segment that contains the polymorphic site. The PCR product is immobilized on a solid support, denatured and hybridized with 2 separate oligonucleotide probes that anneal to the complementary strand of the immobilized PCR 15 product in an allele-specific fashion. The oligonucleotides are identical in sequence except for the polymorphic site (which is typically near the center of the oligonucleotide sequence). The first oligonucleotide can form a perfect and therefore relatively stable double helix with the PCR product containing allele 1, whereas annealing of oligonucleotide 1 to allele-2-containing PCR product will result in a less stable hybrid due 20 to the interruption of the double helix by the mismatched base-pair. Similarly, oligonucleotide 2 will form a stable hybrid with allele-2 containing PCR product but not with PCR product containing allele 1. Heterozygous DNA samples will give rise to a mixed PCR product that will hybridize to both allele-specific oligonucleotides. The allele-specific oligonucleotide probes are typically between 15 and 20 nucleotides in 25 length with the polymorphic site near the center of the oligonucleotide sequence, as a mismatch near the center is expected to have to have the most destabilizing effect on a heteroduplex.

Prior to performing the allele-specific oligonucleotide-hybridization assay for the A and G alleles at the 24d1 locus, genomic DNA or cDNA reverse-transcribed 30 from RNA is subjected to PCR using the following primers:

TGGCAAGGGTAAACAGATCC

(SEQ ID NO:13)

CTCAGGCACTCCTCTCAACC

(SEQ ID NO:14)

Prior to performing the allele-specific oligonucleotide-hybridization assay for the two 24d2 alleles, genomic DNA or cDNA reverse-transcribed from RNA is subjected to PCR using the following primers:

ACATGGTTAAGGCCTGTTGC (SEQ ID NO:24)  
5 GCCACATCTGGCTTGAATT (SEQ ID NO:25)

The PCR is performed in standard PCR-reaction buffer (e.g., 1X GeneAmp reaction buffer from Perkin Elmer with 1.5 mM Mg<sup>++</sup>) for 35-30 cycles using an annealing temperature of 60°C.

After PCR, the reaction mixture is boiled for 3 minutes and then chilled on  
10 ice. One volume of 20X SSC buffer is added and approximately 2 µl of the mixture  
spotted onto two duplicate nylon filters (one for each allele) that have been pre-wetted in  
10X SSC buffer. Alternatively, a dot-blotting or slot-blotting apparatus may be used. The  
membranes are soaked in 0.5M NaOH/1.5M NaCl solution, neutralized in 0.5M  
Tris-HCl, pH 7.5, and subjected to UV crosslinking to form a covalent bond between the  
15 denatured PCR product and the filter.

Examples of oligonucleotide sequences specific for the 24d1 and 24d2 alleles are given in the following table. It is possible to design allele-specific oligonucleotides that differ from the ones shown in size and/or position of the polymorphic site. Oligonucleotides of complementary sequence may be used as well.  
20

Allele	Example of allele-specific oligonucleotides	
24d1:G	5' ATATACGTGCCAGGTGG	(SEQ ID NO:45)
24d1:A	5' ATATACGTACCAGGTGG	(SEQ ID NO:46)
24d2:C	5' TCTATGATCATGAGAGT	(SEQ ID NO:47)
25 24d2:G	5' TCTATGATGATGAGAGT	(SEQ ID NO:48)

The oligonucleotides are radiolabeled at the 5' end using gamma <sup>32</sup>P ATP and T4 polynucleotide kinase using standard procedures (Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 11.31). One membrane containing PCR amplified 24d1 locus is  
30 subjected to hybridization with the labeled oligonucleotide probe specific for the 24d1:G allele. The duplicate membrane is hybridized with the oligonucleotide specific for the 24d1:A allele. Similarly, duplicate membranes containing PCR amplified 24d2 locus are

subjected to separate hybridizations with the two allele-specific oligonucleotides for 24d2. The stringency of the hybridization conditions (hybridization temperature, salt concentration of the hybridization and post-hybridization wash solutions, temperature and duration of the post-hybridization washes) are empirically determined to optimize 5 sensitivity and specificity of the assay. Guidelines for suitable ranges of hybridization conditions are available in most standard laboratory manuals (e.g., Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 11.45-61).

After the last post-hybridization wash, radiolabeled probe that is bound to 10 the spotted PCR product is detected by autoradiography. DNA samples from patient who are homozygous for the 24d1G allele give rise to a positive hybridization signal with the 24d1G-specific oligonucleotide but not with the 24d1A-specific oligonucleotide probe. DNA samples from 24d1:A homozygotes give rise to a positive signal with the 15 24d1:A-specific, but not with the 24d1:G-specific probe. Heterozygous samples are positive for both probes. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of hybridization results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

**Example 9 HH Diagnostic: Allele-specific PCR assay**

20 As discussed above, an allele-specific PCR assay (Newton et al, Nucleic Acids Res. 17:2503-2516 (1989)) can be used to discriminate between normal and mutated alleles of the hemochromatosis gene.

The allele-specific PCR assay exploits differences in priming efficiency of a perfectly-matched PCR primer and a mismatched PCR primer. Typically, the two 25 allele-specific primers are identical except for the allele-specific nucleotide at the 3' end. The primer specific for allele 1 can form a perfect duplex upon annealing to denatured target DNA containing allele 1, whereas its 3' nucleotide will not be base-paired after annealing to allele-2-containing target DNA. Conversely, the allele-2-specific primer can form a perfect double helix after annealing to allele-2-containing DNA but will have an 30 unpaired 3' nucleotide when annealed to allele-1-containing DNA. Only the cognate primer can be efficiently extended by DNA polymerase. Each allele-specific primer is used in combination with a third, common PCR primer. Depending on the genotype of

the DNA sample, either one or the other or both primer-pairs will give rise to a PCR product.

Examples of PCR primer pairs for allele-specific amplification of the 24d1 and 24d2 loci are given in the following table. Suitable alternative allele-specific primers 5 may have more or less nucleotides at their 5' end. It is also possible to design allele-specific primers that can anneal to the other strand of the target DNA. The common PCR primer may be any non-repetitive sequence of 10 or more nucleotides on the complementary strand that is within "PCRable distance" of the allele-specific primer and has a suitable annealing temperature. Suitable primer pairs can be selected using 10 published guidelines (e.g., Kramer, M.F and Coen, D.M. in Current Protocols in Molecular Biology, Ausubel, F.M. et al., eds., Wiley, Chapter 15.03) or by using primer-picking programs such as PRIMER (Lincoln, S.E., Daly, M.J., Lander, E.S. 1991. PRIMER: A Computer Program for Automatically Selecting PCR Primers. Version 0.5 Manual. MIT Center for Genome Research and Whitehead Institute 15 for Biomedical Research. Nine Cambridge Center. Cambridge, Massachusetts 02142) or OSP (Hillier, L. and Green, P. (1991): OSP: A computer program for choosing PCR and DNA sequencing primers. PCR Methods and Applications, 1:124-128).

Allele	Allele-specific PCR primer	SEQ ID NO:	Common PCR primer	SEQ ID NO:	Size (bp)
24d1:G	5' TGGGTGCTCCACCTGGC	49	TGGCAAGGGTAAACAGATCC	13	296
24d1:A	5' TGGGTGCTCCACCTGGT	50	TGGCAAGGGTAAACAGATCC	13	296
24d2:C	5' CACACGGCGACTCTCATG	51	ACATGGTTAAGGCCTGTTGC	24	159
24d2:G	5' CACACGGCGACTCTCATC	52	ACATGGTTAAGGCCTGTTGC	24	159

The PCR is performed according to standard protocols procedures (e.g., 25 Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 14.18) and the reaction mixture analyzed by electrophoresis on a polyacrylamide or an agarose gel. The PCR product is visualized by EtBr staining. The stringency of the PCR reaction conditions is empirically determined (by changing parameters such as annealing temperature of MgCl<sub>2</sub> 30 concentration) to optimize sensitivity and allele-specificity of the assay.

DNA samples from patient who are homozygous for the 24d1:G allele give rise to a positive PCR reaction with the primer pair containing the 24d1:G-specific primer but not with the 24d1:A-specific primer. DNA samples from 24d1:A homozygotes give rise to a positive signal with the 24d1:A-specific, but not the 24d1:G-specific PCR primer. Heterozygous samples are positive in both reactions. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of PCR results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

10 **Example 10 HH Diagnostic: Template-directed incorporation assay**

As discussed above, the template-directed incorporation assay can be used to discriminate between normal and mutated alleles of the hemochromatosis gene. In this assay, an oligonucleotide primer is designed that anneals to the target DNA such that its 3' end is immediately adjacent to the polymorphic position. DNA polymerase and 4 different dideoxy nucleotides are added. Depending on the allele present, the primer is extended by one of two alternative dideoxy nucleotides.

In one embodiment of this assay (Chen & Kwok, *Nucleic Acids Res.* 25:347-353 (1997)), the primer carries a fluorescent moiety (fluorescein, the "donor") at its 5' end, and the two allele-specific dideoxynucleotides carry another fluorescent dye (ROX, the "acceptor" molecule). After extension of the 5' fluorescein-labeled primer molecule with the ROX-labeled ddNTP dyes, both donor and acceptor are attached to the same molecule and thus in close proximity. Upon excitation of a fluorescein molecule that is in close proximity to a ROX molecule, a physical phenomenon called fluorescence resonance energy transfer (FRET) can take place, i.e., part of the excitation energy is transferred from the fluorescein molecule to the ROX molecule, which in turn emits a photon. Since the emission spectrum of the acceptor is different than that of the donor, the FRET can be analyzed by measuring the ROX-emission upon excitation of fluorescein. Two separate extension reactions, one with the ROX-labeled ddNTP specific for allele 1 and one with the ROX-labeled ddNTP specific for allele 2, are performed, and each extension reaction is followed by measuring the FRET from fluorescein to ROX. The target region is typically preamplified by PCR.

Examples of oligonucleotide primers and dideoxynucleotide combinations suitable for the discrimination between the 2 respective 24d1 and 24d2 alleles are given in the following table. Two alternative sets are given, one for each strand.

locus	Primer	SEQ ID NO:	ROX-ddNTP	ROX-ddNTP (mutant allele)
			(normal allele)	
5	24d1 (1) F-GGAAGAGCAGAGATATAACGT	53	ROX-ddG	ROX-ddA
	24d1 (2) F-GGCCTGGGTGCTCCACCTGG	54	ROX-ddC	ROX-ddU
	24d2 (3) F-AGCTGTTCGTGTCTATGAT	55	ROX-ddC	ROX-ddG
	24d2 (4) F-CTCCACACGGCGACTCTCAT	56	ROX-ddG	ROX-ddC

10 After PCR amplification of the 24d1 or 24d2 locus using standard conditions (see above), the PCR product is purified by gel-electrophoresis. Two separate primer-extension reactions (each containing fluorescein-labeled primer, the allele-specific ROX-labeled ddNTP and three unlabeled ddNTPs) are set up and the reaction performed by thermocycling (35 cycles) between 93°C and 50°C. NaOH is added to the reaction mixtures, and the incorporation of ROX-labeled ddNTP is measured by determining ROX emission (605 nm) upon excitation of fluorescein (488 nm) on a fluorescence spectrophotometer. The data are normalized, processed and plotted as described by Chen & Kwok, Nucleic Acids Res. 25:347-353 (1997)).

15 DNA samples that are homozygous for the normal 24d1 allele will give rise to a positive FRET signal after extension of primer (1) with ROX-ddG whereas the extension-reaction of primer (1) in the presence of ROX-ddA will be negative. In contrast, DNA samples that are homozygous for the mutant 24d1 allele will be positive only in the reaction with ROX-ddA. Heterozygous samples will be positive with both ROX-ddG and ROX-ddA, but the FRET signal will be lower than with homozygous samples. Extension reactions containing Primer (2) and either ROX-ddC or ROX-ddU are analyzed in an analogous fashion, as are the 24d2 genotyping reactions based on allele-specific extension of either primer (3) or primer (4). In order to facilitate the interpretation of the results, DNA samples of known genotype are processed along with unknown DNA samples.

**Example 11 HH Diagnostic: PNA-mediated PCR-clamping Assay**

Many diagnostic methods involve the formation of a hybrid comprising the test DNA and an allele specific probe, usually an DNA oligonucleotide. It is possible to use a peptide nucleic acid oligonucleotide (PNA) probe instead. PNA differ from DNA in that the DNA ribose-phosphate backbone is replaced by a peptide backbone. Due to this chemical difference, PNA-DNA hybrids differ from DNA-DNA hybrids in several respects: PNA-DNA hybrids have a higher thermal stability (because of the lack of electrostatic repulsion between the two backbones); the difference in melting temperature between a perfectly matched and a mismatched hybrid is larger for PNA-DNA than for their DNA-DNA counterparts thus increasing the specificity of the interaction; PNA-DNA hybrids are no substrate for DNA polymerase, i.e., the PNA cannot serve as a PCR primer.

In the following example (based on Orum et al., Nucleic Acids Res. 21:5332-5336 (1993) and Thiede et al. Nucleic Acids Res. 24, 983-984 (1996)), an allele-specific PNA oligonucleotide competes with the 3' end of a generic DNA-oligonucleotide primer for annealing to the target DNA. If the PNA oligonucleotide matches the sequence of the target strand, it will out-compete the PCR primer resulting in a negative PCR reaction. If the target DNA differs from the PNA probe at one position, the PNA-DNA interaction is much weaker, the PCR primer can anneal and give rise to an amplification product.

The DNA sample to be tested is split into four aliquots. The first aliquot receives a PNA-oligonucleotide that matches the normal 24d1 sequence, the second receives an PNA-oligonucleotide that matches the mutant 24d1 allele, the third and fourth aliquots receive PNA oligos that match normal and mutated 24d2 alleles, respectively.

The reactions are complemented with PCR primers to amplify the 24d1 and 24d2 loci, respectively. The various combinations of PNA oligonucleotides and PCR primers are specified below. In this reaction the cognate PNA probe will abolish a reaction. In order to discriminate between specific inhibition and other causes for negative PCR reaction (such as unspecific inhibitors or omission of essential ingredients) PCR primers specific for another, unrelated genomic locus can be included (which should be amplifiable regardless of the which PNA oligonucleotide is present and regardless of the genotype at 24d1 or 24d2 of the DNA sample).

	Allele	PNA	SEQ ID NO:	PCR primer 1	SEQ ID NO:
	24d1:G	GCTCCACCTGGCACG	57	CTCAGGCACTCCTCTCAACC	14
	24d1:A	GCTCCACCTGGTACG	58	CTCAGGCACTCCTCTCAACC	14
	24d2:C	GCGACTCTCATCATC	59	GCCACATCTGGCTTGAAATT	25
5	24d2:G	GCGACTCTCATGATC	60	GCCACATCTGGCTTGAAATT	25
	Allele	PCR primer 2	SEQ ID NO:	Size (bp)	
	24d1:G	GGAAGAGCAGAGATATACGT	53	131	
	24d1:A	GGAAGAGCAGAGATATACGT	53	131	
10	24d2:C	AGCTGTTCGTGTCTATGAT	55	87	
	24d2:G	AGCTGTTCGTGTCTATGAT	55	87	

The PCR is performed according to standard protocols procedures (e.g., Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 14.18) and the reaction mixture analyzed by electrophoresis on a polyacrylamide or an agarose gel. The PCR product is visualized by EtBr staining. The stringency of the PCR reaction conditions is empirically determined (by changing parameters such as annealing temperature of MgCl<sub>2</sub> concentration) to optimize sensitivity and allele-specificity of the assay.

20 DNA samples from patients who are homozygous for the 24d1:G allele fail to amplify in presence of the 24d1:G-specific PNA but should give rise to a 131-bp PCR product in presence of the 24d1:A-specific PNA oligonucleotide. DNA samples from 24d1:A homozygotes will be negative in the reaction containing the 24d1:A-specific PNA but positive in the reaction with the 24d1:G-specific PNA molecule. Heterozygous

25 samples will be positive in both reactions. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of PCR results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

**Example 12 HH Diagnostic: Ligase-Chain-Reaction Assay**

The ligase chain reaction (LCR; Wu & Wallace, Genomics 4: 560-569 (1989)) is an amplification method which is based on the template-dependent ligation of two adjacent oligonucleotides. The DNA sample is denatured in the presence of two pairs of oligonucleotides. Upon lowering the reaction temperature, pair 1 will anneal side-by-side on one strand, pair 2 will anneal side-by-side at the identical position on the complementary strand. Two of the oligonucleotides carry a phosphate group at their 5' end thus allowing the enzyme DNA ligase to form a covalent bond between the two oligonucleotides annealed on the same strand. After ligation, the temperature is raised again, and another annealing and ligation cycle is performed. Since non-ligated oligonucleotide pairs can anneal to the ligation products formed in the previous cycle, the amount of ligated oligonucleotides will double with each reaction cycle leading to an exponential amplification of double-stranded DNA consisting of the two ligated complementary oligonucleotide-pairs. Because the ligation does not occur in the presence of a mismatch between the template and one of the two oligonucleotides at any of the positions flanking the ligation junction, an allele-specific LCR amplification assays can be developed (Barany, Proc. Natl. Acad. Sci. USA 88: 189-193 (1991)).

Traditionally, the LCR oligonucleotides are radiolabeled and the LCR-amplification product is detected as a radioactive electrophoresis band, which is larger than the input oligonucleotides. Modern high-throughput incarnations of this method use fluorescently-labeled oligonucleotides in combination with ABI-type sequencers or capillary-electrophoresis systems to resolve input from product oligonucleotides. In the following example, the LCR-product is detected by a solid-phase-capture/detection-tagging strategy similar to that described above for OLA (Nickerson et al., in Current Protocols in Human Genetics, Ausubel, F.M. et al., eds., Wiley, Chapter 2.6), i.e., one of the oligonucleotides is biotinylated and its ligation partner is digoxigenin labeled; hence only the ligated product will bind to a streptavidin-coated plate and give rise to a positive reaction with an anti-digoxigenin antibody.

To increase the number of target molecules prior to performing the allele-specific LCR assay for the A and G alleles the 24d1 and 24d2 loci may be preamplified from total genomic DNA or cDNA reverse-transcribed from RNA by PCR

using the following primer pairs. This preamplification step is optional. Alternatively one can start with total genomic DNA and perform more LCR cycles to amplify the two loci during the LCR itself.

24d1:

5	TGGCAAGGGTAAACAGATCC	(SEQ ID NO:13)
	CTCAGGCACTCCTCTCAACC	(SEQ ID NO:14)

24d2:

ACATGGTTAAGGCCTGTTGC	(SEQ ID NO:24)
GCCACATCTGGCTTGAAATT	(SEQ ID NO:25)

10 The PCR is performed in standard PCR-reaction buffer (e.g., 1X GeneAmp reaction buffer from Perkin Elmer with 1.5 mM Mg<sup>++</sup>) for 35-30 cycles using an annealing temperature of 60°C.

Two allele-specific LCR-reactions are set up for each locus containing thermostable ligase, and the following combination of oligonucleotides:

15	Allele	oligonucleotide-pair 1	SEQ ID NO:	oligonucleotide-pair 2	SEQ ID NO:
	24d1:G	bio-GCCTGGGTGCTCCACCTGGC	61	bio-GAAGAGCAGAGATATACGTG	63
		pACGTATATCTCTGCTCTTCC-dig	62	pCCAGGTGGAGCACCCAGGCC-dig	64
	24d1:A	bio-GCCTGGGTGCTCCACCTGGT	65	bio-GAAGAGCAGAGATATACGTA	67
		pACGTATATCTCTGCTCTTCC-dig	66	pCCAGGTGGAGCACCCAGGCC-dig	68
	24d2:C	bio-TCCACACGGCGACTCTCATG	69	bio-GCTGTTCGTGTCTATGATC	71
		pATCATAGAACACGAACAGCT-dig	70	pATGAGAGTCGCCGTGTGGAG-dig	72
	24d2:G	bio-TCCACACGGCGACTCTCATC	73	bio-GCTGTTCGTGTCTATGATG	75
		pATCATAGAACACGAACAGCT-dig	74	pATGAGAGTCGCCGTGTGGAG-dig	76

20

The reaction mixes are subjected to 5-10 thermocycles (for PCR amplified targets) or 25-30 thermocycles (for non-amplified samples), with each cycle consisting of a 30 sec denaturation step at 94°C and a 2 min. ligation step at 60°C.

After the last cycle, the reaction mixtures are transferred to

25 streptavidin-coated microtiter plates to capture biotinylated oligonucleotides. Un-ligated 3'-digoxigenin-labeled oligonucleotides are removed by denaturation and extensive washing. Finally, captured and digoxigenin-containing (i.e., ligated) products are detected with an anti-digoxigenin Fab fragment that is conjugated to alkaline phosphatase,

whose presence in turn is assayed by a suitable colorimetric reaction, similar to the detection procedure described above for OLA assays.

### **Example 13 RFLP-Southern Analysis**

5 Genomic DNA from individuals can be digested using restriction  
endonucleases and size fractionated in agarose gels by electrophoresis (Kan and Dozy,  
Lancet ii:910-912 (1978)). The DNA fragments are then transferred to nylon membranes  
(or nitrocellulose) and fixed by standard techniques such as chemical or UV crosslinking.  
A DNA probe such as the cDNA or genomic DNA surrounding the mutation can be  
10 labeled by either <sup>32</sup>P or other conventional methods and hybridized to the filters, washed  
and exposed to X-ray film. For detection of the 24d1 mutation, either Rsa I or Sna BI  
restriction endonucleases can be used. In both cases the 24d1 mutation creates an  
additional site. For detection of the 24d2 mutation, either Bcl I, Sau 3A, Mbo I, or Dpn  
II restriction endonucleases can be used. In all cases the 24d2 mutation destroys a site.

15

### Example 14 RFLP-PCR Analysis

Genomic DNA from individuals can be amplified using the polymerase chain reaction using oligonucleotide primers that flank the 24d1 and 24d2 mutations. For example the following sets of primers can be used:

20

24d1 5' TGGCAAGGGTAAACAGATCC 3' (SEQ ID NO:13)  
5' CTCAGGCACTCCTCTCAACC 3' (SEQ ID NO:14)  
PCR product = 390 bp

5' GCCACATCTGGCTTGAAATT 3' (SEQ ID NO:25)  
PCR product = 208 bp

subjected to restriction endonuclease digestion using the same enzymes described in the RFLP - Southern Analysis example. For detection of the 24d1 mutation, either Rsa I or Sna BI restrictions endonucleases can be used. The wild type (unmutated) allele will have a 250 bp and a 140 bp band following Rsa I digestions and size fractionation on agarose gels with ethidium bromide staining. The mutant allele will produce 3 bands of 250 bp,

111 bp, and 29 bp under the same conditions. For detection of the 24d2 mutation, either Bcl I, Sau 3A, Mbo I, or Dpn II restriction endonucleases can be used. In all cases the 24d2 mutation destroys a site. In the example of using Bcl I the wild type allele will result in band sizes of 138 bp and 70 bp. The mutant allele destroys a site resulting in a  
5 band size of 208 bp.

#### INCORPORATION BY REFERENCE

All references (including books, articles, papers, patents, and patent applications) cited herein are hereby expressly incorporated by reference in their entirety  
10 for all purposes.

#### EQUIVALENTS

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and  
15 this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

WHAT IS CLAIMED IS:

- 1               1. An isolated nucleic acid comprising a nucleic acid sequence selected  
2 from the group consisting of:
  - 3               a. nucleic acid sequences corresponding to the nucleic acid of  
4 SEQ ID NO:1;
  - 5               b. nucleic acid sequences corresponding to the nucleic acid  
6 sequences selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID  
7 NO:7;
  - 8               c. nucleic acid sequences corresponding to the nucleic acid  
9 sequence of SEQ ID NO:9; and
  - 10              d. nucleic acid sequences corresponding to the nucleic acid  
11 sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and  
12 SEQ ID NO:12.
- 1               2. The nucleic acid of claim 1, wherein the nucleic acid is genomic  
2 DNA.
- 1               3. The nucleic acid of claim 2, wherein the DNA is cDNA.
- 1               4. The nucleic acid of claim 1, wherein the nucleic acid is a nucleic  
2 acid sequence corresponding to the nucleic acid of SEQ ID NO:1.
- 1               5. The nucleic acid of claim 1, wherein the nucleic acid is a nucleic  
2 acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:9.
- 1               6. The nucleic acid of claim 1 wherein the nucleic acid is a nucleic  
2 acid sequence corresponding to a nucleic acid sequence selected from the group consisting  
3 of SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.

1               7.     The nucleic acid of claim 1, wherein the nucleic  
2     acid sequence corresponding to a nucleic acid sequence selected from the group consisting  
3     of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

1               8.     A nucleic acid comprising an RNA equivalent of the nucleic acid of  
2     claim 1.

1               9.     A cloning vector comprising a coding sequence of a nucleic acid as  
2     set forth in any one of claims 1 through 7 and a replicon operative in a host cell for the  
3     vector.

1               10.    An expression vector comprising a coding sequence of a nucleic  
2     acid set forth in any one of claims 1 through 7 operably linked with a promoter sequence  
3     capable of directing expression of the coding sequence in host cells for the vector.

1               11.    Host cells transformed with a vector as set forth in any one of  
2     claims 9 and 10.

1               12.    A method of producing a mutant HH polypeptide comprising:  
2                a.     transforming host cells with a vector capable of expressing a  
3     polypeptide from a nucleic acid sequence as set forth in any one of claims 6 and 7;  
4                b.     culturing the cells under conditions suitable for production of  
5     the polypeptide; and  
6                c.     recovering the polypeptide.

1               13.    A peptide product selected from the group consisting of:  
2                a.     a polypeptide having the amino acid sequence corresponding  
3     to the sequence of SEQ ID NO:2;  
4                b.     a polypeptide having the amino acid sequence corresponding  
5     to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8;  
6                c.     a peptide comprising at least 6 amino acid residues  
7     corresponding to the sequence of SEQ ID NO:2; and

8                   d.     a peptide comprising at least 6 amino acid residues  
9 corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

1                  14.   The peptide product of claim 13, wherein the peptide is labelled.

1                  15.   The peptide product of claim 13, wherein the peptide is a fusion  
2   protein.

1                  16.   Use of a peptide as set forth in any one of claims 13 through 15 as  
2   an immunogen for the production of antibodies.

1                  17.   An antibody produced in accordance with claim 16.

1                  18.   The antibody of claim 17, wherein the antibody is labelled.

1                  19.   The antibody of claim 17, wherein the antibody is bound to a solid  
2   support.

1                  20.   The antibody of claim 17, wherein the antibody is monoclonal.

1                  21.   A method to determine the presence or absence of the common  
2   hereditary hemochromatosis (HH) gene mutation in an individual comprising:  
3                   providing DNA or RNA from the individual; and  
4                   assessing the DNA or RNA for the presence or absence of the HH-  
5   associated allele A of a base-pair mutation designated herein 24d1,  
6                   wherein, as a result, the absence of the allele indicates the absence of the  
7   HH gene mutation in the genome of the individual and the presence of the allele indicates  
8   the presence of the HH gene mutation in the genome of the individual.

1                  22.   The method of claim 21, wherein the method further comprises  
2   assessing the RNA or DNA for the presence of 24d2.

1               23. The method of claim 21, wherein the method further comprises  
2 assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,  
3 HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;  
4 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-  
5 1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-  
6 4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-  
7 1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,  
8 D6S105:124; D6S306:238; D6S464:206; and D6S1001:180,

1               24. The method of claim 22, wherein the method further comprises  
2 assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,  
3 HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;  
4 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-  
5 1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-  
6 4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-  
7 1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,  
8 D6S105:124; D6S306:238; D6S464:206; or D6S1001:18.

1               25. A method for diagnosing whether a patient is afflicted with  
2 hereditary hemochromatosis (HH) disease, comprising:  
3               a. contacting cells of the patient with antibodies directed against  
4 an epitope on an HH protein product corresponding substantially to SEQ ID NO:2 and  
5               b. observing whether the antibodies localize on the cells,  
6 wherein, the observing step, if antibodies do not localize to the cell it is  
7 likely that the patient is afflicted with HH.

1               26. The method of claim 25, wherein the method is conducted *in vitro*.

1               27. The method of claim 25, wherein the method is conducted *in vivo*.

1               28. A method for treating a patient diagnosed as having hereditary  
2 hemochromatosis (HH) disease and homozygous for a 24d1(A) mutation, comprising

3 delivering a polypeptide corresponding to the amino acid sequence of SEQ ID NO:2 to  
4 tissues of the patient.

1 29. The method of claim 28, wherein the polypeptide is delivered  
2 directly to the tissues.

1 30. The method of claim 28, wherein the polypeptide is delivered  
2 intravenously.

1 31. The method of claim 28, wherein the polypeptide is delivered to the  
2 tissues through gene therapy.

1 32. An animal model for hereditary hemochromatosis (HH) disease,  
2 comprising a mammal possessing a mutant or knocked-out HH gene.

1 33. Metal chelation agents derived from nucleic acid sequences in  
2 accordance with claim 1 or from a peptide product in accordance with Claim 13 in a  
3 physiologically acceptable carrier.

1 34. The chelation agent of claim 33, wherein the metal is selected from  
2 the group consisting of iron, mercury, cadmium, lead, and zinc.

1 35. A method to screen mammals for susceptibility to metal toxicities,  
2 comprising, screening such mammals for a mutation in the HH gene and wherein those  
3 mammals identified as having a mutation are more susceptible to metal toxicities than  
4 mammals not identified as having a mutation.

1 36. The method of claim 35, wherein the metal is selected from the  
2 group consisting of iron, mercury, cadmium, lead, and zinc.

1 37. A method for selecting patients infected with hepatitis virus for  $\alpha$ -  
2 interferon treatment, comprising screening such patients for a mutation in the HH gene

3 and wherein those patients not identified as having a mutation are selected to proceed with  
4  $\alpha$ -interferon treatment and those identified as having a mutation are selected to undergo  
5 phlebotomy prior to  $\alpha$ -interferon treatment.

1               38. A T-cell differentiation factor comprising a moiety selected from the  
2 group consisting of molecules derived from nucleic acid sequences in accordance with  
3 claim 1 and from a peptide product in accordance with claim 13.

1               39. A method for screening potential therapeutic agents for activity in  
2 connection with HH disease, comprising:

3                         providing a screening tool selected from the group consisting of a  
4 cell line, a cell free extract, and a mammal containing or expressing a defective HH gene  
5 or gene product;

6                         contacting the screening tool with the potential therapeutic agent;  
7 and

8                         assaying the screening tool for an activity selected from the group  
9 consisting of HH protein folding, iron uptake, iron transport, iron metabolism, receptor-  
10 like activities, upstream processes, downstream processes, gene transcription, and  
11 signaling events.

1               40. A therapeutic agent for the mitigation of injury due to oxidative  
2 processes *in vivo*, comprising a moiety selected from the group consisting of molecules  
3 derived from nucleic acid sequences in accordance with claim 1 and from a peptide  
4 produce in accordance with claim 13.

1               41. A method for diagnosing a patient as having an increased risk of  
2 developing HH disease, comprising:

3                         providing DNA or RNA from the individual; and  
4                         assessing the DNA or RNA for the presence or absence of  
5 the HH-associated allele A or a base mutation designated herein 24d1 in combination with  
6 assessing the DNA or RNA for the HH-associated allele G of a base mutation designated  
7 herein 24d2,

8               wherein, as a result, the absence of the alleles indicates the absence of the  
9   HH gene mutation in the genome of the individual and the presence of the alleles  
10   indicates the presence of the HH gene mutation in the genome of the individual and an  
11   increase risk of developing HH disease.

1               42.   The method of claim 41, wherein the method further comprises  
2   assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,  
3   HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;  
4   1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-  
5   1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-  
6   4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-  
7   1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,  
8   D6S105:124; D6S306:238; D6S464:206; and D6S1001:180.

1               43.   A therapeutic agent for the mitigation of iron overload, comprising  
2   a moiety selected from the group consisting of molecules derived from nucleic acid  
3   sequences in accordance with claim 1 and from a peptide product in accordance with  
4   claim 13.

1               44.   A method for treating hereditary hemochromatosis (HH) disease  
2   comprising:  
3                 providing an antibody directed against an HH protein sequence or  
4   peptide product; and  
5                 delivering the antibody to affected tissues or cells in a patient having  
6   HH.

1               45.   An antisense oligonucleotide directed against a transcriptional  
2   product of a nucleic acid sequence selected from the group consisting of SEQ ID NO:1,  
3   SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID  
4   NO:11, and SEQ ID NO:12.

1                  46. An oligonucleotide of at least 8 nucleotides in length selected from  
2 nucleotides 1-46; 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080;  
3 1083-1109; 1106-1304; 1301-1366; 1363-1386; 1389-1514; 1516-1778; 1773-1917; 1921-  
4 2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422; 2420-2464; 2465-2491; 2488-2568;  
5 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-3042; 3420-3435; 3451-3708; 3703-  
6 3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978; 3974-3992; 3990-4157; 4153-4251;  
7 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-4400; 4398-4436; 4444-4547; 4572-  
8 4714; 4709-4777; 5165-5397; 5394-6582; 5578-5696; 5691-5709; 5708-5773; 5773-5816;  
9 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-6133; 6150-6296; 6292-6354; 6356-  
10 6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917; 6913-7027; 7023-7061; 7056-7124;  
11 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-9037; 9486-9502; 9743-9811; 9808-  
12 9831; 9829-9866; 9862-9986; 9983-10075; 10072-10091; 10091-10195; 10247-10263;  
13 10262-10300; 10299-10448; 10448-10539; 10547-10564; 10580-10612; 10608-10708;  
14 10703-10721; 10716-10750; 10749-10774; 10774-10800; and 10796-10825 of SEQ ID  
15 NO:1, 3, 5, or 7.

1                  47. An oligonucleotide pair comprising an oligonucleotide of claim 46 and  
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,  
3 or 7.

1                  48. An oligonucleotide of at least 9 nucleotides in length selected from  
2 nucleotides 1-47; 47-124; 119-370; 364-395; 389-541; 537-647; 642-1005; 1000-1081;  
3 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-1515; 1515-1918; 1920-2011; 2050-  
4 2147; 2153-2210; 2233-2369; 2366-2423; 2419-2465; 2464-2492; 2487-2569; 2871-2935;  
5 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-3771; 3773-3841; 3839-3963; 3963-  
6 3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283; 4283-4334; 4336-4401; 4397-4437;  
7 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-5710; 5707-5774; 5772-5817; 5817-  
8 5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134; 6149-6355; 6355-6556; 6554-6576;  
9 6574-6793; 6787-7125; 7318-7508; 7881-8001; 7997-8073; 8072-8099; 8999-9038; 9485-  
10 9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987; 9982-10076; 10071-10092; 10090-  
11 10196; 10246-10264; 10261-10301; 10298-10449; 10447-10540; 10546-10565; 10579-  
12 10751; 10748-10775; 10773-10801; and 10795-10825 of SEQ ID NO:1, 3, 5, or 7.

1               49. An oligonucleotide pair comprising an oligonucleotide of claim 48 and  
2   an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,  
3   or 7.

1               50. An oligonucleotide of at least 10 nucleotides in length selected from  
2   nucleotides 1-48; 46-125; 118-1006; 999-1082; 1081-1111; 1104-1306; 1299-1368; 1361-  
3   1388; 1387-1516; 1514-1919; 1919-2012; 2049-2148; 2152-2211; 2232-2370 2365-2424;  
4   2418-2466; 2463-2493; 2486-2570; 2870-2936; 2934-3003; 2998-3044; 3418-3437; 3449-  
5   3772; 3772-3842; 3838-3964; 3962-3994; 3988-4284; 4282-4335; 4335-4402; 4396-4438;  
6   4442-4549; 4570-4779; 5163-5711; 5706-5775; 5771-5818; 5816-5851; 5867-6047; 6040-  
7   6077; 6071-6110; 6111-6135; 6148-6356; 6354-6577; 6573-7126; 7317-7509; 7880-8074;  
8   8071-8100; 8998-9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093;  
9   10089-10197; 10245-10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566;  
10   10578-10752; 10747-10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

1               51. An oligonucleotide pair comprising an oligonucleotide of claim 50 and  
2   an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,  
3   or 7.

1               52. An oligonucleotide of at least 11 nucleotides in length selected from  
2   nucleotides 1-49; 45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212;  
3   2231-2371; 2364-2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-  
4   3438; 3448-3773; 3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403;  
5   4395-4439; 4441-4550; 4569-4780; 5162-5712; 5705-5776; 5770-5819; 5815-5852; 5886-  
6   6111; 6100-6136; 6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101;  
7   8997-9040; 9483-9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-  
8   10542; 10544-10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3,  
9   5, or 7.

1               53. An oligonucleotide pair comprising an oligonucleotide of claim 26 and  
2   an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,  
3   or 7.

1               54. An oligonucleotide of at least 12 nucleotides in length selected from  
2   nucleotides 1-50, 44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213;  
3   2230-2372; 2363-2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-  
4   3774; 3770-3844; 3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781;  
5   5161-5713; 5704-5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-  
6   6579; 6571-7128; 7315-7511; 7878-8076; 8069-8102; 8996-9041; 9482-9506; 9739-  
7   10199; 10243-10267; 10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-  
8   10754; 10745-10778; and 10770-10825 of SEQ ID NO:1, 3, 5, or 7.

1               55. An oligonucleotide pair comprising an oligonucleotide of claim 54 and  
2   an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,  
3   or 7.

1               56. An oligonucleotide of at least 13 nucleotides in length selected from  
2   nucleotides 1-51; 43-1391; 1384-1519; 1511-1922; 1916-2015; 2046-2151; 2149-2214;  
3   2229-2469; 2460-2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-  
4   3967; 3959-4287; 4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821;  
5   5813-5854; 5884-6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-  
6   8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544;  
7   10542-10567; 10575-10779; and 10769-10825 of SEQ ID NO:1, 3, 5, or 7.

1               57. An oligonucleotide pair comprising an oligonucleotide of claim 56  
2   and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3   5, or 7.

1               58. An oligonucleotide of at least 14 nucleotides in length selected from  
2   nucleotides 1-52; 42-1392; 1383-1520; 1510-1923; 1915-2016; 2045-2152; 2148-2215;  
3   2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-3776; 3768-3968; 3959-4288; 4278-

4 4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822; 5812-5855; 5883-6114; 6107-6139;  
5 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-8078; 8067-8104; 8994-9043; 9480-  
6 9508; 9737-10201; 10241-10454; 10442-10545; 10541-10568; and 10574-10825 of SEQ  
7 ID NO:1, 3, 5, or 7.

1 59. An oligonucleotide pair comprising an oligonucleotide of claim 58  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3 5, or 7.

1 60. An oligonucleotide of at least 15 nucleotides in length selected from  
2 nucleotides 1-53; 41-1393; 1382-1521; 1509-1924; 1914-2017; 2044-2153; 2147-2216;  
3 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-3777; 3767-3969; 3958-4289; 4277-  
4 4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823; 5811-5856; 5882-6115; 6106-6140;  
5 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-9044; 9479-9509; 9736-10202;  
6 10240-10546; 10540-10569; and 10573-10825 of SEQ ID NO:1, 3, 5, or 7.

1 61. An oligonucleotide pair comprising an oligonucleotide of claim 60  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3 5, or 7.

1 62. An oligonucleotide of at least 16 nucleotides in length selected from  
2 nucleotides 1-1394; 1381-1925; 1913-2018; 2043-2154; 2146-2217; 2226-2576; 2864-  
3 3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444; 4436-4555; 4564-4785; 5157-5857;  
4 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-8106; 8992-9045; 9478-9510; 9735-  
5 10203; 10239-10547; 10539-10570; and 10572-10825 of SEQ ID NO:1, 3, 5, or 7.

1 63. An oligonucleotide pair comprising an oligonucleotide of claim 62  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3 5, or 7.

1 64. An oligonucleotide of at least 17 nucleotides in length selected from  
2 nucleotides 1-1926; 1912-2019; 2042-2155; 2145-2218; 2225-2577; 2863-3051; 3411-

3 3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786; 5156-5858; 5880-6117; 6104-6142;  
4 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-9511; 9734-10204; 10238-10548;  
5 10538-10571; and 10571-10825 of SEQ ID NO:1, 3, 5, or 7.

1 65. An oligonucleotide pair comprising an oligonucleotide of claim 64  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3 5, or 7.

1 66. An oligonucleotide of at least 18 nucleotides in length selected from  
2 nucleotides 1-2020; 2041-2156; 2144-2219; 2224-2578; 2862-3052; 3410-3780; 3764-  
3 4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118; 6103-6143; 6140-7134; 7309-7517;  
4 7872-8108; 8990-9047; 9476-9512; 9733-10205; 10237-10549; 10537-10572; and 10570-  
5 10825 of SEQ ID NO:1, 3, 5, or 7.

1 67. An oligonucleotide pair comprising an oligonucleotide of claim 66  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,  
3 5, or 7.

1 68. An oligonucleotide of at least 8 nucleotides in length selected from  
2 nucleotides 1-55; 55-251; 250-306; 310-376; 380-498; 500-528; 516-543; 541-578; 573-  
3 592; 590-609; 611-648; 642-660; 664-717; 712-727; 725-763; 772-828; 813-874; 872-  
4 928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-  
5 1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9,  
6 10, 11 or 12.

1 69. An oligonucleotide pair comprising an oligonucleotide of claim 68  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1 70. An oligonucleotide of at least 9 nucleotides in length selected from  
2 nucleotides 1-56; 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-  
3 593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-

4 929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-  
5 1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9,  
6 10, 11 or 12.

1 71. An oligonucleotide pair comprising an oligonucleotide of claim 70  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1 72. An oligonucleotide of at least 10 nucleotides in length selected from  
2 nucleotides 1-57; 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-  
3 594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-  
4 1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109;  
5 2114-2202; and 2451-2471 of SEQ ID NO:9, 10, 11 or 12.

1 73. An oligonucleotide pair comprising an oligonucleotide of claim 72  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1 74. An oligonucleotide of at least 11 nucleotides in length selected from  
2 nucleotides 1-58; 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-  
3 612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185;  
4 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-2110; 2113-2203; and 2450-2472 of  
5 SEQ ID NO:9, 10, 11 or 12.

1 75. An oligonucleotide pair comprising an oligonucleotide of claim 76  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1 76. An oligonucleotide of at least 12 nucleotides in length selected from  
2 nucleotides 1-255; 246-310; 306-380; 376-502; 496-596; 586-613; 607-664; 660-767;  
3 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-1211; 1436-1487; 1478-1632; 1999-  
4 2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ ID NO:9, 10, 11 or 12.

1           77. An oligonucleotide pair comprising an oligonucleotide of claim 76  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1           78. An oligonucleotide of at least 13 nucleotides in length selected from  
2 nucleotides 1-311; 305-381; 375-503; 495-614; 606-665; 659-768; 767-1051; 1049-1076;  
3 1071-1121; 1110-1187; 1181-1212; 1435-1633; 1998-2060; 2052-2205 and 2448-2474 of  
4 SEQ ID NO:9, 10, 11 or 12.

1           79. An oligonucleotide pair comprising an oligonucleotide of claim 78  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1           80. An oligonucleotide of at least 14 nucleotides in length selected from  
2 nucleotides 1-312; 304-382; 374-504; 494-615; 605-666; 658-769; 766-1052; 1048-1077;  
3 1070-1188; 1180-1213; 1434-1634; 1997-2061; 2051-2206; and 2447-2475 of SEQ ID  
4 NO:9, 10, 11 or 12.

1           81. An oligonucleotide pair comprising an oligonucleotide of claim 80  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1           82. An oligonucleotide of at least 15 nucleotides in length selected from  
2 nucleotides 1-313; 303-383; 373-505; 493-616; 604-667; 657-770; 765-1053; 1047-1078;  
3 1069-1189; 1179-1214; 1433-1635; 1996-2062; 2050-2207; and 2446-2476 of SEQ ID  
4 NO:9, 10, 11 or 12.

1           83. An oligonucleotide pair comprising an oligonucleotide of claim 82  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO 9, 10,  
3 11, or 12.

1               84. An oligonucleotide of at least 16 nucleotides in length selected from  
2 nucleotides 1-314; 302-384; 372-668; 656-771; 764-1054; 1046-1079; 1068-1190; 1178-  
3 1215; 1432-1636; 1995-2208; and 2445-2477 of SEQ ID NO:9, 10, 11 or 12.

1               85. An oligonucleotide pair comprising an oligonucleotide of claim 84  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1               86. An oligonucleotide of at least 17 nucleotides in length selected from  
2 nucleotides 1-315; 301-385; 371-669; 655-772; 763-1055; 1045-1080; 1067-1191; 1177-  
3 1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ ID NO:9, 10, 11 or 12.

1               87. An oligonucleotide pair comprising an oligonucleotide of claim 86  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1               88. An oligonucleotide of at least 18 nucleotides in length selected from  
2 nucleotides 1-773; 762-1056; 1044-1081; 1066-1192; 1176-1217; 1430-1638; 1993-2210;  
3 and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

1               89. An oligonucleotide pair comprising an oligonucleotide of claim 88  
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,  
3 11, or 12.

1               90. A kit for detection of a polymorphism in the HH gene in a patient  
2 sample, the kit comprising at least one oligonucleotide of at least 8 nucleotides in length  
3 selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, or 12, wherein  
4 the oligonucleotide is used to amplify a region of HH DNA or RNA in a patient sample.

1               91. The kit of claim 90, further comprising at least a second  
2 oligonucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11,  
3 or 12, wherein the first and second oligonucleotides comprise a primer pair.

1/11




FIG. 1

## SUBSTITUTE SHEET (RULE 26)

2/11

PATIENTS	MARKERS							373-8
	241-4	65-2	65-1	241-6	241-29	24d1	241-5	
HC2	144 144	161 159	208 206	193 205	117 113	A A	108 108	169 169
HC22	144 144	159 161	206 208	205 193	113 117	A A	108 108	169 169
HC25	144 144	167 159	210 206	205 205	113 113	A A	108 108	169 169
HC29	144 144	159 159	206 208	205 205	113 113	A A	108 108	169 169
HC41	144 144	159 159	206 206	205 205	113 113	A A	108 108	169 169
HC50	144 144	161 159	210 206	193 205	119 113	A A	108 108	169 169
HC75	144 144	159 159	206 206	205 205	113 113	A A	108 108	169 169
HC87	144 144	161 159	208 206	193 205	117 113	A A	108 108	169 169
HC91	144 144	208 206	193 205	117 113	A A	108 108	167 169	139 169
HC125	146 144	161 159	210 206	205 205	115 113	A A	108 108	169 169
HC143	146 146	161 159	210 206	193 205	117 113	A A	108 108	169 169

FIG. 2

3/11

-360 tctaagggtt agataaaaatt tttaaatgta tgattgaatt ttgaaaatca  
 -310 taaatatatta aatatctaaa gttcagatca gaacattgcg aagctacttt  
 -260 ccccaatcaa caacacccct tcaggattta aaaaccaagg gggacactgg  
 -210 atcacctagt gtttcacaag caggtacctt ctgtgttagg agagagagaa  
 -160 ctaaagtctt gaaagacctg ttgctttca ccaggaagtt ttactggc  
  
 -110 tctcctgagc ctaggcaata gctgttagggt gacttctgga gccatccccg  
 -60 ttccccgccc ccccaaaaaga agcggagatt taacggggac gtgcggccag  
 -10 agctgggaa  
 1 ATGGGCCCGC GAGCCAGGCC GGCGCTTCTC CTCCTGATGC TTTTGCAGAC  
 51 CGCGGTCCCTG CAGGGGCGCT TGCTGCgtga gtccgagggc tgcgggcgaa  
  
 101 ctaggggcgc ggcgggggtg gaaaaatcga aactagcttt ttctttgcgc  
 151 ttgggaggtt gctaactttg gaggacctgc tcaaccctat ccgcaagccc  
 201 ctctccctac ttctcgctc cagacccctg gagggagtgc ctaccactga  
 251 actgcagata ggggtccctc gccccaggac ctgccccctc ccccggtctgt  
 301 cccggctctg cggagtgact ttggaaacccg cccactccct tcccccaact  
  
 351 agaatgcttt taaataaaatc tcgttagtcc tcacttgagc tgagctaaac  
 401 ctggggctcc ttgaacctgg aactcgggtt tatttccaat gtcagctgt  
 451 cagtttttc cccagtcatc tccaaacagg aagttcttcc ctgagtgctt  
 501 gccgagaagg ctgagcaaac ccacagcagg atccgcacgg ggtttccacc  
 551 tcagaacgaa tgcgttggc ggtggggcg cgaaagagtg gcgttgggga  
  
 601 tctgaattct tcaccattcc acccaactttt ggtgagacct ggggtggagg  
 651 tctctaggggt gggaggctcc tgagagaggc ctacctcggg cctttccccca  
 701 ctcttggcaa ttgttcttt gcctggaaaa ttaagtatat gttagtttg  
 751 aacgtttgaa ctgaacaatt ctctttcgg ctaggctta ttgatttgca  
 801 atgtgctgtg taattaagag gcctctctac aaagtactga taatgaacat  
  
 851 gtaagcaatg cactcacttc taagttacat tcatactga tcttatttga  
 901 ttttcactag gcatagggag gtaggagcta ataatacgtt tattttacta  
 951 gaagttaact ggaattcaga ttatataact ctttcaggt tacaaagaac  
 1001 ataaataatc tggtttctg atgttatttc aagtaactaca gctgcttcta  
 1051 atcttagttg acagtgattt tgccctgttag tgttagcacag tggctgttgg  
  
 1101 gtcacacgcc ggcctcagca cagcactttg agtttggta ctacgtgtat  
 1151 ccacattta cacatgacaa gaatgaggca tggcacggcc tgcttcctgg  
 1201 caaatttatt caatggtaca ctgggctttg gtggcagagc tcatactcc  
 1251 acttcatacg tatgattctt aaacatcaca ctgcattaga ggttgaataa  
 1301 taaaattca tggtagcag aaatattcat tggtaacaag tggtaatgag  
  
 1351 tcccagccat gtgttgcact gttcaagccc caagggagag agcaggaaaa  
 1401 caagtctta ccctttgata ttttgcattc tagtgggaga gatgacaata  
 1451 agcaaatgag cagaaagata tacaacatca ggaatcatg ggtgttgtga  
 1501 gaagcagaga agtcaggcga agtcaactctg gggctgacac ttgagcagag  
 1551 acatgaagga aataagaatg atattgactg ggagcagtat ttcccaggca  
  
 1601 aactgagtgg gcctggcaag ttggattaaa aagcgggttt tctcagcact  
 1651 actcatgtgt gtgtgtgtgg gggggggggg cggcgtgggg gtgggaaggg  
 1701 ggactaccat ctgcattgttag gatgtctagc agtatactgt cctccctact  
 1751 cactagggtgc taggagcact ccccccgtct tgacaaccaa aaatgtctct  
 1801 aaactttgcc acatgtcacc tagtagacaa actcctgggtt aagaagctcg

FIG. 3  
(1 of 5)

SUBSTITUTE SHEET (RULE 26)

4/11

1851 ggttaaaaaa aataaacaag tagtgctggg gagtagaggc caagaagtag  
 1901 gtaatgggct cagaagagga gccacaaaaca aggttgtgc ggcgcctgt  
 1951 ggctgtggtg tgaattctag ccaaggagta acagtatct gtcacaggct  
 2001 tttaaaagat tgctctggct gctatgtgga aagcagaatg aagggagcaa  
 2051 cagtaaaagc agggagccca gccaggaagc tgttacacag tccaggcaag  
  
 2101 aggttagtgg a gtgggctggg tgggaacaga aaagggagtg acaaaccatt  
 2151 gtctcctgaa tatattctga aggaagtgc tgaaggattc tatgttgt  
 2201 gagagaaaaga gaagaattgg ctgggtgtag tagctcatgc caaggaggag  
 2251 gccaaggaga gcagattct gagctcagga gttcaagacc agcctggca  
 2301 acacagcaaa accccttctc tacaaaaaat acaaaaatta gctgggtgt  
  
 2351 gtggcatgca cctgtatcc tagctactcg ggaggcttag gtggagggt  
 2401 ttgcttgagc ccaggaagtt gaggctgcag tgagccatga ctgtccact  
 2451 gtacttcagc ctaggtgaca gagcaagacc ctgtctccc tgacccctg  
 2501 aaaaagagaa gatTTAAAGT tgactttgtt ctttattttt attttattgg  
 2551 cctgagcagt gggtaattt gcaatgcatt ttctgagatg gtgaaggcag  
  
 2601 aggaaaagagc agtttgggtt aatcaagga tctgcatttgg gacatgtt  
 2651 agtttggat tccagtcagg cttccaaatgg gtgaggccac ataggcagtt  
 2701 cagttaaga attcaggacc aaggctggc acggctggc acattctgt  
 2751 tcccagcact ttggggctg aggccaggtag atcatttgag gtcaggagtt  
 2801 tgagacaagc ttggccaaca tggtaaacccatgtctac taaaataca  
  
 2851 aaaaatttagcc tgggtgtggg ggcacgcct atagtcggcag gttttcagga  
 2901 ggcttagta ggagaatccc ttgaaccagg gaggtgcagg ttgcagttag  
 2951 ctgagattgt gccactgcac tccagcctgg gtgatagagt gagactctgt  
 3001 ctcaaaaaaaa aaaaaaaaaa aaaaaaaaaa aactgaagga attattcc  
 3051 aggatttggg tctaatttgc cctgagcacc aactccttagt ttcaactacc  
  
 3101 atggctagac acaccttaac atttctaga atccaccagg tttagtggag  
 3151 tctgtctaat catgagtatt ggaataggat ctggggcag tgaggggg  
 3201 gcagccacgt gtggcagaga aaagcacaca agggaaagagc acccaggact  
 3251 gtcatatgga agaaagacag gactgcaact cacccttcac aaaaatggag  
 3301 ccagacacag ctgatggat gagttgtgc aggtgtgtgg agcctcaaca  
  
 3351 tcctgctccc ctctactac acatggtaa ggctgttgc tctgtctcca  
 3401 gGTTCACACT CTCTGCACTA CCTCTTCATG GGTGCCTCAG AGCAGGACCT  
 3451 TGGTCTTCC TTGTTGAAG CTTTGGCTA CGTGGATGAC CAGCTTTCG

G      T

3501 TGTTCTATGA TCATGAGAGT CGCCGTGTGG AGCCCCGAAC TCCATGGGTT  
 3551 TCCAGTAGAA TTTCAAGCCA GATGTGGCTG CAGCTGAGTC AGAGTCTGAA  
  
 3601 AGGGTGGGAT CACATGTTCA CTGTTGACTT CTGGACTATT ATGGAAAATC  
 3651 ACAACCACAG CAAGGgtatg tggagaggg gcctcacctt cctgaggttg  
 3701 tcagagctt tcatctttc atgcattttc aagaaaaacag ctggaaagtct  
 3751 gaggtcttgt gggacaggg aagaggaaag gaatttgctt cctgagatca  
 3801 tttggtcctt gggatggtg gaaataggga cctatttcctt tggttgcagt  
  
 3851 taacaaggct gggattttt ccagAGTCCC ACACCCCTGCA GGTCACTCTG  
 3901 GGCTGTAAA TGCAAGAAGA CAACAGTACCG GAGGGCTACT GGAAGTACGG  
 3951 GTATGATGGG CAGGACCACC TTGAATTCTG CCCTGACACA CTGGATTGGA  
 4001 GAGCAGCAGA ACCCAGGGCC TGGCCCACCA AGCTGGAGTG GGAAAGGCAC  
 4051 AAGATTGGG CCAGGCAGAA CAGGGCCTAC CTGGAGAGGG ACTGCCCTGC

*FIG. 3*  
(2 of 5)

SUBSTITUTE SHEET (RULE 26)

5/11

4101 ACAGCTGCAG CAGTTGCTGG AGCTGGGGAG AGGTGTTTG GACCAACAAG  
 4151 gtatggtggaa aacacacttc tgcccata ctctagtggc agagtggagg  
 4201 agggtgcagg gcacggaatc cctgggtggaa gttcagagg tggctgaggc  
 4251 tgtgtgcctc tccaaattct gggaaaggac ttctcaatc ctagagtctc  
 4301 taccttataa ttgagatgt a tgagacagcc acaagtcatg ggtttaattt  
  
 4351 ctttctcca tgcataatggc tcaaaggaa gtgtctatgg cccttgcttt  
 4401 ttattnaacc aataatctt tgcataattna tacctgtttaa aaattcagaa  
 4451 atgtcaaggc cgggcacggt ggctcacccc tgcataatccca gcactttggg  
 4501 aggccgaggc ggggtggtcac aaggctcagga gttttagagcc agcctgacca  
 4551 acatggtgaa acccgctct aaaaaatac aaaaatttagc tggtcacagt  
  
 4601 catgcgcacc tgcataatggc gctaatttggaa aggctgaggc aggagcatcg  
 4651 cttgaacctg ggaagcggaa gttgcactga gccaagatcg cgccactgca  
 4701 ctccagccca ggcagcagag tgagactcca tctaaaaaaaaaaaaaaaaaa  
 4751 aaaaaaaaagag aattcagaga tctcagctat catatgaata ccaggacaaa  
 4801 atatcaagtg aggccactta tcagagttaga agaatcctt aggttaaaag  
  
 4851 ttttttcat agaacatagc aataatcaact gaagctaccc atcttacaag  
 4901 tccgcttctt ataacaatgc ctccttagtt gaccagggtg aaactgacca  
 4951 tctgttatca atcattttca atgcacataa aggcaattt tatctatcag  
 5001 aacaaagaac atgggttaaca gatatgtata tttcatgtg aggagaacaa  
 5051 gctgatctga ctgctctcca agtgacactg tgtagagtc caatcttagg  
  
 5101 acacaaaatg gtgtctctcc tgcataatggaa gtttgcataatggaa aaagggtatt  
 5151 tccttcctcc aacccataga aggaagtgaa agttccagtc ttccctggcaa  
 5201 gggtaaacag atccccctcc ctcataccctc ctcttcctg tcaagTGCCT  
 5251 CCTTTGGTGA AGGTGACACA TCATGTGACC TCTTCAGTGA CCACTCTACG  
 5301 GTGTCGGGCC TTGAACTACT ACCCCCCAGAA CATCACCATG AAGTGGCTGA  
  
 5351 AGGATAAGCA GCCAATGGAT GCCAAGGGAGT TCGAACCTAA AGACGTATTG  
 5401 CCCAATGGGG ATGGGACCTA CCAGGGCTGG ATAACCTTGG CTGTACCCCC

## A

5451 TGGGGAAGAG CAGAGATATA CGTGCCAGGT GGAGCACCCA GGCCTGGATC  
 5501 AGCCCCCTCAT TGTGATCTGG Ggtatgtac tgatgagagc caggagctga  
 5551 gaaaatctat tgggggttga gaggagtgcc tgaggaggtt attatggcag  
  
 5601 tgagatgagg atctgcttt tggtaggggg tggctgagg gtggcaatca  
 5651 aaggctttaa cttgttttt ctgttttagA GCCCTCACCG TCTGGCACCC  
 5701 TAGTCATTGG AGTCATCAGT GGAATTGCTG TTTTTGTCGT CATCTTGTTC  
 5751 ATTGGAATT TGTTCATAAT ATTAAGGAAG AGGCAGGGTT CAAgtgagta  
 5801 ggaacaaggg ggaagtctct tagtacctct gccccaggc acagtggaa  
  
 5851 gaggggcaga ggggatctgg catccatggg aagcattttt ctcatttata  
 5901 ttctttgggg acaccagcag ctccctggaa gacagaaaat aatggttctc  
 5951 cccagaatga aagtctctaa ttcaacaaac atttcagag cacctactat  
 6001 tttgcagag ctgtttaagg tagtacaggg gctttaggt tgagaagtca  
 6051 ctgtggctat tctcagaacc caaatctgtt agggaaatgaa attgatacgca  
  
 6101 agtaaatgtt gttaaagaag accccatgg gtcctaaagc aggcaggaaag  
 6151 caaatgctt ggggtgtcaaa ggaaagaatg atcacattca gctggggatc  
 6201 aagatagcct tctggatctt gaaggagaag ctggattcca ttaggtgagg  
 6251 ttgaagatgtt gggaggtctt acacagacgg agcaaccatg ccaagttagga  
 6301 gagtataagg catactggaa gattagaaat aattactgtt ccttaaccct

FIG. 3  
(3 of 5)

SUBSTITUTE SHEET (RULE 26)

6/11

6351 gagtttgcgt agctatca caccattat gcatttctac cccctgaaca  
 6401 tctgtgggt agggaaaaga gaatcagaaa gaagccagct catacagagt  
 6451 ccaagggtct tttggatat tggttatga tcactgggt gtcattgaag  
 6501 gatcctaaga aaggaggacc acgatctccc ttatatggt aatgtttgt  
 6551 taagaagttt gatgagaggt gaggagacca gttagaaagc caataagcat  
  
 6601 ttccagatga gagataatgg ttcttggaaat ccaatagtgc ccaggtctaa  
 6651 attgagatgg gtgaatgagg aaaataagga agagagaaga ggcaagatgg  
 6701 tgccttagtt tggatgcct cttccctggg tctcttgct ccacAGGAGG  
 6751 AGCCATGGGG CACTACGTCT TAGCTAACG TGAGTGAAC acgcac  
 6801 gactcaactgt gggaggaga caaaaactaga gactcaaaga gggagtgcat  
  
 6851 ttatgagctc ttcatgttgc aggagagagt tgaacctaaa catagaaatt  
 6901 gcctgaccaa ctccctgatt ttagccttct ctgttcattt cctcaaaaag  
 6951 atttccccat ttaggtttct gaggccctgc atgccgggtga tccctagctg  
 7001 tgacctctcc cctggaactg tctctcatga acctcaagct gcatctagag  
 7051 gcttccttca tttccctcgat cacccatcgag acatacacct atgtcatttc  
  
 7101 atttcctatt tttggaaagag gactccttaa atttggggga cttacatgat  
 7151 tcattttaac atctgagaaa agctttaac cctggggacgt ggctagtc  
 7201 aaccttacca gattttaca catgtatcta tgcattttct ggaccgggttc  
 7251 aacttttct ttaaatcctc tctctgtgtt acccagtaac tcatttgtca  
 7301 ccaagccttgc gggattcttc catctgattt tgatgtgagt tgacacagcta  
  
 7351 tgaaggctgt acactgcacg aatggaaagag gcacccgtcc cagaaaaagc  
 7401 atcatggcta tctgtgggtt gtatgatggg tggggggatc aggttaggagg  
 7451 caaatatctt gaaagggggtt gtgaagaggt gttttttctt attggcatga  
 7501 aggtgtcata cagatttgca aagtttaatg gtgccttcat ttgggatgct  
 7551 actctagat tccagacctg aagaatcaca ataattttctt acctggcttc  
  
 7601 tccttgggtt gataatgaaa attatgataa ggatgataaa agcacttact  
 7651 tcgtgtcga ctcttctgag cacctactt catgcattac tgcattgtact  
 7701 tcttacaata attctatgat ataggtacta ttatccccat ttctttttta  
 7751 aatgaagaaa gtgaagtagg ccgggcacgg tggctcacgc ctgtatccc  
 7801 agcactttgg gaggccaaag cggtggatc acgaggtcag gagatcgaga  
  
 7851 ccatcctggc taacatgggt aaaccccatc tctaataaaa atacaaaaaa  
 7901 ttagctggc gtgggtggcag acgcctgttag tcccaagctac tcggaaaggct  
 7951 gaggcaggag aatggcatga acccaggagg cagagcttc agtgagccga  
 8001 gtttgcggca ctgcactcca gccttaggtga cagagtggaa ctccatctca  
 8051 aaaaaataaaa aataaaaata aaaaaatgaa aaaaaaaaaga aagtgaagta  
  
 8101 tagagtatct catagtttgt cagtgataga aacaggtttc aaactcagtc  
 8151 aatctgaccg ttgtatcat ctcagacacc actacattca gtgtttttaga  
 8201 tgccttagat aaatagagaa ggaaggagat ggcttttctc ttgtctcatt  
 8251 gtgttttctc tgagttagct tgaatcacat gaaggggaaac agcagaaaaac  
 8301 aaccaactga tcctcagctg tcatgtttcc tttaaaagtc cctgaaggaa  
  
 8351 ggccctggaa tggactccc ttgctcttct gttgctcttct ttggcattca  
 8401 ttctttggaa ccctacgcaa ggactgtat tggggggac agctagtggc  
 8451 cctgctggc ttcacacacg gtgtccccc tagggcagtg cctctggagt  
 8501 cagaactctg gtggatttc cctcaatgaa gtggagtaag ctctctcatt  
 8551 ttgagatggt ataatggaa ccaccaagtg gcttagagga tgccaggc

FIG. 3  
(4 of 5)

7/11

8601 cttccatgga gccactgggg ttccggtgca cattaaaaaa aaaatctaac  
 8651 caggacattc aggaattgc agattctggg aaatcagttc accatgtca  
 8701 aaagagtctt tttttttttt ttgagactct attgccagg ctggagtgca  
 8751 atggcatgat ctcggctcac tgtaacctc gcctcccagg ttcaagcgat  
 8801 tctcctgtct cagcctccca agtagctggg attacaggcg tgcaccacca  
  
 8851 tgcccgctca atttttgtat ttttagtaga gacagggtt caccatgttg  
 8901 gccaggctgg ttcgaactc tcctgacctc gtgatccgccc tgcctcgccc  
 8951 tcccaaagtg ctgagattac aggtgtgagc caccctgccc agccgtcaaa  
 9001 agagtcttaa tatatatatac cagatggcat gtgtttactt tatgttacta  
 9051 catgcacttg gctgcataaa tgtggtacaa gcattctgtc ttgaaggca  
  
 9101 ggtgcttcag gataccatat acagctcaga agtttcttct ttaggcatta  
 9151 aatttttagca aagatatactc atctcttctt ttaaaccatt ttctttttt  
 9201 gtggtagaa aagttatgtt gaaaaaaagta aatgtgattt acgctcattt  
 9251 tagaaaagct ataaaatgaa tacaattaaa gctgttattt aattagccag  
 9301 tgaaaaacta ttaacaactt gtctattacc tgtagtattt attgttgcatt  
  
 9351 taaaaatgca tatactttaa taaaatgtata ttgtattgtt tactgcatga  
 9401 ttttattgaa gttcttggc atcttgttta tataacttaat cgctttgtca  
 9451 ttttggagac atttattttt cttcttaattt ctttacattt tgtcttacgg  
 9501 aatatttca ttcaactgtt gtagccaat taatcgtgtt tcttacttct  
 9551 agggacattt tgcgtctaagt tgtaagacat tggttattttt accagcaaac  
  
 9601 cattctgaaa gcatatgaca aattatttct ctcttaatat cttaactatac  
 9651 tgaaaggcaga ctgctataag gcttcactta ctcttctacc tcataaggaa  
 9701 tatgttacaa ttaatttttattt aggtaagcat ttgttttata ttggttttat  
 9751 ttcacctggg ctgagatttcc aagaaacacc ccagtcttca cagtaacaca  
 9801 tttcaactaac acatttacta aacatcagca actgtggcct gttaattttt  
  
 9851 ttaatagaaaa tttaagtcc tcattttctt tcgggttttt ttaagcttaa  
 9901 tttttctggc ttatttcata aattcttaag gtcaactaca ttggaaaaat  
 9951 caaagacctg cattttaaat tcttattcac ctctggcaaa accattcaca  
 10001 aaccatggta gtaaaagagaa gggtgacacc ttgtggccat aggttaatgt  
 10051 accacgggttccgggtgacc agagatgcag cgctgagggt tttcctgaag  
  
 10101 gtaaaaggaat aaagaatggg tggaggggcg tgcaactggaa atcacttgta  
 10151 gagaaaagcc cctgaaaatt tgagaaaaca aacaagaaaac tacttaccag  
 10201 ctatttgaat tgctggaaatc acaggccatt gctgagctgc ctgaactggg  
 10251 aacacaacag aaggaaaaca aaccactctg ataatcattt agtcaagtac  
 10301 agcaggtgat tgaggactgc tgagaggtac aggccaaaat tcttatgttg  
  
 10351 tattataata atgtcatctt ataatactgt cagtatttttta taaaacattc  
 10401 ttcacaaact cacacacatt taaaacaaa acactgtctc taaaatcccc  
 10451 aaattttca taaac

*FIG. 3*  
(5 of 5)

8/11

ggggacactg gatcacctag tgtttccaaa gcaggtacct tctgctgttag gagagagaga  
 actaaagtc taaaagacct gttgttttc accaggaagt ttactgggc atctcctgag  
 cctaggcaat agctgttaggg tgacttctgg agccatcccc gttcccccgcc ccccaaaaag  
 aagcgagat ttaacgggga cgtcgccca gagctggga a

atggggcccg cgagccaggc  
 M G P R A R

cggcgcttct cctcctgatg cttttcaga ccgcggcttgc acggggcgcc ttgctgcgtt  
 P A L L L L M L L Q T A V L Q G R L L R

cacactctct gcaactaccc ttcatgggtg cttcagagca ggaccttggc ctttccttgt  
 S H S L H Y L F M G A S E Q D L G L S L  
 24d2G 24d7

ttgaagcttt gggctacgtg gatgaccagc tggtcggtt ctatgatcat gagagtgcgc  
 F E A L G Y V D D Q L F V F Y D H E S R  
 D C

gtgtggagcc ccgaactcca tgggtttcca gtagaatttc aagccagatg tggctgcagc  
 R V E P R T P W V S S R I S S Q M W L Q

tgagtcagag tctgaaaggg tgggatcaca tggtcactgt tgacttctgg actattatgg  
 L S Q S L K G W D H M F T V D F W T I M

aaaatcacaa ccacagcaag gagtcccaca ccctgcaggt catcctggc tggaaatgc  
 E N H N H S K E S H T L Q V I L G C E M

aagaagacaa cagtaccgag ggctactgga agtacgggta tgatgggcag gaccaccc  
 Q E D N S T E G Y W K Y G Y D G Q D H L

aattctgccc tgacacactg gattggagag cagcagaacc cagggcctgg cccaccaagc  
 E F C P D T L D W R A A E P R A W P T K

tggagtgaaa aaggcacaag attcggccca ggcagaacag ggcctacctg gagagggact  
 L E W E R H K I R A R Q N R A Y L E R D

gccctgcaca gctgcagcag ttgctggagc tggggagagg tggttggac caacaagtgc  
 C P A Q L Q Q L L E L G R G V L D Q Q V

cctcttggt gaaggtgaca catcatgtga cctcttcagt gaccactcta cgggtgcggg  
 P P L V K V T H H V T S S V T T L R C R

ccttgaacta ctaccccccag aacatcacca tgaagtggct gaaggataag cagccaatgg  
 A L N Y Y P Q N I T M K W L K D K Q P M

atgcacccaa gttcgaacct aaagacgtat tgcccaatgg ggtatggacc taccagggt  
 D A K E F E P K D V L P N G D G T Y Q G

A 24d1

ggataaacctt ggctgtaccc cctggggaaag agcagagata tacgtgcacag gtggagcacc  
 W I T L A V P P G E E Q R Y T C Q V E H  
 Y

caggcctgga tcagccccctc attgtgatct gggagccctc accgtctggc accctagtca  
 P G L D Q P L I V I W E P S P S G T L V

ttggagtcat cagtggatt gctgttttg tcgtcatctt gttcattggaa attttgtca  
 I G V I S G I A V F V V I L F I G I L F

taatattaag gaagaggcag ggtaaagag gagccatggg gcaactacgtc ttagctgaac  
 I I L R K R Q G S R G A M G H Y V L A E

gtgagtga  
 R E \*

ca cgcagcctgc agactcactg tggaaaggag aaaaaactag agactcaaag  
 agggagtgca ttatgatct cttcatgtt caggagagat tgaaacctaa acatagaaat  
 tgcctgacga actccttgc tttggccatt tcctcaaaaa gattccccca

*FIG. 4*

SUBSTITUTE SHEET (RULE 26)

9/11

**PCR Primers used for Amplification Of 24d1 Alleles**

24d1.P1 (forward primer)

5'-TGGCAAGGGTAAACAGATCC-3' (SEQ ID NO:13)

24d1.P2 (reverse primer)

5'-CTCAGGCACTCCTCTCAACC-3' (SEQ ID NO:14)

**OLA Oligonucleotides for 24d1**

## Upstream Oligonucleotides (5'-biotinylated)

24d1.A (common allele)

5'-bio-GGAAGAGCAGAGATATACGTG-3'

(SEQ ID NO:15)

24d1.B (hemochromatosis allele)

5'-bio-GGAAGAGCAGAGATATACGTA-3'

(SEQ ID NO:16)

## Downstream Oligonucleotides (5'-phosphorylated)

24d1.X 5'-p-CCAGGTGGAGCACCCAGG-dig-3'

(SEQ ID NO:17)

**FIG. 5**

5'-TATTCCTCCTCCAACCTATAGAAGGAAGTGAAGTTCCAGTCTTCTGGCAAGGGTAAACAGATCCCC  
24d1.P1  
 TCTCCTCATCCTTCTCTTCTGTCAAGTGCCCTCTGGTGAAGGTGACACATCATGTGACCTCTCAG  
 TGACCACTCTACGGTGTGGGCCTTGAACTACTACCCCCAGAACATCACCATGAAGTGGCTGAAGGATA  
 AGCAGCCAATGGATGCCAAGGAGTTCGAACCTAAAGACGTATTGCCAATGGGATGGACCTACCAAGG  
 GCTGGATAACCTTGGCTGTACCCCTGGGAAGAGCAGAGATATACGTGCCAGGTGGAGCACCCAGGC  
 CTGGATCAGCCCTCATTGTATCTGGGTATGTGACTGTGAGAGCCAGGAGCTGAGAAAATCTATTGG  
24d1.P2  
GGGTTGAGAGGAGTGCCTGAGGAGGTAAATTATGGCAGTGAGATGAGGATCTGCTCTTGTAGGGGTG  
GGCTGAGGGTGGCAATCAAAGGCTTAACCT-3' (SEQ ID NO:20)

**FIG. 6A**

5'-TATTCCTCCTCCAACCTATAGAAGGAAGTGAAGTTCCAGTCTTCTGGCAAGGGTAAACAGATCCCC  
24d1.P1  
 TCTCCTCATCCTTCTCTTCTGTCAAGTGCCCTCTGGTGAAGGTGACACATCATGTGACCTCTCAG  
 TGACCACTCTACGGTGTGGGCCTTGAACTACTACCCCCAGAACATCACCATGAAGTGGCTGAAGGATA  
 AGCAGCCAATGGATGCCAAGGAGTTCGAACCTAAAGACGTATTGCCAATGGGATGGACCTACCAAGG  
 GCTGGATAACCTTGGCTGTACCCCTGGGAAGAGCAGAGATATACGTAccAGGTGGAGCACCCAGGC  
 CTGGATCAGCCCTCATTGTATCTGGGTATGTGACTGTGAGAGCCAGGAGCTGAGAAAATCTATTGG  
24d1.P2  
GGGTTGAGAGGAGTGCCTGAGGAGGTAAATTATGGCAGTGAGATGAGGATCTGCTCTTGTAGGGGTG  
GGCTGAGGGTGGCAATCAAAGGCTTAACCT-3' (SEQ ID NO:21)

**FIG. 6B****SUBSTITUTE SHEET (RULE 26)**

10/11

HH Protein RLA hMHC	M G P R A R P A L L I M I L Q T A V L Q G R R L L R S H S L H Y L F M G A S E Q D L G L S L F E A L G Y V D D Q L F V E - M G S I P P R T L L L L A G A L T L K D T Q A G S H S M R Y F Y T S V S R P G L G E P R F T I I V G Y V D D T Q F V R - M A V M A S P R T L V L L L S G A L A L T Q T W A G S H S M R Y F E T S V S R P G R G E P R F I A V G Y V D D T Q F V R
HH Protein RLA hMHC	Y D H E - S R R V E P P R T P W V S S R I S S Q M W L Q L S Q S L R G W D H M F T V D F E W T I M E N H N S - K E S H T F D S D A A S S P R M E Q R A P W M G - Q V E P E Y W D Q Q T Q I A K D T A Q T F R V N L N T A L R Y Y N O S A A G S H T F D S D A A S S Q R M E P R A P W I E - Q E G P E Y W D G E T R K V K A H S Q T H R V D L G T L R G Y Y N O S E A G S H T
HH Protein RLA hMHC	* Q V I L G C E M Q E D N - S T E G Y W K Y G Y D G Q D H L E F C P D T L D W R A A E P R A W P T K L E W E R H K I R A E Q T M F G C E V W A D G R F F H G Y R Q Y A Y D G A D Y I A L N E D L R S W T A A D T A A Q N T Q R K W E A A G E A E L Q M M F G C D P Y G S D W R F L R G Y H Q Y A Y D G K D Y I A L K E D L R S W T A A D M A A Q T T K H K W E A A H V A E
HH Protein RLA hMHC	* R Q N R A Y L E R D C P A Q L Q Q L L E L G R G V E D Q Q Q V P F L V K V T H H V T S S - V T T L R C H A L N Y P O N T R - H R A Y L E R E C V E W L R Y L E M G K E T L Q R A D P P K A H V T H H P A S D R E A T L R C W A L G F Y P A E E Q - L R A Y L E G T C V E W L R Y L E N G K E T L Q R T D A P K T H M T H A V S D H E A T L R C W A L S F Y P A E E
HH Protein RLA hMHC	* T M K W L K D - - K Q P M D A K E F E P K D V L P N G D G T Y Q G M W I T L A V P P G E Q R Y T Q C V E H P G L D Q P L S L T W Q R D G E D Q T Q D T E L V E T R - - P G G D G T F Q K W A V V V P S G E E Q R Y T C R V Q H E G L P E P L T L T W Q R D G E D Q T Q D T E L V E T R - - P A G D G T F Q K W A V V V P S G O E Q R Y T C H V Q H E G L P K P L
HH Protein RLA hMHC	* I V I W E P S P S - G T E V I G V I S G I A V F V V I L F I G I L F I I L R K Q G S R G A M G H Y V I A E R E - - - T L T W E P P A Q P T A L I V G I V A G - V L C V L L I L G A V V A V V R R K H S S D G K G G R Y T P A A G G H R D Q T L R W E P S S Q P T I P I V G I I A G L V I L F G A V I T G A V V A A V M W R R K S S D R K G G S Y S Q A A S S D S A Q
HH Protein RLA hMHC	- - - - - G S D D S I M P - - - G S D D V S L T A C K V

FIG. 7

11/11




FIG. 8

**PCR Primers used for Amplification Of 24d2 Alleles**

24.P2.1 (forward primer)

5'-ACATGGTTAAGGCCTGTTGC-3' (SEQ ID NO:24)

24.P2.2 (reverse primer)

5'-GCCACATCTGGCTTGAAATT-3' (SEQ ID NO:25)

**OLA Oligonucleotides for 24d2**

Upstream Oligonucleotides (5'-biotinylated)

24d2.A (common allele)

5'-bio-AGCTGTTCGTGTCTATGATC-3'

(SEQ ID NO:26)

24d2.B (hemochromatosis allele)

5'-bio-AGCTGTTCGTGTCTATGATG-3'

(SEQ ID NO:27)

Downstream Oligonucleotides (5'-phosphorylated)

24d2.X 5'-p-ATGAGAGTCGCCGTGTGGA-dig-3'

(SEQ ID NO:28)

FIG. 9

**SUBSTITUTE SHEET (RULE 26)**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/06254

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet.

US CL : 424/136, 185; 435/6, 91.2; 514/126; 530/350; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/136, 185; 435/6, 91.2; 514/126; 530/350; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG: hereditary hemochromatosis, satellite sequences

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Totaro et al. New polymorphisms and markers in the HLA class I region: relevance to hereditary hemochromatosis (HFE). Hum. Genet. 19 April 1995, Vol. 95, pages 429-434, especially pages 431-432.	23, 24, 39 and 42
X	Jouet et al. Isolation of YAC clones containing class I HLA genes which map in the vicinity of the hereditary haemachromatosis gene. J. Med. Genet. 22 August 1991. Vol.,28, No. 8, page 572.	23, 24, 39 and 42
X	Calandro et al. Characterization of a recombinant that locates the hereditary hemochromatosis gene telomeric to HLA-F. Hum. Genet. 13 September 1995. Vol. 96 pages 339-342. especially pages 340-341.	23, 24, 39 and 42

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	
"E"	earlier document published on or after the international filing date	"X"
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"&"

Date of the actual completion of the international search	Date of mailing of the international search report
18 JULY 1997	10 SEP 1997

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  WILLIAM SANDALS Telephone No. (703) 308-0196
---	---

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/06254
---

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Totaro et al. Hereditary hemochromatosis: Generation of a transcription map within a refined and extended map of the HLA class I region. Genomics. 06 March 1996. Vol. 31, pages 319-326, especially figure 1 and Tables 1 and 2.	23, 24, 39 and 42
X,P	Feder et al. A novel MHC class I-like gene is mutated in patients with hereditary haemachromatosis. Nature Genet. 01 August 1996. Vol. 13, pages 399-408, see entire document.	1-91
X, P	Jazwinska et al. Hemochromatosis and "HLA-H": Definite! Hepatology. February 1997. Vol. 25, No. 2, pages 495-496.	1-91

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US97/06254

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
1-31, 37, 40-44 and 46-91
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US97/06254

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

C12Q 1/68; C12P 19/34; C07K 13/00; C07H 21/04; A61K 38/00, 39/00, 39/395